

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 April 2001 (19.04.2001)

PCT

(10) International Publication Number  
WO 01/27150 A2

|   |                               |  |   |  |
|---|-------------------------------|--|---|--|
| (51) International Patent Classification <sup>7</sup> :                                   | C07K 14/435,<br>C12Q 1/25     | 09/458,144<br>09/457,898<br>PCT/US99/29405   | 9 December 1999 (09.12.1999)<br>9 December 1999 (09.12.1999)  | US<br>US   |
| (21) International Application Number:  | PCT/US00/28477                |  | 10 December 1999 (10.12.1999)   | US   |
| (22) International Filing Date:   | 13 October 2000 (13.10.2000)  | 60/211,627<br>60/211,687<br>60/211,609<br>60/211,626<br>60/211,880<br>60/211,607<br>60/211,766<br>60/211,888<br>60/212,070 | 14 June 2000 (14.06.2000)<br>14 June 2000 (14.06.2000)<br>14 June 2000 (14.06.2000)<br>14 June 2000 (14.06.2000)<br>14 June 2000 (14.06.2000)<br>14 June 2000 (14.06.2000)<br>14 June 2000 (14.06.2000)<br>14 June 2000 (14.06.2000)<br>14 June 2000 (14.06.2000) | US<br>US<br>US<br>US<br>US<br>US<br>US<br>US<br>US |
| (25) Filing Language:   | English                       |  |   |  |
| (26) Publication Language:  | English                       |  |   |  |
| (30) Priority Data:   |                               |  |   |  |
| 09/418,529  | 14 October 1999 (14.10.1999)  | US   |   |  |
| 09/418,917  | 15 October 1999 (15.10.1999)  | US   |   |  |
| 09/418,922  | 15 October 1999 (15.10.1999)  | US   |   |  |
| 09/444,341  | 19 November 1999 (19.11.1999) | US   |   |  |
| 09/444,338  | 19 November 1999 (19.11.1999) | US   |   |  |
| 09/458,477  | 9 December 1999 (09.12.1999)  | US   |   |  |
| 09/457,556  | 9 December 1999 (09.12.1999)  | US   |   |  |
| (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications: |                               |  |   |  |
|   |                               | US   | 09/418,529 (CIP)  |  |
|   |                               | Filed on   | 14 October 1999 (14.10.1999)  |  |
|   |                               | US   | 09/418,917 (CIP)  |  |
|   |                               | Filed on   | 15 October 1999 (15.10.1999)  |  |

[Continued on next page]

(54) Title: ANTHOZOA DERIVED CHROMOPHORES/FLUOROPHORES AND METHODS FOR USING THE SAME

cDNA sequence of drFP583

GTCCTCCCAAGCAGTGGTATCAACGCAGAGTACGGGGGAGTTTCAGCCAGTGACGGT  
CAGTGACAGGGTGAGCCACTTGGTATACCAACAAATGAGGTCTTCCAAGAATGTTA  
TCAAGGAGTTTCATGAGGTTTAAGGTTTCGCATGGAAGGAACGGTCAATGGGCACGAGT  
TTGAAATAGAAAGCGAAGGAGAGGGGAGGCCATACGAAGGCCACAATACCGTAAAGC  
TTAAGGTAACCAAGGGGGGACCTTTGCCATTGCTTGGGATATTTGTCAACCAAT  
TTCAGTATGGAAGCAAGGTATATGTCAAGCACCTGCGGACATACCAGACTATAAAA  
AGCTGTCAATTCCTGAAGGATTTAAATGGGAAAGGGTCATGAACCTTGAAGACGGTG  
GCGTCGTTACTGTAACCCAGGATTCAGGTTTGCAGGATGGCTGTTTCATCTACAAGT  
CAAGTTCATTGGCGTTGAACCTTCCTTCCGATGGACCTGTTATGCAAAAGAAGACAA  
TGGGCTGGGAAGCCAGCACTGAGCGTTTGTATCCTCGTGATGGCGTGTGAAAGGAG  
AGATTTCATAAGGCTCTGAAGCTGAAAGACGGTGGTCATTACCTAGTTGAATTCAAA  
GTATTTCATGGCAAGAAGCCTGTGCAGCTACCAGGGTACTACTATGTTGACTCCA  
AACTGGATATAACAAGCCACAACGAAGACTATACAATCGTTGAGCAGTATGAAAGAA  
CCGAGGGACGCCACCATCTGTTCTTTAAGGCTGAACCTTGCGTCAGACGTGGGTGAG  
CGGTAATGACCACAAAGGCAGCGAAGAAAACCATGATCGTTTTTTTAGGTTGGC  
AGCCTGAAATCGTAGGAAATACATCAGAAATGTTACAAACAGG (SEQ ID NO:11)

amino acid sequence of drFP583

Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val  
Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu  
Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val  
Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln  
Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro  
Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val  
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser  
Leu Gln Asp Gly Cys Phe Ile Tyr Lys Ser Ser Ser Leu Ala Leu Asn  
Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu  
Ala Ser Thr Glu Arg Leu Gly His Tyr Leu Val Glu Phe Lys Ser Ile  
Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr Tyr Tyr Val Asp  
Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu  
Gln Tyr Glu Arg Thr Glu Gly Arg His His Leu Phe Leu  
(SEQ ID NO:12)

(57) Abstract: Anthozoa derived chromo/fluoroproteins and mutants thereof, as well as nucleic acid compositions encoding the same, are provided. Specific proteins of interest include chromo/fluoroproteins from the following specific anthozoa species: Anemonia majano, Clavularia sp., Zoanthus sp., Zoanthus sp., Discosoma striata, Discosoma sp. "red", Anemonia sulcata, Discosoma sp. "green", Discosoma sp. "magenta", and mutants thereof. Also provided are fragments of the subject proteins and nucleic acids encoding the same, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications that include the subject proteins are provided.

WO 01/27150 A2



- |          |                               |   |
|----------|-------------------------------|---|
| US       | 09/418,922 (CIP)              | (72) Inventors; and   |
| Filed on | 15 October 1999 (15.10.1999)  | (75) Inventors/Applicants ( <i>for US only</i> ): LUKYANOV,         |
| US       | 09/444,341 (CIP)              | Sergey Anatolievich [RU/RU]; ul. Golubinskaya d. 13/1               |
| Filed on | 19 November 1999 (19.11.1999) | kv.161, Moscow (RU). FRADKOV, Arcady Fedorovich                     |
| US       | 09/444,338 (CIP)              | [RU/RU]; ul. Dnepropetrovskaya, 35/2-14, Moscow,                    |
| Filed on | 19 November 1999 (19.11.1999) | 113570 (RU). LABAS, Yulii Aleksandrovich [RU/RU];                   |
| US       | 09/458,477 (CIP)              | ul. Generala Tyuleneva, 35-416, Moscow, 117465 (RU).                |
| Filed on | 9 December 1999 (09.12.1999)  | MATZ, Mikhail Vladimirovich [RU/RU]; ul. Teplii stan                |
| US       | 09/457,556 (CIP)              | 7/2-28, Moscow, 117465 (RU). TERSKIKH, Alexey                       |
| Filed on | 9 December 1999 (09.12.1999)  | [RU/US]; 1760 Halford Ave. #163, Santa Clara, CA 95051              |
| US       | 09/458,144 (CIP)              | (US).   |
| Filed on | 9 December 1999 (09.12.1999)  | (74) Agent: FIELD, Bret, E.; Bozicevic, Field & Francis LLP,        |
| US       | 09/457,898 (CIP)              | Suite 200, 200 Middlefield Road, Menlo Park, CA 94025               |
| Filed on | 9 December 1999 (09.12.1999)  | (US).   |
| US       | 60/211,627 (CIP)              | (81) Designated States ( <i>national</i> ): AE, AG, AL, AM, AT, AU, |
| Filed on | 14 June 2000 (14.06.2000)     | AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,                 |
| US       | 60/211,687 (CIP)              | DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,                 |
| Filed on | 14 June 2000 (14.06.2000)     | HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,             |
| US       | 60/211,609 (CIP)              | LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,                     |
| Filed on | 14 June 2000 (14.06.2000)     | NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,             |
| US       | 60/211,626 (CIP)              | TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.                         |
| Filed on | 14 June 2000 (14.06.2000)     | (84) Designated States ( <i>regional</i> ): ARIPO patent (GH, GM,   |
| US       | 60/211,607 (CIP)              | KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian                   |
| Filed on | 14 June 2000 (14.06.2000)     | patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European               |
| US       | 60/211,766 (CIP)              | patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,             |
| Filed on | 14 June 2000 (14.06.2000)     | IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,               |
| US       | 60/211,888 (CIP)              | CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).                        |
| Filed on | 14 June 2000 (14.06.2000)     |   |
| US       | 60/212,070 (CIP)              |   |
| Filed on | 14 June 2000 (14.06.2000)     |   |
| US       | PCT/US99/29405 (CIP)          |   |
| Filed on | 10 December 1999 (10.12.1999) |   |
- (71) Applicant (*for all designated States except US*): CLON-TECH LABORATORIES INC. [US/US]; 1020 East Meadow Drive, Palo Alto, CA 94303 (US).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## ANTHOZOA DERIVED CHROMOPHORES/FLUOROPHORES AND METHODS FOR USING THE SAME

### CROSS REFERENCE TO RELATED APPLICATIONS

5 This application is a continuation-in-part of the following applications: application serial no. 09/418,529 filed October 14, 1999; application serial no. 09/418,917 filed October 15, 1999; application serial no. 09/418,922 filed October 15, 1999; application serial no. 09/444,338 filed November 19, 1999; application serial no. 09/444,341 filed November 19, 1999; application serial no. 09/457,556 filed December 9, 1999; application serial no. 09/458,477 filed December 9, 1999; application serial no. 09/458,144 filed  
10 December 9, 1999; application serial no. 09/457,898 filed December 9, 1999; as well as application serial no. 60/211,627 filed on June 14, 2000; application serial no. 60/211,687 filed on June 14, 2000; application serial no. 60/211,609 filed on June 14, 2000; application serial no. 60/211,626 filed on June 14, 2000; application serial no. 60/211,880 filed on June 14, 2000; application serial no. 60/211,607 filed on June 14, 2000; application serial no. 60/211,766 filed on June 14, 2000; application serial no. 60/211,888 filed on June  
15 14, 2000; and application serial no. 60/212/070 filed on June 14, 2000; the disclosures of which applications are herein incorporated by reference. This application also claims priority to International Application Serial No. PCT/US99/29405 filed December 10, 1999.

### INTRODUCTION

#### 20 Field of the Invention

The field of this invention is chromoproteins, specifically fluorescent proteins.

#### Background of the Invention

Labeling is a tool for marking a protein, cell, or organism of interest and plays a prominent role in many biochemistry, molecular biology and medical diagnostic applications. A variety of different labels have  
25 been developed, including radiolabels, chromolabels, fluorescent labels, chemiluminescent labels, etc. However, there is continued interest in the development of new labels. Of particular interest is the development of new protein labels, including chromo- and fluorescent protein labels.

#### Relevant Literature

U.S. Patents of interest include: 6,066,476; 6,020,192; 5,985,577; 5,976,796; 5,968,750; 5,968,738;  
30 5,958,713; 5,919,445 and 5,874,304. Also of interest are: Matz, M.V., *et al.* (1999) *Nature Biotechnol.*, 17:969-973; Living Colors Red Fluorescent Protein (October 1999) *CLONTECHniques XIV* (4):2-6; Living

Colors Enhanced GFP Vectors (April 1996) *CLONTECHniques* XI(2):2-3; Haas, J., *et al.* (1996) *Curr. Biol.* 6:315-324; Rizzuto, R., *et al.* (1996) *Curr. Biol.* 6:183-188; and Kozak, M. (1987) *Nucleic Acids Res.* 15:8125-8148; Lukyanov, K., *et al* (2000) *J Biol Chemistry* 275(34):25879-25882.

5

#### SUMMARY OF THE INVENTION

Anthozoa derived chromo/fluoroproteins and mutants thereof, as well as nucleic acid compositions encoding the same, are provided. Specific proteins of interest include chromo/fluoroproteins from the following specific anthozoa species: *Anemonia majano*, *Clavularia* sp., *Zoanthus* sp., *Zoanthus* sp., *Discosoma striata*, *Discosoma* sp. "red", *Anemonia sulcata*, *Discosoma* sp "green", *Discosoma* sp."magenta", and mutants thereof. Also provided are fragments of the subject proteins and nucleic acids encoding the same, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications that include the subject proteins are provided.

15

#### BREIF DESCRIPTION OF THE FIGURES

Figure 1 provides the nucleotide and amino acid sequence of amFP486.  
Figure 2 provides the nucleotide and amino acid sequence of cFP484.  
Figure 3 provides the nucleotide and amino acid sequence of zFP506.  
Figure 4 provides the nucleotide and amino acid sequence of zFP538.  
Figure 5 provides the nucleotide and amino acid sequence of dsFP483.  
Figure 6 provides the nucleotide and amino acid sequence of drFP583.  
Figure 7 provides the nucleotide and amino acid sequence of asFP600.  
Figure 8 provides the nucleotide and amino acid sequence of dgFP512.  
Figure 9 provides the nucleotide and amino acid sequence of dmFP592.

25

#### DEFINITIONS

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual" (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins eds. (1985)); "Transcription and Translation" (B.D. Hames & S.J. Higgins eds. (1984)); "Animal Cell Culture" (R.I. Freshney, ed. (1986)); "Immobilized Cells and Enzymes" (IRL Press, (1986)); B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

35

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in either single stranded form or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.

A DNA "coding sequence" is a DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and synthetic DNA sequences. A polyadenylation signal and transcription termination sequence may be located 3' to the coding sequence.

As used herein, the term "hybridization" refers to the process of association of two nucleic acid strands to form an antiparallel duplex stabilized by means of hydrogen bonding between residues of the opposite nucleic acid strands.

The term "oligonucleotide" refers to a short (under 100 bases in length) nucleic acid molecule.

"DNA regulatory sequences", as used herein, are transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for and/or regulate expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site, as well as protein binding domains responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Various promoters, including inducible promoters, may be used to drive the various vectors of the present invention.

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

A cell has been "transformed" or "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by

mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, heterologous DNA includes coding sequence in a construct where portions of genes from two different sources have been brought together so as to produce a fusion protein product. Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

As used herein, the term "reporter gene" refers to a coding sequence attached to heterologous promoter or enhancer elements and whose product may be assayed easily and quantifiably when the construct is introduced into tissues or cells.

The amino acids described herein are preferred to be in the "L" isomeric form. The amino acid sequences are given in one-letter code (A: alanine; C: cysteine; D: aspartic acid; E: glutamic acid; F: phenylalanine; G: glycine; H: histidine; I: isoleucine; K: lysine; L: leucine; M: methionine; N: asparagine; P: proline; Q: glutamine; R: arginine; S: serine; T: threonine; V: valine; W: tryptophan; Y: tyrosine; X: any residue). NH<sub>2</sub> refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, *J Biol. Chem.*, 243 (1969), 3552-59 is used.

The term "immunologically active" defines the capability of the natural, recombinant or synthetic chromo/fluorescent protein, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. As used herein, "antigenic amino acid sequence" means an amino acid sequence that, either alone or in association with a carrier molecule, can elicit an antibody response in a mammal. The term "specific binding," in the context of antibody binding to an antigen, is a term well understood in the art and refers to binding of an antibody to the antigen to which the antibody was raised, but not other, unrelated antigens.

As used herein the term "isolated" is meant to describe a polynucleotide, a polypeptide, an antibody, or a host cell that is in an environment different from that in which the polynucleotide, the polypeptide, the antibody, or the host cell naturally occurs.

#### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Anthozoa derived chromo/fluoroproteins and mutants thereof, as well as nucleic acid compositions encoding the same, are provided. Specific proteins of interest include chromo/fluoroproteins from the following specific anthozoa species: *Anemonia majano*, *Clavularia* sp., *Zoanthus* sp., *Zoanthus* sp., *Discosoma striata*, *Discosoma* sp. "red", *Anemonia sulcata*, *Discosoma* sp "green", *Discosoma* sp. "magenta", and mutants thereof. Also provided are fragments of the subject proteins and nucleic acids encoding the same, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and

nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications that include the subject proteins are provided. In further describing the subject invention, the subject nucleic acid compositions will be described first, followed by a discussion of the subject protein compositions, antibody compositions and transgenic cells/organisms. Next a review of representative methods in which the subject proteins find use is provided.

Before the subject invention is further described, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

In this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

#### NUCLEIC ACID COMPOSITIONS

As summarized above, the subject invention provides nucleic acid compositions encoding Anthozoa chromo- and fluoroproteins and mutants thereof, as well as fragments and homologues of these proteins. By nucleic acid composition is meant a composition comprising a sequence of DNA having an open reading frame that encodes an Anthozoa chromo/fluoro polypeptide of the subject invention, i.e., an Anthozoa chromo/fluoroprotein gene, and is capable, under appropriate conditions, of being expressed as an Anthozoa chromo/fluoro protein according to the subject invention. Also encompassed in this term are nucleic acids that are homologous, substantially similar or identical to the nucleic acids encoding proteins of the present invention. Thus, the subject invention provides genes and coding sequences thereof encoding the proteins of the subject invention, as well as homologs thereof. The subject nucleic acids are isolated, i.e., are present in other than their natural environment.

Specific nucleic acid compositions of interest are those that encode chromo/fluoroproteins (and mutants thereof) from the following specific anthozoa species: *Anemonia majano*, *Clavularia* sp., *Zoanthus* sp., *Zoanthus* sp., *Discosoma striata*, *Discosoma* sp. "red", *Anemonia sulcata*, *Discosoma* sp "green", *Discosoma* sp. "magenta." Each of these particular types of nucleic acid compositions of interest is now discussed in greater detail individually.

#### *Anemonia majano*

In these embodiments, the nucleic acid compositions are found in, or derived from a nucleic acid found in, an organism from Sub-class Zoantharia, often Order Actiniaria, more often Sub-order Endomyaria,

usually Family Actiniidae, and more usually Genus *Anemonia*, where in many embodiments, the organism is *Anemonia majano*, where the specific protein of interest from *Anemonia majano* is amFP486 (i.e., NFP-1), and homologues/mutants, e.g., Mut15, Mut32, thereof are of particular interest in many embodiments. The wild type cDNA coding sequence for amFP486 is provided in SEQ ID NO: 01.

5  
*Clavularia sp.*

In these embodiments, the nucleic acids are found in or derived from nucleic acids found in organisms from Sub-class Alcyonaria, often Order Stolonifera, and more often the Family Clavulariidae, where the organism is usually from the Genus *Clavularia*, and in certain embodiments, the organism is *Clavularia sp.*, where the specific fluorescent protein from *Clavularia sp.* is cFP484 (i.e., NFP-2), and homologues/mutants, e.g.,  $\Delta 19$  cFP484 and  $\Delta 38$  cFP484, thereof are of particular interest in many embodiments. The wild type cDNA coding sequence for cFP484 is provided in SEQ ID No: 03.

10  
*Zoanthus sp. I*

In these embodiments, the nucleic acids are found in or derived from nucleic acids found in an organism from Sub-class Zoantharia, often Order Zoanthidea, more often Sub-order Brachygnathia, usually Family Zoanthidae, and more usually Genus *Zoanthus*, where in certain embodiments, the organism is *Zoanthus sp.*, where the specific fluorescent protein is zFP506 (i.e., NFP-3), and homologues/mutants, e.g., N65M variant of zFP506, thereof are of particular interest in many embodiments. The wild type cDNA coding sequence for zFP506 is provided in SEQ ID Nos: 05.

20  
*Zoanthus sp. II*

In these embodiments, the nucleic acids are found in or derived from nucleic acids found in an organism from Sub-class Zoantharia, often Order Zoanthidea, more often Sub-order Brachygnathia, usually Family Zoanthidae, and more usually Genus *Zoanthus*, where in certain embodiments, the organism is *Zoanthus sp.*, where the specific fluorescent protein is zFP538 (NFP-4), and homologues/mutants, e.g., M128 variant of zFP538, thereof are of particular interest in many embodiments. The wild type cDNA coding sequence for zFP538 is provided in SEQ ID NO: 07.

30  
*Discosoma striata*

In these embodiments, the nucleic acids are found in or derived from a nucleic acid found in an organism from Sub-class Zoantharia, often Order Corallimopharia, more often Family Discosomatidae, and usually Genus *Discosoma*, where in certain embodiments, the organism is *Discosoma striata*, where the specific fluorescent protein is dsFP483 (NFP-5), and homologues/mutants thereof are of particular interest in many embodiments. The wild type cDNA coding sequence for dsFP483 is provided in SEQ ID NO: 09.



*Discosoma sp. "red"*

In these embodiments, the nucleic acids are found in or derived from nucleic acids found in an organism from Sub-class Zoantharia, often Order Corallimopharia, more often Family Discosomatidae, and usually Genus *Discosoma*, where in certain embodiments, the organism is *Discosoma sp. "red"*, where the specific fluorescent protein is drFP583 (NFP-6), and homologues/mutants thereof, e.g., E5, E8, E5up, E5down, E57, AG4, AG4H, are of particular interest in many embodiments. The wild type cDNA coding sequence for drFP583 is provided in SEQ ID NO: 11.

*Anemonia sulcata*

In these embodiments, the nucleic acid is found in or derived from a nucleic acid found in an organism from Sub-class Zoantharia, often Order Actiniaria, more often Sub-Order Endomyaria, usually Family Actiniidae, and more usually Genus *Anemonia*, e.g., where in certain embodiments the organism is *Anemonia sulcata*, where the specific fluorescent protein asFP600 (NFP-7), and homologues/mutants thereof, e.g. Mut1, are of particular interest in many embodiments. The wild type cDNA coding sequence for asFP600 is provided in SEQ ID NO:14.

*Discosoma sp "green"*

In these embodiments, the nucleic acid is found in or derived from a nucleic acid found in an organism from Sub-class Zoantharia, often Order Corallimopharia, more often Family Discosomatidae, and usually Genus *Discosoma*, where in certain embodiments, the organism is *Discosoma sp. "green"*, where the specific fluorescent protein is dmFP592 (NFP-8), and homologues/mutants thereof are of particular interest in many embodiments. The wild type cDNA coding sequence for dgFP512 is provided in SEQ ID NO: 15.

*Discosoma sp. "magenta"*

In these embodiments, the nucleic acid is a nucleic acid found in or derived from a nucleic acid found in an organism from Sub-class Zoantharia, often Order Corallimopharia, more often Family Discosomatidae, and usually Genus *Discosomam* where in certain embodiments, the organism is *Discosoma sp. "magenta"*, where the specific fluorescent protein is dmFP592 (NFP-9), and homologues/mutants thereof are of particular interest in many embodiments. The wild type cDNA coding sequence for dmFP592 is provided in SEQ ID NO: 17.

In addition to the above described specific nucleic acid compositions, also of interest are homologues of the above sequences. With respect to homologues of the subject nucleic acids, the source of homologous genes may be any species of plant or animal. In certain embodiments, sequence similarity between homologues is at least about 20%, sometimes at least about 25 %, and may be 30 %, 35%, 40%, 50%, 60%, 70% or higher, including 75%, 80%, 85%, 90% and 95% or higher. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 nt long, more usually at least

about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul *et al.* (1990), *J. Mol. Biol.* 215:403-10 (using default settings, i.e. parameters  $w=4$  and  $T=17$ ). The sequences provided herein are essential for recognizing related and homologous nucleic acids in database searches. Of particular interest in certain

5   embodiments are nucleic acids of substantially the same length as the nucleic acid identified as SEQ ID NOS:01 to 17, where by substantially the same length is meant that any difference in length does not exceed about 20 number %, usually does not exceed about 10 number % and more usually does not exceed about 5 number %; and have sequence identity to any of these sequences of at least about 90%, usually at least about 95% and more usually at least about 99% over the entire length of the nucleic acid. In many embodiments, the

10   nucleic acids have a sequence that is substantially similar (i.e. the same as) or identical to the sequences of SEQ ID NOS: 01, 03, 05, 07, 09, 11, 13, 15, or 17. By substantially similar is meant that sequence identity will generally be at least about 60%, usually at least about 75% and often at least about 80, 85, 90, or even 95%.

Nucleic acids encoding mutants of the chromo/fluoroproteins of the invention are also provided.

15   Mutant nucleic acids can be generated by random mutagenesis or targeted mutagenesis, using well-known techniques which are routine in the art.

In some embodiments, chromo- or fluorescent proteins encoded by nucleic acids encoding homologues or mutants have the same fluorescent properties as the wild-type fluorescent protein. In other embodiments, homologue or mutant nucleic acids encode chromo- or fluorescent proteins with altered spectral properties, as

20   described in more detail herein.

Nucleic acids of the subject invention may be cDNA or genomic DNA or a fragment thereof. In certain embodiments, the nucleic acids of the subject invention include one or more of the open reading frame encoding specific fluorescent proteins and polypeptides, and introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but

25   possibly further in either direction. The subject nucleic acids may be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome, as described in greater detail below.

The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 5' and 3' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when

30   present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding the protein.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It may further include 5' and 3' un-translated regions found in the mature mRNA. It

35   may further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, *etc.*, including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kbp or smaller; and

substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue and stage specific expression.

The nucleic acid compositions of the subject invention may encode all or a part of the subject chromo-  
5 /fluorescent proteins. Double or single stranded fragments may be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, *etc.* For the most part, DNA fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and may be at least about 50 nt. In some embodiments, the subject nucleic acid molecules may be about 100 nt, about 200 nt, about 300 nt, about 400 nt, about 500 nt, about 600 nt, about 700 nt, or  
10 about 720 nt in length. The subject nucleic acids may encode fragments of the subject proteins or the full-length proteins, e.g., the subject nucleic acids may encode polypeptides of about 25 aa, about 50 aa, about 75 aa, about 100 aa, about 125 aa, about 150 aa, about 200 aa, about 210 aa, about 220 aa, about 230 aa, or about 240 aa, up to the entire protein.

The subject nucleic acids are isolated and obtained in substantial purity, generally as other than an  
15 intact chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a nucleic acid of the subject invention or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The subject polynucleotides (*e.g.*, a polynucleotide having a sequence of SEQ ID NOS: 01 to 17 *etc.*),  
20 the corresponding cDNA, the full-length gene and constructs of the subject polynucleotides are provided. These molecules can be generated synthetically by a number of different protocols known to those of skill in the art. Appropriate polynucleotide constructs are purified using standard recombinant DNA techniques as described in, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY, and under current regulations described in United States Dept.  
25 of HHS, National Institute of Health (NIH) Guidelines for Recombinant DNA Research.

Also provided are nucleic acids that encode fusion proteins of the subject proteins, or fragments thereof, which are fused to a second protein, *e.g.*, a degradation sequence, a signal peptide, *etc.* Fusion proteins may comprise a subject polypeptide, or fragment thereof, and a non-anthozoa polypeptide ("the fusion partner") fused in-frame at the N-terminus and/or C-terminus of the subject polypeptide. Fusion  
30 partners include, but are not limited to, polypeptides that can bind antibody specific to the fusion partner (*e.g.*, epitope tags); antibodies or binding fragments thereof; polypeptides that provide a catalytic function or induce a cellular response; ligands or receptors or mimetics thereof; and the like. In such fusion proteins, the fusion partner is generally not naturally associated with the subject anthozoa portion of the fusion protein, and is typically not an anthozoa protein or derivative/fragment thereof, *i.e.*, it is not found in Anthozoa species.

35 Also provided are constructs comprising the subject nucleic acids inserted into a vector, where such constructs may be used for a number of different applications, including propagation, protein production, *etc.* Viral and non-viral vectors may be prepared and used, including plasmids. The choice of vector will depend

on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in culture. Still other vectors are suitable for transfer and expression in cells in a whole animal or person. The choice of appropriate vector is well within the skill of the art. Many such vectors are available commercially. To prepare the constructs, the partial or full-length polynucleotide is inserted into a vector typically by means of DNA ligase attachment to a cleaved restriction enzyme site in the vector. Alternatively, the desired nucleotide sequence can be inserted by homologous recombination in vivo. Typically this is accomplished by attaching regions of homology to the vector on the flanks of the desired nucleotide sequence. Regions of homology are added by ligation of oligonucleotides, or by polymerase chain reaction using primers comprising both the region of homology and a portion of the desired nucleotide sequence, for example.

Also provided are expression cassettes or systems that find use in, among other applications, the synthesis of the subject proteins. For expression, the gene product encoded by a polynucleotide of the invention is expressed in any convenient expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Suitable vectors and host cells are described in U.S. Patent No. 5,654,173. In the expression vector, a subject polynucleotide, e.g., as set forth in SEQ ID NOS:01 to 17, is linked to a regulatory sequence as appropriate to obtain the desired expression properties. These regulatory sequences can include promoters (attached either at the 5' end of the sense strand or at the 3' end of the antisense strand), enhancers, terminators, operators, repressors, and inducers. The promoters can be regulated or constitutive. In some situations it may be desirable to use conditionally active promoters, such as tissue-specific or developmental stage-specific promoters. These are linked to the desired nucleotide sequence using the techniques described above for linkage to vectors. Any techniques known in the art can be used. In other words, the expression vector will provide a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. These control regions may be native to the subject species from which the subject nucleic acid is obtained, or may be derived from exogenous sources.

Expression vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding heterologous proteins. A selectable marker operative in the expression host may be present. Expression vectors may be used for, among other things, the production of fusion proteins, as described above.

Expression cassettes may be prepared comprising a transcription initiation region, the gene or fragment thereof, and a transcriptional termination region. Of particular interest is the use of sequences that allow for the expression of functional epitopes or domains, usually at least about 8 amino acids in length, more usually at least about 15 amino acids in length, to about 25 amino acids, and up to the complete open reading frame of the gene. After introduction of the DNA, the cells containing the construct may be selected by means of a selectable marker, the cells expanded and then used for expression.

The above described expression systems may be employed with prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression. For large scale production of the protein, a unicellular organism, such as *E. coli*, *B. subtilis*, *S. cerevisiae*, insect cells in combination with baculovirus vectors, or cells of a higher organism such as vertebrates, e.g. COS 7 cells, HEK 293, CHO, Xenopus Oocytes, etc., may be used as the expression host cells. In some situations, it is desirable to express the gene in eukaryotic cells, where the expressed protein will benefit from native folding and post-translational modifications. Small peptides can also be synthesized in the laboratory. Polypeptides that are subsets of the complete protein sequence may be used to identify and investigate parts of the protein important for function.

Specific expression systems of interest include bacterial, yeast, insect cell and mammalian cell derived expression systems. Representative systems from each of these categories is provided below:

Bacteria. Expression systems in bacteria include those described in Chang *et al.*, *Nature* (1978) 275:615; Goeddel *et al.*, *Nature* (1979) 281:544; Goeddel *et al.*, *Nucleic Acids Res.* (1980) 8:4057; EP 0 036,776; U.S. Patent No. 4,551,433; DeBoer *et al.*, *Proc. Natl. Acad. Sci. (USA)* (1983) 80:21-25; and Siebenlist *et al.*, *Cell* (1980) 20:269.

Yeast. Expression systems in yeast include those described in Hinnen *et al.*, *Proc. Natl. Acad. Sci. (USA)* (1978) 75:1929; Ito *et al.*, *J. Bacteriol.* (1983) 153:163; Kurtz *et al.*, *Mol. Cell. Biol.* (1986) 6:142; Kunze *et al.*, *J. Basic Microbiol.* (1985) 25:141; Gleeson *et al.*, *J. Gen. Microbiol.* (1986) 132:3459; Roggenkamp *et al.*, *Mol. Gen. Genet.* (1986) 202:302; Das *et al.*, *J. Bacteriol.* (1984) 158:1165; De Louvencourt *et al.*, *J. Bacteriol.* (1983) 154:737; Van den Berg *et al.*, *Bio/Technology* (1990) 8:135; Kunze *et al.*, *J. Basic Microbiol.* (1985) 25:141; Cregg *et al.*, *Mol. Cell. Biol.* (1985) 5:3376; U.S. Patent Nos. 4,837,148 and 4,929,555; Beach and Nurse, *Nature* (1981) 300:706; Davidow *et al.*, *Curr. Genet.* (1985) 10:380; Gaillardin *et al.*, *Curr. Genet.* (1985) 10:49; Ballance *et al.*, *Biochem. Biophys. Res. Commun.* (1983) 112:284-289; Tilburn *et al.*, *Gene* (1983) 26:205-221; Yelton *et al.*, *Proc. Natl. Acad. Sci. (USA)* (1984) 81:1470-1474; Kelly and Hynes, *EMBO J.* (1985) 4:475479; EP 0 244,234; and WO 91/00357.

Insect Cells. Expression of heterologous genes in insects is accomplished as described in U.S. Patent No. 4,745,051; Friesen *et al.*, "The Regulation of Baculovirus Gene Expression", in: *The Molecular Biology Of Baculoviruses* (1986) (W. Doerfler, ed.); EP 0 127,839; EP 0 155,476; and Vlak *et al.*, *J. Gen. Virol.* (1988) 69:765-776; Miller *et al.*, *Ann. Rev. Microbiol.* (1988) 42:177; Carbonell *et al.*, *Gene* (1988) 73:409; Maeda *et al.*, *Nature* (1985) 315:592-594; Lebacqz-Verheyden *et al.*, *Mol. Cell. Biol.* (1988) 8:3129; Smith *et al.*, *Proc. Natl. Acad. Sci. (USA)* (1985) 82:8844; Miyajima *et al.*, *Gene* (1987) 58:273; and Martin *et al.*, *DNA* (1988) 7:99. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts are described in Luckow *et al.*, *Bio/Technology* (1988) 6:47-55, Miller *et al.*, *Generic Engineering* (1986) 8:277-279, and Maeda *et al.*, *Nature* (1985) 315:592-594.

Mammalian Cells. Mammalian expression is accomplished as described in Dijkema *et al.*, *EMBO J.* (1985) 4:761, Gorman *et al.*, *Proc. Natl. Acad. Sci. (USA)* (1982) 79:6777, Boshart *et al.*, *Cell* (1985) 41:521 and U.S. Patent No. 4,399,216. Other features of mammalian expression are facilitated as described

in Ham and Wallace, *Meth. Enz.* (1979) 58:44, Barnes and Sato, *Anal. Biochem.* (1980) 102:255, U.S. Patent Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, WO 90/103430, WO 87/00195, and U.S. RE 30,985.

When any of the above host cells, or other appropriate host cells or organisms, are used to replicate and/or express the polynucleotides or nucleic acids of the invention, the resulting replicated nucleic acid,  
5 RNA, expressed protein or polypeptide, is within the scope of the invention as a product of the host cell or organism. The product is recovered by any appropriate means known in the art.

Once the gene corresponding to a selected polynucleotide is identified, its expression can be regulated in the cell to which the gene is native. For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence inserted into the genome of the cell at location sufficient to at least enhance  
10 expressed of the gene in the cell. The regulatory sequence may be designed to integrate into the genome via homologous recombination, as disclosed in U.S. Patent Nos. 5,641,670 and 5,733,761, the disclosures of which are herein incorporated by reference, or may be designed to integrate into the genome via non-homologous recombination, as described in WO 99/15650, the disclosure of which is herein incorporated by reference. As such, also encompassed in the subject invention is the production of the subject proteins without  
15 manipulation of the encoding nucleic acid itself, but instead through integration of a regulatory sequence into the genome of cell that already includes a gene encoding the desired protein, as described in the above incorporated patent documents.

Also provided are homologs of the subject nucleic acids. Homologs are identified by any of a number of methods. A fragment of the provided cDNA may be used as a hybridization probe against a cDNA library  
20 from the target organism of interest, where low stringency conditions are used. The probe may be a large fragment, or one or more short degenerate primers. Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 6×SSC (0.9 M sodium chloride/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in 1×SSC (0.15 M sodium chloride/0.015 M sodium citrate). Sequence identity may be determined by hybridization under stringent  
25 conditions, for example, at 50°C or higher and 0.1×SSC (15 mM sodium chloride/0.15 mM sodium citrate). Nucleic acids having a region of substantial identity to the provided sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided sequences under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes.

Also of interest are promoter elements of the subject genomic sequences, where the sequence of the 5'  
30 flanking region may be utilized for promoter elements, including enhancer binding sites, e.g., that provide for regulation of expression in cells/tissues where the subject proteins gene are expressed.

Also provided are small DNA fragments of the subject nucleic acids, which fragments are useful as primers for PCR, hybridization screening probes, etc. Larger DNA fragments, i.e., greater than 100 nt are useful for production of the encoded polypeptide, as described in the previous section. For use in geometric  
35 amplification reactions, such as geometric PCR, a pair of primers will be used. The exact composition of the primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art. It is preferable to choose a pair of primers

that will generate an amplification product of at least about 50 nt, preferably at least about 100 nt. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. Amplification primers hybridize to complementary strands of DNA, and will prime towards each other.

5           The DNA may also be used to identify expression of the gene in a biological specimen. The manner in which one probes cells for the presence of particular nucleotide sequences, as genomic DNA or RNA, is well established in the literature. Briefly, DNA or mRNA is isolated from a cell sample. The mRNA may be amplified by RT-PCR, using reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the subject DNA sequences. Alternatively, 10 the mRNA sample is separated by gel electrophoresis, transferred to a suitable support, *e.g.* nitrocellulose, nylon, *etc.*, and then probed with a fragment of the subject DNA as a probe. Other techniques, such as oligonucleotide ligation assays, *in situ* hybridizations, and hybridization to DNA probes arrayed on a solid chip may also find use. Detection of mRNA hybridizing to the subject sequence is indicative of Anthozoa protein gene expression in the sample.

15           The subject nucleic acids, including flanking promoter regions and coding regions, may be mutated in various ways known in the art to generate targeted changes in promoter strength, sequence of the encoded protein, properties of the encoded protein, including fluorescent properties of the encoded protein, *etc.* The DNA sequence or protein product of such a mutation will usually be substantially similar to the sequences provided herein, *e.g.* will differ by at least one nucleotide or amino acid, respectively, and may differ by at 20 least two but not more than about ten nucleotides or amino acids. The sequence changes may be substitutions, insertions, deletions, or a combination thereof. Deletions may further include larger changes, such as deletions of a domain or exon, *e.g.* of stretches of 10, 20, 50, 75, 100, 150 or more aa residues. Techniques for *in vitro* mutagenesis of cloned genes are known. Examples of protocols for site specific mutagenesis may be found in Gustin *et al.* (1993), *Biotechniques* 14:22; Barany (1985), *Gene* 37:111-23; Colicelli *et al.* (1985), *Mol. Gen.* 25 *Genet.* 199:537-9; and Prentki *et al.* (1984), *Gene* 29:303-13. Methods for site specific mutagenesis can be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, CSH Press 1989, pp. 15.3-15.108; Weiner *et al.* (1993), *Gene* 126:35-41; Sayers *et al.* (1992), *Biotechniques* 13:592-6; Jones and Winistorfer (1992), *Biotechniques* 12:528-30; Barton *et al.* (1990), *Nucleic Acids Res* 18:7349-55; Marotti and Tomich (1989), *Gene Anal. Tech.* 6:67-70; and Zhu (1989), *Anal Biochem* 177:120-4. Such mutated nucleic acid 30 derivatives may be used to study structure-function relationships of a particular chromo/ fluorescent protein, or to alter properties of the protein that affect its function or regulation.

Of particular interest in many embodiments is the following specific mutation protocol, which protocol finds use in mutating chromoproteins into fluorescent mutants. In this protocol, the sequence of the candidate protein is aligned with the amino acid sequence of *Aequorea victoria* wild type GFP, according to 35 the protocol reported in Matz *et al.*, "Fluorescent proteins from nonbioluminescent Anthozoa species," *Nature Biotechnology* (October 1999) 17: 969-973. Residue 148 of the chromoprotein is identified and then changed to Ser, *e.g.*, by site directed mutagenesis, which results in the production of a fluorescent mutant of the wild

type chromoprotein. See e.g., NFP-7 described below, which wild type protein is a chromoprotein that is mutated into a fluorescent protein by substitution of Ser for the native Ala residue at position 148.

Also of interest are humanized versions of the subject nucleic acids. As used herein, the term "humanized" refers to changes made to the a nucleic acid sequence to optimize the codons for expression of the protein in human cells (Yang et al., *Nucleic Acids Research* 24 (1996), 4592-4593).

In many embodiments, proteins found in bioluminescent species are not included within the scope of the invention. In certain embodiments, the GFP homolog and nucleic acids encoding the same from *Renilla reniformis* are not included within the scope of the subject invention.

#### 10 PROTEIN/POLYPEPTIDE COMPOSITIONS

Also provided by the subject invention are Anthozoa chromo- and fluorescent proteins and mutants thereof, as well as polypeptide compositions related thereto. As the subject proteins are chromoproteins, they are colored proteins, which may be fluorescent, low or non- fluorescent. As used herein, the terms chromoprotein and fluorescent protein do not include luciferases, such as *Renilla luciferase*. The term polypeptide composition as used herein refers to both the full-length protein, as well as portions or fragments thereof. Also included in this term are variations of the naturally occurring protein, where such variations are homologous or substantially similar to the naturally occurring protein, and mutants of the naturally occurring proteins, as described in greater detail below. The subject polypeptides are present in other than their natural environment.

In many embodiments, the subject proteins have an absorbance maximum ranging from about 300 to 700, usually from about 350 to 650 and more usually from about 400 to 600 nm. Where the subject proteins are fluorescent proteins, by which is meant that they can be excited at one wavelength of light following which they will emit light at another wavelength, the excitation spectra of the subject proteins typically ranges from about 300 to 700, usually from about 350 to 650 and more usually from about 400 to 600 nm while the emission spectra of the subject proteins typically ranges from about 400 to 800, usually from about 425 to 775 and more usually from about 450 to 750 nm. The subject proteins generally have a maximum extinction coefficient that ranges from about 10,000 to 50,000 and usually from about 15,000 to 45,000. The subject proteins typically range in length from about 150 to 300 and usually from about 200 to 300 amino acid residues, and generally have a molecular weight ranging from about 15 to 35 kDa, usually from about 17.5 to 32.5 kDa.

In certain embodiments, the subject proteins are bright, where by bright is meant that the chromoproteins and their fluorescent mutants can be detected by common methods (e.g., visual screening, spectrophotometry, spectrofluorometry, fluorescent microscopy, by FACS machines, etc.) Fluorescence brightness of particular fluorescent proteins is determined by its quantum yield multiplied by maximal extinction coefficient. Brightness of a chromoproteins may be expressed by its maximal extinction coefficient.

In certain embodiments, the subject proteins fold rapidly following expression in the host cell. By rapidly folding is meant that the proteins achieve their tertiary structure that gives rise to their chromo- or



fluorescent quality in a short period of time. In these embodiments, the proteins fold in a period of time that generally does not exceed about 3 days, usually does not exceed about 2 days and more usually does not exceed about 1 day.

Specific proteins of interest are chromo/fluoroproteins (and mutants thereof) from the following specific anthozoa species: *Anemonia majano*, *Clavularia* sp., *Zoanthus* sp., *Zoanthus* sp., *Discosoma striata*, *Discosoma* sp. "red", *Anemonia sulcata*, *Discosoma* sp "green", *Discosoma* sp."magenta." Each of these particular types of polypeptide compositions of interest is now discussed in greater detail individually.

#### *Anemonia majano*

The proteins of this embodiment have an absorbance maximum ranging from about 250 to 650, usually from about 400 to 500 and more usually from about 440 to 480 nm while the emission maximum typically ranges from about 270 to 670, usually from about 420 to 520 and more usually from about 460 to 500 nm. The subject proteins typically range in length from about 200 to 250, usually from about 210 to 240 amino acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22.50 to 27.50 kDa. Of particular interest in many embodiments is amFP486 (NFP-1), which has an amino acid sequence as shown in SEQ ID NO:02. Also of interest are mutants of this sequence, e.g., Mut15, Mut32, and the like.

#### *Clavularia* sp.

The proteins of this embodiment have an absorbance maximum that typically ranges from about 250 to 650, usually from about 400 to 500 and more usually from about 440 to 480 nm and an emission maximum that typically ranges from about 270 to 670, usually from about 420 to 520 and more usually from about 460 to 500 nm, where the subject proteins typically range in length from about 225 to 300, usually from about 250 to 275 amino acid residues, and generally have a molecular weight ranging from about 25 to 35, usually from about 27.50 to 32.50 kDa. Of particular interest is the cFP484 protein having the sequence shown in SEQ ID NO:04, as well as mutants thereof, e.g.,  $\Delta 19$  cFP484 and  $\Delta 38$  cFP484 (NFP-2), and the like.

#### *Zoanthus* sp I.

The proteins of this embodiment have an absorbance maximum that typically ranges from about 300 to 700, usually from about 450 to 550 and more usually from about 480 to 510 nm and an emission maximum that typically ranges from about 320 to 720, usually from about 470 to 570 and more usually from about 500 to 530 nm. The subject proteins typically range in length from about 200 to 250, usually from about 220 to 240 amino acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22.50 to 27.50 kDa. Of particular interest is the protein zFP506 (NFP-3) which has an amino acid sequence as shown in SEQ ID NO:06, as well as mutants of this protein, e.g., the N65M variant, and the like.

*Zoanthus sp. II*

The proteins of this embodiment have an excitation maximum that typically ranges from about 300 to 650, usually from about 475 to 575 and more usually from about 500 to 550 nm and an emission maximum that typically ranges from about 310 to 660, usually from about 485 to 585 and more usually from about 510 to 560 nm. The subject proteins typically range in length from about 200 to 250, usually from about 220 to 240 amino acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22.50 to 27.50 kDa. Of particular interest is the protein sFP538 (NFP-4) which has an amino acid sequence as shown in SEQ ID NO:08, as well as mutants thereof, e.g., the M128 variant, etc.

10 *Discosoma striata*

The proteins of this embodiment have an excitation maximum that typically ranges from about 240 to 640, usually from about 500 to 600 and more usually from about 530 to 560 nm and an emission maximum that typically ranges from about 280 to 680, usually from about 540 to 640 and more usually from about 570 to 600 nm. The subject proteins typically range in length from about 200 to 250, usually from about 220 to 240 amino acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22.50 to 27.50 kDa. Of particular interest in many embodiments is the protein dsFP483 (NFP-5) which has an amino acid sequence as shown in SEQ ID NO:10, as well as mutants thereof.

*Discosoma sp. "red"*

20 The proteins of this embodiment have an absorbance maximum that typically ranges from about 250 to 750, usually from about 500 to 600 and more usually from about 540 to 580 nm and have an emission maximum that typically ranges from about 275 to 775, usually from about 525 to 625 and more usually from about 565 to 605 nm. The subject proteins typically range in length from about 200 to 250, usually from about 220 to 240 amino acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22.50 to 27.50 kDa. Of particular interest is the drFP583 (NFP-6) protein that has an amino acid sequence as shown in SEQ ID NO:12, as well as mutants thereof, e.g., E5, E8, E5up, E5down, E57, AG4, AG4H, etc.

*Anemonia sulcata*

30 The proteins of this embodiment have an absorbance maximum that typically ranges from about 370 to 770, usually from about 520 to 620 and more usually from about 560 to 580 nm and an emission maximum that typically ranges from about 395 to 795, usually from about 545 to 645 and more usually from about 585 to 605 nm. The subject proteins typically range in length from about 200 to 250, usually from about 220 to 240 amino acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22.50 to 27.50 kDa. Of particular interest is the asFP600 (NFP-7) protein that has an amino acid sequence as shown in SEQ ID NO:14, as well as mutants thereof, e.g. Mut1, etc.

*Discosoma sp. "green"*

The proteins of this embodiment have an absorbance maximum that typically ranges from about 300 to 700, usually from about 450 to 650 and more usually from about 490 to 510 nm and an emission maximum that typically ranges from about 310 to 710, usually from about 460 to 660 and more usually from about 500 to 520 nm. The subject proteins typically range in length from about 200 to 250, usually from about 220 to 240 amino acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22.50 to 27.50 kDa. Of particular interest is the dgFP512 protein (NFP-8) protein that has an amino acid sequence as shown in SEQ ID NO:16, as well as mutants thereof.

10 *Discosoma sp. "magenta"*

The proteins of this embodiment have an absorbance maximum that typically ranges from about 375 to 775, usually from about 525 to 625 and more usually from about 560 to 590 nm and an emission maximum that typically ranges from about 395 to 795, usually from about 545 to 645 and more usually from about 580 to 610 nm. The subject proteins typically range in length from about 200 to 250, usually from about 220 to 240 amino acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22.50 to 27.50 kDa. Of particular interest is the dmFP592 (NFP-9) protein that has an amino acid sequence as shown in SEQ ID NO:18, as well as mutants thereof.

Homologs or proteins (or fragments thereof) that vary in sequence from the above provided specific amino acid sequences of the subject invention, i.e., SEQ ID NOS: 02 to 18, are also provided. By homolog is meant a protein having at least about 10%, usually at least about 20 % and more usually at least about 30 %, and in many embodiments at least about 35 %, usually at least about 40% and more usually at least about 60 % amino acid sequence identity to the protein of the subject invention, as determined using MegAlign, DNASTAR (1998) clustal algorithm as described in D. G. Higgins and P.M. Sharp, "Fast and Sensitive multiple Sequence Alignments on a Microcomputer," (1989) CABIOS, 5: 151-153. (Parameters used are ktuple 1, gap penalty 3, window, 5 and diagonals saved 5). In many embodiments, homologues of interest have much higher sequence identity, e.g., 65%, 70%, 75%, 80%, 85%, 90% or higher.

Also provided are proteins that are substantially identical to the wild type protein, where by substantially identical is meant that the protein has an amino acid sequence identity to the sequence of wild type protein of at least about 60%, usually at least about 65% and more usually at least about 70 %, where in some instances the identity may be much higher, e.g., 75%, 80%, 85%, 90%, 95% or higher.

In many embodiments, the subject homologues have structural features found in the above provided specific sequences, where such structural features include the  $\beta$ -can fold.

Proteins which are mutants of the above-described naturally occurring proteins are also provided. Mutants may retain biological properties of the wild-type (e.g., naturally occurring) proteins, or may have biological properties which differ from the wild-type proteins. The term "biological property" of the subject proteins includes, but is not limited to, spectral properties, such as absorbance maximum, emission maximum, maximum extinction coefficient, brightness (e.g., as compared to the wild-type protein or another reference

protein such as green fluorescent protein from *A. victoria*), and the like; *in vivo* and/or *in vitro* stability (e.g., half-life); etc. Mutants include single amino acid changes, deletions of one or more amino acids, N-terminal truncations, C-terminal truncations, insertions, etc.

5 Mutants can be generated using standard techniques of molecular biology, e.g., random mutagenesis, and targeted mutagenesis. Several mutants are described herein. Given the guidance provided in the Examples, and using standard techniques, those skilled in the art can readily generate a wide variety of additional mutants and test whether a biological property has been altered. For example, fluorescence intensity can be measured using a spectrophotometer at various excitation wavelengths.

10 Those proteins of the subject invention that are naturally occurring proteins are present in a non-naturally occurring environment, e.g., are separated from their naturally occurring environment. In certain embodiments, the subject proteins are present in a composition that is enriched for the subject protein as compared to its naturally occurring environment. For example, purified protein is provided, where by purified is meant that the protein is present in a composition that is substantially free of non-Anthozoa chromo/fluoroprotein derived proteins, where by substantially free is meant that less than 90 %, usually less than 60 % and more usually less than 50 % of the composition is made up of non-Anthozoa derived  
15 chromoproteins or mutants thereof. The proteins of the subject invention may also be present as an isolate, by which is meant that the protein is substantially free of other proteins and other naturally occurring biologic molecules, such as oligosaccharides, polynucleotides and fragments thereof, and the like, where the term “substantially free” in this instance means that less than 70 %, usually less than 60% and more usually less than 50 % of the composition containing the isolated protein is some other naturally occurring biological  
20 molecule. In certain embodiments, the proteins are present in substantially pure form, where by “substantially pure form” is meant at least 95%, usually at least 97% and more usually at least 99% pure.

In addition to the naturally occurring proteins, polypeptides which vary from the naturally occurring proteins, e.g., the mutant proteins described above, are also provided. Generally such polypeptides include an  
25 amino acid sequence encoded by an open reading frame (ORF) of the gene encoding an Anthozoa protein, including the full length protein and fragments thereof, particularly biologically active fragments and/or fragments corresponding to functional domains, e.g., transmembrane domain, and the like; and including fusions of the subject polypeptides to other proteins or parts thereof. Fragments of interest will typically be at least about 10 aa in length, usually at least about 50 aa in length, and may be as long as 300 aa in length or  
30 longer, but will usually not exceed about 1000 aa in length, where the fragment will have a stretch of amino acids that is identical to the subject protein of at least about 10 aa, and usually at least about 15 aa, and in many embodiments at least about 50 aa in length. In some embodiments, the subject polypeptides are about 25 aa, about 50 aa, about 75 aa, about 100 aa, about 125 aa, about 150 aa, about 200 aa, about 210 aa, about 220 aa, about 230 aa, or about 240 aa in length, up to the entire protein. In some embodiments, a  
35 protein fragment retains all or substantially all of a biological property of the wild-type protein.

The subject proteins and polypeptides may be obtained from naturally occurring sources or synthetically produced. For example, wild type proteins may be derived from biological sources which express

the proteins, e.g., Anthozoa species, such as the specific ones listed above. The subject proteins may also be derived from synthetic means, e.g. by expressing a recombinant gene or nucleic acid coding sequence encoding the protein of interest in a suitable host, as described above. Any convenient protein purification procedures may be employed, where suitable protein purification methodologies are described in Guide to Protein Purification, (Deuthser ed.) (Academic Press, 1990). For example, a lysate may prepared from the original source and purified using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, and the like.

#### ANTIBODY COMPOSITIONS

Also provided are antibodies that specifically bind to the subject fluorescent proteins. Suitable antibodies are obtained by immunizing a host animal with peptides comprising all or a portion of the subject protein. Suitable host animals include mouse, rat sheep, goat, hamster, rabbit, *etc.* The origin of the protein immunogen will generally be an Anthozoa species. The host animal will generally be a different species than the immunogen, *e.g.*, mice, *etc.*

The immunogen may comprise the complete protein, or fragments and derivatives thereof. Preferred immunogens comprise all or a part of the protein, where these residues contain the post-translation modifications found on the native target protein. Immunogens are produced in a variety of ways known in the art, *e.g.*, expression of cloned genes using conventional recombinant methods, isolation from Anthozoa species, *etc.*

For preparation of polyclonal antibodies, the first step is immunization of the host animal with the target protein, where the target protein will preferably be in substantially pure form, comprising less than about 1% contaminant. The immunogen may comprise the complete target protein, fragments or derivatives thereof. To increase the immune response of the host animal, the target protein may be combined with an adjuvant, where suitable adjuvants include alum, dextran, sulfate, large polymeric anions, oil & water emulsions, *e.g.* Freund's adjuvant, Freund's complete adjuvant, and the like. The target protein may also be conjugated to synthetic carrier proteins or synthetic antigens. A variety of hosts may be immunized to produce the polyclonal antibodies. Such hosts include rabbits, guinea pigs, rodents, *e.g.* mice, rats, sheep, goats, and the like. The target protein is administered to the host, usually intradermally, with an initial dosage followed by one or more, usually at least two, additional booster dosages. Following immunization, the blood from the host will be collected, followed by separation of the serum from the blood cells. The Ig present in the resultant antiserum may be further fractionated using known methods, such as ammonium salt fractionation, DEAE chromatography, and the like.

Monoclonal antibodies are produced by conventional techniques. Generally, the spleen and/or lymph nodes of an immunized host animal provide a source of plasma cells. The plasma cells are immortalized by fusion with myeloma cells to produce hybridoma cells. Culture supernatant from individual hybridomas is screened using standard techniques to identify those producing antibodies with the desired specificity. Suitable animals for production of monoclonal antibodies to the human protein include mouse, rat, hamster,

*etc.* To raise antibodies against the mouse protein, the animal will generally be a hamster, guinea pig, rabbit, *etc.* The antibody may be purified from the hybridoma cell supernatants or ascites fluid by conventional techniques, *e.g.* affinity chromatography using protein bound to an insoluble support, protein A sepharose, *etc.*

5           The antibody may be produced as a single chain, instead of the normal multimeric structure. Single chain antibodies are described in Jost *et al.* (1994) J.B.C. 269:26267-73, and others. DNA sequences encoding the variable region of the heavy chain and the variable region of the light chain are ligated to a spacer encoding at least about 4 amino acids of small neutral amino acids, including glycine and/or serine. The protein encoded by this fusion allows assembly of a functional variable region that retains the specificity  
10          and affinity of the original antibody.

          Also of interest in certain embodiments are humanized antibodies. Methods of humanizing antibodies are known in the art. The humanized antibody may be the product of an animal having transgenic human immunoglobulin constant region genes (see for example International Patent Applications WO 90/10077 and WO 90/04036). Alternatively, the antibody of interest may be engineered by recombinant DNA techniques to  
15          substitute the CH1, CH2, CH3, hinge domains, and/or the framework domain with the corresponding human sequence (see WO 92/02190).

          The use of Ig cDNA for construction of chimeric immunoglobulin genes is known in the art (Liu *et al.* (1987) P.N.A.S. 84:3439 and (1987) J. Immunol. 139:3521). mRNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA. The cDNA of interest may be amplified by the  
20          polymerase chain reaction using specific primers (U.S. Patent nos. 4,683,195 and 4,683,202). Alternatively, a library is made and screened to isolate the sequence of interest. The DNA sequence encoding the variable region of the antibody is then fused to human constant region sequences. The sequences of human constant regions genes may be found in Kabat *et al.* (1991) Sequences of Proteins of Immunological Interest, N.I.H. publication no. 91-3242. Human C region genes are readily available from known clones. The choice of  
25          isotype will be guided by the desired effector functions, such as complement fixation, or activity in antibody-dependent cellular cytotoxicity. Preferred isotypes are IgG1, IgG3 and IgG4. Either of the human light chain constant regions, kappa or lambda, may be used. The chimeric, humanized antibody is then expressed by conventional methods.

          Antibody fragments, such as Fv, F(ab')<sub>2</sub> and Fab may be prepared by cleavage of the intact protein,  
30          *e.g.* by protease or chemical cleavage. Alternatively, a truncated gene is designed. For example, a chimeric gene encoding a portion of the F(ab')<sub>2</sub> fragment would include DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.

          Consensus sequences of H and L J regions may be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C  
35          region segments. C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.

Expression vectors include plasmids, retroviruses, YACs, EBV derived episomes, and the like. A convenient vector is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and expressed. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The resulting chimeric antibody may be joined to any strong promoter, including retroviral LTRs, *e.g.* SV-40 early promoter, (Okayama *et al.* (1983) Mol. Cell. Bio. 3:280), Rous sarcoma virus LTR (Gorman *et al.* (1982) P.N.A.S. 79:6777), and moloney murine leukemia virus LTR (Grosschedl *et al.* (1985) Cell 41:885); native Ig promoters, *etc.*

#### TRANSGENICS

The subject nucleic acids can be used to generate transgenic, non-human plants or animals or site specific gene modifications in cell lines. Transgenic cells of the subject invention include on or more nucleic acids according to the subject invention present as a transgene, where included within this definition are the parent cells transformed to include the transgene and the progeny thereof. In many embodiments, the transgenic cells are cells that do not normally harbor or contain a nucleic acid according to the subject invention. In those embodiments where the transgenic cells do naturally contain the subject nucleic acids, the nucleic acid will be present in the cell in a position other than its natural location, *i.e.* integrated into the genomic material of the cell at a non-natural location. Transgenic animals may be made through homologous recombination, where the endogenous locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like.

Transgenic organisms of the subject invention include cells and multicellular organisms, *e.g.*, plants and animals, that are endogenous knockouts in which expression of the endogenous gene is at least reduced if not eliminated. Transgenic organisms of interest also include cells and multicellular organisms, *e.g.*, plants and animals, in which the protein or variants thereof is expressed in cells or tissues where it is not normally expressed and/or at levels not normally present in such cells or tissues.

DNA constructs for homologous recombination will comprise at least a portion of the gene of the subject invention, wherein the gene has the desired genetic modification(s), and includes regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown *et al.* (1990), Meth. Enzymol. 185:527-537.

For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, *e.g.* mouse, rat, guinea pig, *etc.* Such cells are grown on an appropriate fibroblast-feeder

layer or grown in the presence of leukemia inhibiting factor (LIF). When ES or embryonic cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting offspring screened for the construct. By providing for a different phenotype of the blastocyst and the genetically modified cells, chimeric progeny can be readily detected.

The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in *in vitro* culture. The transgenic animals may be any non-human mammal, such as laboratory animals, domestic animals, etc. The transgenic animals may be used in functional studies, drug screening, etc. Representative examples of the use of transgenic animals include those described *infra*.

Transgenic plants may be produced in a similar manner. Methods of preparing transgenic plant cells and plants are described in U.S. Pat. Nos. 5,767,367; 5,750,870; 5,739,409; 5,689,049; 5,689,045; 5,674,731; 5,656,466; 5,633,155; 5,629,470 ; 5,595,896; 5,576,198; 5,538,879; 5,484,956; the disclosures of which are herein incorporated by reference. Methods of producing transgenic plants are also reviewed in Plant Biochemistry and Molecular Biology (eds Lea & Leegood, John Wiley & Sons)(1993) pp 275-295. In brief, a suitable plant cell or tissue is harvested, depending on the nature of the plant species. As such, in certain instances, protoplasts will be isolated, where such protoplasts may be isolated from a variety of different plant tissues, e.g. leaf, hypocotyl, root, etc. For protoplast isolation, the harvested cells are incubated in the presence of cellulases in order to remove the cell wall, where the exact incubation conditions vary depending on the type of plant and/or tissue from which the cell is derived. The resultant protoplasts are then separated from the resultant cellular debris by sieving and centrifugation. Instead of using protoplasts, embryogenic explants comprising somatic cells may be used for preparation of the transgenic host. Following cell or tissue harvesting, exogenous DNA of interest is introduced into the plant cells, where a variety of different techniques are available for such introduction. With isolated protoplasts, the opportunity arise for introduction via DNA-mediated gene transfer protocols, including: incubation of the protoplasts with naked DNA, e.g. plasmids, comprising the exogenous coding sequence of interest in the presence of polyvalent cations, e.g. PEG or PLO; and electroporation of the protoplasts in the presence of naked DNA comprising the exogenous sequence of interest. Protoplasts that have successfully taken up the exogenous DNA are then selected, grown into a callus, and ultimately into a transgenic plant through contact with the appropriate amounts and ratios of stimulatory factors, e.g. auxins and cytokinins. With embryogenic explants, a



convenient method of introducing the exogenous DNA in the target somatic cells is through the use of particle acceleration or "gene-gun" protocols. The resultant explants are then allowed to grow into chimera plants, cross-bred and transgenic progeny are obtained. Instead of the naked DNA approaches described above, another convenient method of producing transgenic plants is *Agrobacterium* mediated transformation. With  
5 *Agrobacterium* mediated transformation, co-integrative or binary vectors comprising the exogenous DNA are prepared and then introduced into an appropriate *Agrobacterium* strain, e.g. *A. tumefaciens*. The resultant bacteria are then incubated with prepared protoplasts or tissue explants, e.g. leaf disks, and a callus is produced. The callus is then grown under selective conditions, selected and subjected to growth media to induce root and shoot growth to ultimately produce a transgenic plant.

10

#### UTILITY

The subject chromoproteins and fluorescent mutants thereof find use in a variety of different applications, where the applications necessarily differ depending on whether the protein is a chromoprotein or a fluorescent protein. Representative uses for each of these types of proteins will be described below, where  
15 the follow described uses are merely representative and are in no way meant to limit the use of the subject proteins to those described below.

#### *Chromoproteins*

The subject chromoproteins of the present invention find use in a variety of different applications.  
20 One application of interest is the use of the subject proteins as coloring agents which are capable of imparting color or pigment to a particular composition of matter. Of particular interest in certain embodiments are non-toxic chromoproteins. The subject chromoproteins may be incorporated into a variety of different compositions of matter, where representative compositions of matter include: food compositions, pharmaceuticals, cosmetics, living organisms, e.g., animals and plants, and the like. Where used as a coloring  
25 agent or pigment, a sufficient amount of the chromoprotein is incorporated into the composition of matter to impart the desired color or pigment thereto. The chromoprotein may be incorporated into the composition of matter using any convenient protocol, where the particular protocol employed will necessarily depend, at least in part, on the nature of the composition of matter to be colored. Protocols that may be employed include, but are not limited to: blending, diffusion, friction, spraying, injection, tattooing, and the like.

30 The chromoproteins may also find use as labels in analyte detection assays, e.g., assays for biological analytes of interest. For example, the chromoproteins may be incorporated into adducts with analyte specific antibodies or binding fragments thereof and subsequently employed in immunoassays for analytes of interest in a complex sample, as described in U.S. Patent No. 4,302,536; the disclosure of which is herein incorporated by reference. Instead of antibodies or binding fragments thereof, the subject chromoproteins or  
35 chromogenic fragments thereof may be conjugated to ligands that specifically bind to an analyte of interest, or other moieties, growth factors, hormones, and the like; as is readily apparent to those of skill in the art.

In yet other embodiments, the subject chromoproteins may be used as selectable markers in recombinant DNA applications, e.g., the production of transgenic cells and organisms, as described above. As such, one can engineer a particular transgenic production protocol to employ expression of the subject chromoproteins as a selectable marker, either for a successful or unsuccessful protocol. Thus, appearance of the color of the subject chromoprotein in the phenotype of the transgenic organism produced by a particular process can be used to indicate that the particular organism successfully harbors the transgene of interest, often integrated in a manner that provides for expression of the transgene in the organism. When used as a selectable marker, a nucleic acid encoding for the subject chromoprotein can be employed in the transgenic generation process, where this process is described in greater detail supra. Particular transgenic organisms of interest where the subject proteins may be employed as selectable markers include transgenic plants, animals, bacteria, fungi, and the like.

In yet other embodiments, the chromoproteins (and fluorescent proteins) of the subject invention find use in sunscreens, as selective filters, etc., in a manner similar to the uses of the proteins described in WO 00/46233.

#### *Fluorescent Proteins*

The subject fluorescent proteins of the present invention (as well as other components of the subject invention described above) find use in a variety of different applications, where such applications include, but are not limited to, the following. The first application of interest is the use of the subject proteins in fluorescence resonance energy transfer (FRET) applications. In these applications, the subject proteins serve as donor and/or acceptors in combination with a second fluorescent protein or dye, e.g., a fluorescent protein as described in Matz et al., *Nature Biotechnology* (October 1999) 17:969-973, a green fluorescent protein from *Aequoria victoria* or fluorescent mutant thereof, e.g., as described in U.S. Patent No. 6,066,476; 6,020,192; 5,985,577; 5,976,796; 5,968,750; 5,968,738; 5,958,713; 5,919,445; 5,874,304, the disclosures of which are herein incorporated by reference, other fluorescent dyes, e.g., coumarin and its derivatives, e.g. 7-amino-4-methylcoumarin, aminocoumarin, bodipy dyes, such as Bodipy FL, cascade blue, fluorescein and its derivatives, e.g. fluorescein isothiocyanate, Oregon green, rhodamine dyes, e.g. texas red, tetramethylrhodamine, eosins and erythrosins, cyanine dyes, e.g. Cy3 and Cy5, macrocyclic chelates of lanthanide ions, e.g. quantum dye, etc., chemiluminescent dyes, e.g., luciferases, including those described in U.S. Patent Nos. 5,843,746; 5,700,673; 5,674,713; 5,618,722; 5,418,155; 5,330,906; 5,229,285; 5,221,623; 5,182,202; the disclosures of which are herein incorporated by reference. Specific examples of where FRET assays employing the subject fluorescent proteins may be used include, but are not limited to: the detection of protein-protein interactions, e.g., mammalian two-hybrid system, transcription factor dimerization, membrane protein multimerization, multiprotein complex formation, etc., as a biosensor for a number of different events, where a peptide or protein covalently links a FRET fluorescent combination including the subject fluorescent proteins and the linking peptide or protein is, e.g., a protease specific substrate, e.g., for caspase mediated cleavage, a linker that undergoes conformational change upon receiving a signal which increases or decreases

FRET, e.g., PKA regulatory domain (cAMP-sensor), phosphorylation, e.g., where there is a phosphorylation site in the linker or the linker has binding specificity to phosphorylated/dephosphorylated domain of another protein, or the linker has  $\text{Ca}^{2+}$  binding domain. Representative fluorescence resonance energy transfer or FRET applications in which the subject proteins find use include, but are not limited to, those described in:

5 U.S. Patent Nos. 6,008,373; 5,998,146; 5,981,200; 5,945,526; 5,945,283; 5,911,952; 5,869,255; 5,866,336; 5,863,727; 5,728,528; 5,707,804; 5,688,648; 5,439,797; the disclosures of which are herein incorporated by reference.

The subject fluorescent proteins also find use as biosensors in prokaryotic and eukaryotic cells, e.g. as  $\text{Ca}^{2+}$  ion indicator; as pH indicator, as phosphorylation indicator, as an indicator of other ions, e.g.,

10 magnesium, sodium, potassium, chloride and halides. For example, for detection of Ca ion, proteins containing an EF-hand motif are known to translocate from the cytosol to membranes upon  $\text{Ca}^{2+}$  binding. These proteins contain a myristoyl group that is buried within the molecule by hydrophobic interactions with other regions of the protein. Binding of  $\text{Ca}^{2+}$  induces a conformational change exposing the myristoyl group which then is available for the insertion into the lipid bilayer (called a " $\text{Ca}^{2+}$ -myristoyl switch"). Fusion of  
15 such a EF-hand containing protein to Fluorescent Proteins (FP) could make it an indicator of intracellular  $\text{Ca}^{2+}$  by monitoring the translocation from the cytosol to the plasma membrane by confocal microscopy. EF-hand proteins suitable for use in this system include, but are not limited to: recoverin (1-3), calcineurin B, troponin C, visinin, neurocalcin, calmodulin, parvalbumin, and the like. For pH, a system based on hisactophilins may be employed. Hisactophilins are myristoylated histidine-rich proteins known to exist in  
20 *Dictyostelium*. Their binding to actin and acidic lipids is sharply pH-dependent within the range of cytoplasmic pH variations. In living cells membrane binding seems to override the interaction of hisactophilins with actin filaments. At  $\text{pH} \leq 6.5$  they locate to the plasma membrane and nucleus. In contrast, at pH 7.5 they evenly distribute throughout the cytoplasmic space. This change of distribution is reversible and is attributed to histidine clusters exposed in loops on the surface of the molecule. The reversion of intracellular distribution  
25 in the range of cytoplasmic pH variations is in accord with a pK of 6.5 of histidine residues. The cellular distribution is independent of myristoylation of the protein. By fusing FPs (Fluorescent Proteins) to hisactophilin the intracellular distribution of the fusion protein can be followed by laser scanning, confocal microscopy or standard fluorescence microscopy. Quantitative fluorescence analysis can be done by performing line scans through cells (laser scanning confocal microscopy) or other electronic data analysis  
30 (e.g., using metamorph software (Universal Imaging Corp) and averaging of data collected in a population of cells. Substantial pH-dependent redistribution of hisactophilin-FP from the cytosol to the plasma membrane occurs within 1-2 min and reaches a steady state level after 5-10 min. The reverse reaction takes place on a similar time scale. As such, hisactophilin-fluorescent protein fusion protein that acts in an analogous fashion can be used to monitor cytosolic pH changes in real time in live mammalian cells. Such methods have use in  
35 high throughput applications, e.g., in the measurement of pH changes as consequence of growth factor receptor activation (e.g. epithelial or platelet-derived growth factor) chemotactic stimulation/ cell locomotion, in the detection of intracellular pH changes as second messenger, in the monitoring of intracellular pH in pH

manipulating experiments, and the like. For detection of PKC activity, the reporter system exploits the fact that a molecule called MARCKS (myristoylated alanine-rich C kinase substrate) is a PKC substrate. It is anchored to the plasma membrane via myristoylation and a stretch of positively charged amino acids (ED-domain) that bind to the negatively charged plasma membrane via electrostatic interactions. Upon PKC  
5 activation the ED-domain becomes phosphorylated by PKC, thereby becoming negatively charged, and as a consequence of electrostatic repulsion MARCKS translocates from the plasma membrane to the cytoplasm (called the "myristoyl-electrostatic switch"). Fusion of the N-terminus of MARCKS ranging from the myristoylation motif to the ED-domain of MARCKS to fluorescent proteins of the present invention makes the above a detector system for PKC activity. When phosphorylated by PKC, the fusion protein translocates from  
10 the plasma membrane to the cytosol. This translocation is followed by standard fluorescence microscopy or confocal microscopy e.g. using the Cellomics technology or other High Content Screening systems (e.g. Universal Imaging Corp./Becton Dickinson). The above reporter system has application in High Content Screening, e.g., screening for PKC inhibitors, and as an indicator for PKC activity in many screening scenarios for potential reagents interfering with this signal transduction pathway. Methods of using  
15 fluorescent proteins as biosensors also include those described in U.S. Patent Nos. 972,638; 5,824,485 and 5,650,135 (as well as the references cited therein) the disclosures of which are herein incorporated by reference.

The subject fluorescent proteins also find use in applications involving the automated screening of arrays of cells expressing fluorescent reporting groups by using microscopic imaging and electronic analysis.  
20 Screening can be used for drug discovery and in the field of functional genomics: e.g., where the subject proteins are used as markers of whole cells to detect changes in multicellular reorganization and migration, e.g., formation of multicellular tubules (blood vessel formation) by endothelial cells, migration of cells through Fluoroblok Insert System (Becton Dickinson Co.), wound healing, neurite outgrowth, etc.; where the proteins are used as markers fused to peptides (e.g., targeting sequences) and proteins that allow the detection of  
25 change of intracellular location as indicator for cellular activity, for example: signal transduction, such as kinase and transcription factor translocation upon stimuli, such as protein kinase C, protein kinase A, transcription factor NFkB, and NFAT; cell cycle proteins, such as cyclin A, cyclin B1 and cyclinE; protease cleavage with subsequent movement of cleaved substrate, phospholipids, with markers for intracellular structures such as endoplasmic reticulum, Golgi apparatus, mitochondria, peroxisomes, nucleus, nucleoli,  
30 plasma membrane, histones, endosomes, lysosomes, microtubules, actin) as tools for High Content Screening: co-localization of other fluorescent fusion proteins with these localization markers as indicators of movements of intracellular fluorescent fusion proteins/peptides or as marker alone; and the like. Examples of applications involving the automated screening of arrays of cells in which the subject fluorescent proteins find use include: U.S. Patent No. 5,989,835; as well as WO/0017624; WO 00/26408; WO 00/17643; and WO 00/03246; the  
35 disclosures of which are herein incorporated by reference.

The subject fluorescent proteins also find use in high through-put screening assays. The subject fluorescent proteins are stable proteins with half-lives of more than 24h. Also provided are destabilized

versions of the subject fluorescent proteins with shorter half-lives that can be used as transcription reporters for drug discovery. For example, a protein according to the subject invention can be fused with a putative proteolytic signal sequence derived from a protein with shorter half-life, e.g., PEST sequence from the mouse ornithine decarboxylase gene, mouse cyclin B1 destruction box and ubiquitin, etc. Promoters in signal transduction pathways can be detected using destabilized versions of the subject fluorescent proteins for drug screening, e.g., AP1, NFAT, NFkB, Smad, STAT, p53, E2F, Rb, myc, CRE, ER, GR and TRE, and the like.

The subject proteins can be used as second messenger detectors, e.g., by fusing the subject proteins to specific domains: e.g., PKCgamma Ca binding domain, PKCgamma DAG binding domain, SH2 domain and SH3 domain, etc.

Secreted forms of the subject proteins can be prepared, e.g. by fusing secreted leading sequences to the subject proteins to construct secreted forms of the subject proteins, which in turn can be used in a variety of different applications.

The subject proteins also find use in fluorescence activated cell sorting applications. In such applications, the subject fluorescent protein is used as a label to mark a population of cells and the resulting labeled population of cells is then sorted with a fluorescent activated cell sorting device, as is known in the art. FACS methods are described in U.S. Patent Nos. 5,968,738 and 5,804,387; the disclosures of which are herein incorporated by reference.

The subject proteins also find use as in vivo marker in animals (e.g., transgenic animals). For example, expression of the subject protein can be driven by tissue specific promoters, where such methods find use in research for gene therapy, e.g., testing efficiency of transgenic expression, among other applications. A representative application of fluorescent proteins in transgenic animals that illustrates this class of applications of the subject proteins is found in WO 00/02997, the disclosure of which is herein incorporated by reference.

Additional applications of the subject proteins include: as markers following injection into cells or animals and in calibration for quantitative measurements (fluorescence and protein); as markers or reporters in oxygen biosensor devices for monitoring cell viability; as markers or labels for animals, pets, toys, food, etc.; and the like.

The subject fluorescent proteins also find use in protease cleavage assays. For example, cleavage inactivated fluorescence assays can be developed using the subject proteins, where the subject proteins are engineered to include a protease specific cleavage sequence without destroying the fluorescent character of the protein. Upon cleavage of the fluorescent protein by an activated protease fluorescence would sharply decrease due to the destruction of a functional chromophor. Alternatively, cleavage activated fluorescence can be developed using the subject proteins, where the subject proteins are engineered to contain an additional spacer sequence in close proximity/or inside the chromophor. This variant would be significantly decreased in its fluorescent activity, because parts of the functional chromophor would be divided by the spacer. The spacer would be framed by two identical protease specific cleavage sites. Upon cleavage via the activated protease the spacer would be cut out and the two residual "subunits" of the fluorescent protein would be able

to reassemble to generate a functional fluorescent protein. Both of the above types of application could be developed in assays for a variety of different types of proteases, e.g., caspases, etc.

The subject proteins can also be used in assays to determine the phospholipid composition in biological membranes. For example, fusion proteins of the subject proteins (or any other kind of covalent or non-covalent modification of the subject proteins) that allows binding to specific phospholipids to localize/visualize patterns of phospholipid distribution in biological membranes also allowing colocalization of membrane proteins in specific phospholipid rafts can be accomplished with the subject proteins. For example, the PH domain of GRP1 has a high affinity to phosphatidyl-inositol tri-phosphate (PIP3) but not to PIP2. As such, a fusion protein between the PH domain of GRP1 and the subject proteins can be constructed to specifically label PIP3 rich areas in biological membranes.

Yet another application of the subject proteins is as a fluorescent timer, in which the switch of one fluorescent color to another (e.g. green to red) concomitant with the ageing of the fluorescent protein is used to determine the activation/deactivation of gene expression, e.g., developmental gene expression, cell cycle dependent gene expression, circadian rhythm specific gene expression, and the like

The antibodies of the subject invention, described above, also find use in a number of applications, including the differentiation of the subject proteins from other fluorescent proteins.

#### KITS

Also provided by the subject invention are kits for use in practicing one or more of the above described applications, where the subject kits include a chromo- or fluorescent protein according to the subject methods or a means for making the protein, e.g., a construct comprising a vector that includes a coding region for the subject protein. The protein or construct therefore is present in a suitable storage medium, e.g., buffered solution, typically in a suitable container. Also present in the subject kits may be antibodies to the provided protein. In certain embodiments, the kit comprises a plurality of different vectors each encoding the subject protein, where the vectors are designed for expression in different environments and/or under different conditions, e.g., constitutive expression where the vector includes a strong promoter for expression in mammalian cells, a promoterless vector with a multiple cloning site for custom insertion of a promoter and tailored expression, etc.

The following examples are offered by way of illustration and not by way of limitation.

### EXPERIMENTAL

#### I. Wild-Type Anthozoa Proteins

The following table summarizes the properties of nine specific wild type anthozoa proteins of the subject invention:

**TABLE I**

| NFP | Species                    | Identifier | Absorb.<br>Max.<br>Nm | Emission<br>Max.<br>Nm | Maximum<br>Extinction<br>Coeff. | Relative<br>Quantum<br>Yield* | Relative<br>Brightness<br>** |
|-----|----------------------------|------------|-----------------------|------------------------|---------------------------------|-------------------------------|------------------------------|
| 1   | Anemonia<br>majano         | amFP486    | 458                   | 486                    | 40,000                          | 0.3                           | 0.43                         |
| 2   | Clavularia sp.             | cFP484     | 456                   | 484                    | 35,300                          | 0.6                           | 0.77                         |
| 3   | Zoanthus sp.               | zFP506     | 496                   | 506                    | 35,600                          | 0.79                          | 1.02                         |
| 4   | Zoanthus sp.               | zFP538     | 528                   | 538                    | 20,200                          | 0.52                          | 0.38                         |
| 5   | Discosoma<br>striata       | dsFP483    | 443                   | 483                    | 23,900                          | 0.57                          | 0.50                         |
| 6   | Discosoma<br>sp. "red"     | drFP583    | 558                   | 583                    | 22,500                          | 0.29                          | 0.24                         |
| 7   | Anemonia<br>sulcata        | asFP600    | 572                   | 596                    | 56,200                          | <0.001                        | -                            |
| 8   | Discosoma sp<br>"green"    | dgFP512    | 502                   | 512                    | 20,360                          | 0.3                           | 0.21                         |
| 9   | Discosoma sp.<br>"magenta" | dmFP592    | 573                   | 593                    | 21,800                          | 0.11                          | 0.09                         |

\*relative quantum yield was determined as compared to the quantum yield of *A. victoria* GFP.

\*\*relative brightness is extinction coefficient multiplied by quantum yield divided by the same value for *A. victoria* GFP.

5

## II. amFP486 Characterization and Mutants Thereof

### A. Construction of amFP486 Mutants

Two mutants of amFP486 were generated, Mut15 and Mut32. Compared with wildtype amFP486, Mut15 has the following point mutations: A to G at position 101 (numbered from beginning of ATG); T to C at position 129; AAA to TTG at positions 202-204; C to T at position 240. Mut32 has two amino acid substitutions relative to the wildtype, i.e., Asn-34 to Ser; and Lys-68 to met. Table 2 lists the spectral properties of Mut15 and Mut32.

10

**TABLE 2**

Spectral Properties of the Isolated Mut15 and Mut32

| Species            | NFP<br>Name | Absorbance<br>Maximum<br>nm | Emission<br>Maximum<br>nm | Maximum<br>Extinction<br>Coeff. | Quantum<br>Yield | Relative<br>Brightness<br>* |
|--------------------|-------------|-----------------------------|---------------------------|---------------------------------|------------------|-----------------------------|
| Anemonia<br>majano | Mut15       | 460                         | 485                       | 53,400                          | 0.32             | 0.78                        |
| Anemonia<br>majano | Mut32       | 466                         | 488                       | 36,000                          | 0.42             | 0.69                        |

\*relative brightness is extinction coefficient multiplied by quantum yield divided by the same value for *A. victoria* GFP.

15

### B. Construction and Functional Analysis of Vectors

Mut32 DNA was amplified via PCR and reconstructed to EGFP-N1 backbone with BamHI and NotI restriction enzyme sites. This vector has the same multiple cloning sites as EGFP-N1.

20

Functional tests of the generated vectors was performed by transient transfection in 293 cells. After 24-hour expression, brighter fluorescent intensity and less photobleaching of pCNFPMut32-N1 were observed by microscopy when compared with pECFP-N1 side by side.

Mut32 has fast folding and bright fluorescent intensity, which makes it useful for number of applications. Some fusion proteins were tested, such as PKC-gamma-CNFP. PKC was observed to translocate from cytosol to the plasma membrane when cells were treated with PMA (phorbol 12-myristate 13-acetate).

#### C. Generation of Destabilized amFP486 Vectors as Transcription Reporters

Three destabilized amFP486 vectors were constructed by fusing different mouse ODC degradation domains such as d1, d2 and d376 to the C-terminal of wild type amFP486. The vectors were constructed in EGFP-N1 backbone.

Vectors of pCRE-d1CNFP and pNF- $\kappa$ B-d1CNFP were constructed by placing d1CNFP downstream of cAMP response element (CRE) or NF- $\kappa$ B response element, respectively. Expression of d1CNFP is up-regulated upon activation of these response elements.

#### D. Functional Analysis of Destabilized amFP486

Functional tests of the destabilized amFP486 were performed by transient transfection in 293 cells. After 24-hour expression, the fluorescent intensity was decreased gradually from d2, d1 and d376 because of the fusion with different mouse ODC degradation domains. After 4-hour treatment with protein synthesis inhibitor cycloheximide, d2 fluorescent intensity did not change very much; however, d1 fluorescent intensity decreased further 50% of its original intensity. The half-life of d1 is around 4 hours.

MODCdl is a valuable tool for application as a transcription reporter. However, compared with EGFP-d1 (1-hour half-life), pCNFP-MODCdl half-life (4 hours) is still long, so further mutagenesis for MODC degradation domain is still needed for shorter half-life version.

Functional tests of vectors pCRE-d1CNFP and pNF- $\kappa$ B-d1CNFP were performed by transient transfection in HEK 293 cells. 16 hours post transfection, 10  $\mu$ m forskolin was added to induce CRE and 100 ng/ml TNF-alpha was added to induce NF- $\kappa$ B for 6 hours. Expression of d1CNFP was analysed using FACS Calibur. Up to 7 fold increase of fluorescence in forskolin induced CRE activation and 4 fold increase of fluorescence in TNF-alpha induced NF-KB activation was observed (data not shown).

#### E. Construction and Functional Test for Humanized Mut32 (phCNFP-N1)

Since mammalian expression is a very popular tool, human favored codon version is needed for better expression in mammalian cells. To generate humanized Mut32, the Mut 32 sequence was first changed to human favored codon and 23 oligos (12F and 11R) were designed. Next, four rounds of PCR amplification were performed, each round for 20 cycles. PCR cycle was designed as follows: 94°C for 1 min; 94°C for 1 min; 40°C for 1 min; and 72°C for 1 min. The four rounds were: for 1<sup>st</sup> round, mixing 2  $\mu$ l each of every 4



oligos (60 bp), 5 µl buffer, 1 µl pfu, 1 µl dNTP to make total volume of 50 µl. After 20 cycles of PCR, 5 sets of 150 bp and 1 set of 4 last oligos of 90 bp products were obtained. For 2<sup>nd</sup> round, mixing new crude PCR products 10 µl each, 5 µl buffer, 1 µl pfu, 1 µl dNTP to make total volume of 50 µl. After 20 cycles of PCR, 2 sets of 270 bp and 1 set of 210 bp PCR products were obtained. For 3<sup>rd</sup> round, mixing new crude PCR products. After 20 cycles of PCR, 1 set of 510 bp and 1 set of 450 bp products were obtained. For 4<sup>th</sup> round, mixing new crude products. After 20 cycles of PCR, final PCR product (690 bp) was obtained. Further PCR amplification was performed using 1F and 11R primers. As a result, humanized Mut32 was generated. This humanized Mut32 was constituted into EGFP-N1 backbone.

#### F. Expression of Wildtype and Mutant amFP486 in Mammalian Cells

The original plasmid amFP486 DNAs (wildtype, Mut15 and Mut32 in pQE30) were used to construct N1 version of amFP486 wildtype, Mut15 and Mut32 as described above. The DNAs were inserted into *E. coli* DH5α. HEK 293 cells were transferred with each of the three N1 constructs using Calcium Phosphate method (Clontech product #K2051-1).

The fluorescent intensity of the transfected cells was analyzed on FACS using FL1 (510/30) detecting channel. Five samples were analyzed in parallel for each construct. The observed mean value of FL1 fluorescent intensity of the M1 population of each sample is summarized in Table 3. It shows that the average of the mean value of each construct (Wildtype, Mut15, and Mut32) has no significant difference.

**TABLE 3**

**FL1 Fluorescent Intensity of M1 Population**

| Sample # | Wildtype | Mut15  | Mut32  |
|----------|----------|--------|--------|
| 1        | 82.84    | 106.95 | 84.51  |
| 2        | 77.52    | 108.73 | 91.41  |
| 3        | 111.85   | 97.08  | 91.30  |
| 4        | 113.06   | 90.16  | 98.16  |
| 5        | 104.95   | 86.34  | 111.44 |
| Mean     | 98.04    | 97.85  | 95.36  |

#### G. Generation and Expression of Fusion Protein Mut15-mdm2

The Mut15-mdm2 fusion was generated by the following steps: first, mdm2 DNA was obtained by amplifying human Marathon cDNA library (Burke's Lymphoma) using primers: ATGTGCAATACCAACATGTCTGTACC (SEQ ID No. 19) and CTAGGGGAAATAAGTTAGCAC (SEQ ID No. 20); secondly, the purified PCR product was then amplified with primers:

GGAATTCAGCCATGGTGTGCAATACCAACATGTCTGTACC (SEQ ID No. 21) and

TCCCCCGGGGGGAAATAAGTTAGCAC (SEQ ID No. 22)

in order to add Kozac sequence and restriction sites; thirdly, the purified PCR product from step 2 was digested with EcoR I and Sma I and inserted into EcoR I and SmaI of NFP1Mut15-N1 vector (this vector was

generated using BamH I and Not I sites of the pEGFP-N1 backbone). The generated Mut15-mdm2 fusion was then expressed in HEK293 cells.

#### H. Comparison of the Protein Fluorescent Intensity

5 PQE30 amFP486 wildtype, Mut15 and Mut32 were transformed into DH5 $\alpha$ . The bacteria grew in the presence of 1 mM IPTG overnight to induce the protein expression. Cells were lysed in 100 mM Tris, pH8.0 by sonication. Cell lysate was collected after centrifuge at 3000 rpm for 15 minutes at room temperature. The proteins were purified with TALON Metal Affinity Resin. Briefly, after the protein was absorbed on the resin, the beads were washed in stepwise with first wash, then first elution (50 mM imidazole) and second elution (200 mM imidazole) in 100 mM Tris-HCl, pH 8.0. The protein is found mostly in the second step elution. It was found that Mut32 has the highest bacterial expression level, while Mut15 has the lowest.

15 Samples of each elution fraction were run on SDS-PAGE to check the purity of the proteins. Both wildtype amFP486 and Mut32 show a single band, while Mut15 has two more minor bands with higher molecular weight (data not shown).

20 The protein concentration (fractionII-2) was checked and measured by Bradford assay (Bio-Rad standard assay) using BSA as a standard. The spectra are shown in Figures 8-11. The fluorescence intensity (fraction II-2) was determined with LS50B Luminescence Spectrometer LS50B. EX = 458 nm, EM = 492 nm, both slits = 2.5 nm. Table 4 shows the protein concentration, relative fluorescent (FL) intensity and intensity/ $\mu$ g protein in 700  $\mu$ l volume. It shows that Mut32 is as bright as wildtype, while Mut15 is worse than the wildtype.

**TABLE 4**

|               | Protein Concentration  | Relative FL Intensity | Intensity/ $\mu$ g Protein in 700 $\mu$ l Volume |
|---------------|------------------------|-----------------------|--|
| Wildtype II-2 | 1.26 $\mu$ g/5 $\mu$ l | 37.805/5 $\mu$ l      | 30.00  |
| Mut15II-2     | 0.64 $\mu$ g/5 $\mu$ l | 10.152/5 $\mu$ l      | 15.86  |
| Mut32II-2     | 6.17 $\mu$ g/5 $\mu$ l | 186.474/5 $\mu$ l     | 30.22  |

#### III. Characterization of cFP484 and mutants thereof

##### 25 A. Mutant Generation

Two deletion mutants were generated by two separate PCR reactions:  $\Delta$ 19 cFP484 lacks the N-terminal first 19 amino acids of cFP484, and  $\Delta$ 38 cFP484 lacks the N-terminal first 38 amino acids of cFP484. Mammalian expression vectors containing the DNA encoding the fluorescent protein  $\Delta$ 19 cFP484 or  $\Delta$ 38 cFP484 are generated, which are named as p $\Delta$ 19 NFP2-N1 and p $\Delta$ 38 NFP2-N1, respectively.

30

##### B. Transient Expression of Deletion Mutants of cFP484 in Mammalian Cells

HeLa cells were transiently transfected with mammalian expression vector p $\Delta$ 19 NFP2-N1 which contains the DNA encoding the fluorescent protein  $\Delta$ 19 cFP484. After transfection, cells were incubated for

48 hours at 37°C then fixed in 3.7% formaldehyde. Cells were mounted in mounting medium and observed by fluorescence microscopy. Digital images were taken with MetaMorph software (Universal Imaging Corp.) using a monochrome cooled CCD camera (Roper Scientific). The filter set XF 114 (Omega Optical) was used to visualize fluorescence emitted by  $\Delta 19$  cFP484. The image was pseudocolored.  $\Delta 38$  cFP484 is also  
 5 fluorescent when expressed in HeLa cells.

#### IV. Characterization of zFP506 and Mutants thereof

##### A. Mutant generation

One mutant of zFP506 was generated, N65M. Compared with wild type zFP506, N65M has the  
 10 mutation of from "AAC" to "ATG" which results in the corresponding amino acid change from Asparagine (N) to Methionine (M) at the position of 65. The spectral properties of N65M are listed in Table 5.

**TABLE 5**

##### Spectral Properties of the Isolated N65M

| Species      | NFP Name | Absorbance Maximum Nm | Emission Maximum nm | Maximum Extinction Coeff. | Quantum Yield | Relative Brightness * |
|--------------|----------|-----------------------|---------------------|---------------------------|---------------|-----------------------|
| Zoanthus sp. | N65M     | 496                   | 506                 | 62,000                    | 0.63          | 1.78                  |

15 \*relative brightness is extinction coefficient multiplied by quantum yield divided by the same value for *A. victoria* GFP.

##### B. Construction and Functional Analysis of Vectors

Non-humanized zFP506 DNA was amplified via PCR and reconstructed into EGFP-N1 backbone.  
 20 This vector has the same multiple cloning sites as EGFP-N1. Functional test of the generated vector was performed by transient transfection in 293 cells. 24 hours post transfection, expression of zFP506 was examined under fluorescent microscope. zFP506 showed good fluorescent intensity and comparable to EGFP-N1.

##### 25 C. Generation of Destabilized zFP506 Vectors as Transcription Reporters

Since zFP506 is very stable, it is necessary to generate destabilized versions of zFP506 in order to observe the rapid turnover of the protein. By using the same technology for destabilized EGFP, two destabilized zFP506 vectors were constructed by fusing mouse ODC degradation domain to the C-terminal of zFP506. The d1 version of destabilized zFP506 has three E to A mutations within MODC degradation domain  
 30 comparing to d2 version, therefore result in a shorter half-life of the protein to which MODC degradation domain fused to. Destabilized d1zFP506 and d2zFP506 were constructed in EGFP-N1 backbone

##### D. Functional Analysis of Destabilized zFP506

Wildtype d1zFP506 was transiently transfected into 293 cells. 24 hours after transfection, CHX was  
 35 added to stop protein synthesis. After 4 hour treatment, cells were examined under fluorescent microscope. It

shows that fusion of MODC domain to the zFP506 slightly decreases the fluorescent intensity compared to zFP506 itself. After 4 hour treatment, there is 50% fluorescent intensity decrease.

#### E. Application of Destabilized d1zFP506 as Transcription Reporters

5 Destabilized d1zFP506 was constructed into pCRE-d1GNFP and pNF- $\kappa$ B-d1GNFP vectors. Its expression was regulated under cAMP response element (CRE) or NF- $\kappa$ B response element, respectively. These vectors were transiently transfected into 293 cells, and 24 hours post transfection, the expression of d1GNFP was induced by Forskolin or TNF- $\alpha$ . 6 hours after induction, the culture was analysed by FACS. CRE-d1GNFP showed 7 fold of induction in fluorescence intensity, while 4 fold of induction was obtained in  
10 NF- $\kappa$ B-d1GNFP (data not shown). This demonstrated that the destabilized form of GNFP is applicable as transcription reporters.

#### F. Construction and Functional Test for Humanized zFP506 and Humanized N65M

Since mammalian expression is a very popular tool, human favored codon version is needed for better  
15 expression in mammalian cells. Each piece of human favored codon oligos was linked to form the full length of wild type and/or mutant zFP506 (hGNFP-zFP506; hGNFP-N65M). This humanized zFP506 was constituted into EGFP-N1 backbone.

#### V. Characterization of zFP538 and mutants thereof

20 One mutant of zFP538 was generated, M128V. M128V was generated by introducing a wrong nucleotide in PCR during site-specific mutagenesis at position 65. One bright yellow colony was obtained, and the sequence of this clone was performed. It showed that this clone contained wild type amino acid Lysine (K) at position 65, but had a substitution from Methionine (M) to Valine (V) at position 128 (numbering according to GFP).

25 Further investigations showed that M128V has spectral characteristics very similar to wild type protein zFP538 but folds much faster. Table 6 lists the spectral properties of M128V.

**TABLE 6**

Spectral Properties of the Isolated M128V

| Species      | NFP Name | Absorbance Maximum nm | Emission Maximum nm | Maximum Extinction Coeff. | Quantum Yield | Relative Brightness * |
|--------------|----------|-----------------------|---------------------|---------------------------|---------------|-----------------------|
| Zoanthus sp. | M128V    | 531                   | 540                 | 25,360                    | 0.43          | 0.50                  |

30 \*relative brightness is extinction coefficient multiplied by quantum yield divided by the same value for *A. victoria* GFP.

#### A. Construction and Functional Analysis of Vectors

Both wildtype (wt) and mutant zFP538 DNA were amplified via PCR and reconstructed to EGFP-N1  
35 backbone. This vector has the same multiple cloning sites as EGFP-N1. Both pYNFPwt and pYNFPW128V

keep the same multiple cloning sites as EGFP-N1. Functional test of the generated vectors was performed by transient transfection in 293 cells. After 24-hour expression, pYNFPwt, pYNFPM12V and EYFP were compared side by side: pYNFPwt showed less fluorescent intensity than EYFP (data not shown); however, pYNFPM128V showed as bright fluorescent intensity as EYFP by fluorescent microscopy.

5

#### B. Generation of Destabilized zFP538 Vectors as Transcription Reporters

By using the same technology for destabilized EGFP, destabilized zFP538 vectors were constructed by fusing different mouse ODC degradation domains such as d1 and d2 to the C-terminal of zFP538. The d1 version of destabilized YNFP has three E to A mutations within MODC degradation domain compared to d2 version. Vectors pYNFPM128V-MODCd1 and pYNFPM128V-MODCd2 were constructed in EGFP-N1 backbone.

10

#### C. Functional Analysis of Destabilized zFP538

Functional test of the destabilized zFP538 was performed by transient transfection in 293 cells. After 24-hour expression, the fluorescent intensity was decreased gradually from d2 and d1 because of the fusion with different mouse ODC degradation domains. After 4-hour treatment with protein synthesis inhibitor cycloheximide, d2 fluorescent intensity did not change very much; however, d1 fluorescent intensity decreased further 50% of its original intensity. The half-life of d1 is around 4 hours.

15

M128V has fast folding and bright fluorescent intensity, which makes it useful for number of applications. Some fusion proteins were tested such as PKC-gamma-YNFP (M128V). PKC-gamma was observed to translocate from cytosol to the plasma membrane when cells were treated with PMA (Phorbol 12-Myristate 13-Acetate).

20

#### D. Construction and Functional Test for Humanized M128V

Humanized M128V was generated, and then placed into the pEGFP-N1 backbone. This vector has the same multiple cloning sites as pEGFP-N1. Construction of C1 and pEGFP is in the process.

25

### VI. Characterization of drFP583 and mutants thereof

#### A. Expression in Mammalian Cells

HeLa cells were transfected either with plasmid pDsRed1-N1 (vector containing the DNA encoding drFP583) or plasmid pEGFP-C1 (encoding EGFP from *Aequorea victoria*). Immediately after the transfection, cells were mixed and plated on coverslips. Cells were incubated for 48 hours at 37°C then fixed in 3.7 % formaldehyde. Cells were mounted in mounting medium and observed by fluorescence microscopy. Images were taken from the same field of view with Chroma filter set 31001 for EGFP and filter set 31002 for drFP583 using a cooled CCD camera (Roper Scientific) and MetaMorph software (Universal Imaging). The images were pseudocolored and overlaid. Phase contrast was taken from the same field of view and overlaid.

30

35

## B. Generation of Humanized drFP583

Since mammalian expression is a very popular tool, human favored codon version is needed for better expression in mammalian cells. Humanized drFP583 was therefore generated by changing wild type drFP583 nucleotide sequence to optimize the codons for expression of the fluorescent protein.

## C. Expression of Humanized drFP583 in Mammalian Cells

HeLa cells were transiently co-transfected with plasmids pECFP-Nuc, pEYFP-Tub and pDsRed1-Mito (humanized drFP583). After transfection, cells were incubated for 48 hours at 37 °C then fixed in 3.7 % formaldehyde. Cells were mounted in mounting medium and observed by fluorescence microscopy. Images were taken of one cell co-expressing all three fluorescent proteins with Omega filter set XF 35 for DsRed1-Mito, XF 104 for EYFP-Tub and XF 114 for ECFP-Nuc using a cooled CCD camera (Roper Scientific) and MetaMorph software (Universal Imaging). Individual images were pseudocolored and overlayed to show all three signals in one image. Protein DsRed1-Mito localizes to mitochondria, EYFP-Tub localizes to the microtubular network, and ECFP-Nuc localizes to the nucleus.

As a conclusion, drFP583 does emit to a low extent also in the cyan (ECFP), green (EGFP) and yellow-green (EYFP) emission channels (filter sets). High expression levels or highly concentrated protein in intracellular structures can therefore result in high signal intensities that will give some bleedthrough in the other emission wavelengths. The bleedthrough is small and should not affect multiple labeling recording in most cases.

## D. Mutants of Humanized drFP583

Mutants of humanized drFP583 were generated using error prone PCR technique (Clontech). Mutations occurred at amino acids 42, 71, 105, 120, 161 and 197 (numbering starting from the first Methionine). Table 7 lists the mutants that were generated and their properties.

**TABLE 7**

### Mutants of Humanized drFP583

| Mutant | Mutations                 | Properties  |
|--------|---------------------------|---|
| E5     | V105A, S197T              | Overnight in <i>E. coli</i> emitting green fluorescence; <i>in vitro</i> maturing to red over 28h at 37°C on 80% (retains 20% green peak); folding faster than wild type drFP583 (~28h) |
| E8     | N42H                      | Always two peaks green & red (~1:1) folding faster than E5 (~8h)  |
| E5sup  | V105A                     | red from the beginning; folding faster than E5 (~12h)   |
| E5down | S197T                     | phenotype is similar to E5  |
| E57    | V105A, I161, S197A        | like E5 but folding faster (~8-10h); ~5% of green peak left at the end  |
| AG4    | V71M, V105A, S197T        | bright green, no red at all; fast folding (~16h)  |
| AG4H   | V71M, V105A, Y120H, S197T | like AG4 but twice brighter   |

## E. Characterization and Applications of E5 Mutant

E5 (V105A, S197T) changes its fluorescence from green to red over time both *in vitro* and *in vivo*, in *E. coli* and in mammalian cells. Also, E5 folds faster than wild type drFP583 both in *E. coli* and mammalian cells.

5 Since it allows the "two color" reporting mode for monitoring of the promoter activity, i.e., for both active or shutdown state of the promoter, there is a separate color, serving as an indicator of that state, E5 can be used as a transcriptional reporter. Different from "one color" mode, "two color" mode has a measurable signal (color) present for both states of the process as opposed to "one color" mode (e.g. destabilized GFP) wherein the absence of the color is an indicator of the second state. Namely, newly produced E5 protein  
10 fluoresces in green, indicating on-going promoter activity. Over time, the protein will mature, acquiring the red fluorescence. So if the promoter is no longer active, all the protein will eventually mature, resulting in the dominant red fluorescence. In case the promoter is still active both red and green fluorescence will be readily detected. Thus E5 as a "two color" reporter allows study of gene expression similar to destabilized GFP, but with permanent "signature" of past gene activity in the cells, tissues or entire organism. For example, at the  
15 tissue level, E5 may help to distinguish the stem cells from differentiated cells. Providing the promoter is only active in the stem cells, the E5 reporter will label the stem cell population in green and red, the progenitor cells would be labeled predominantly in red, the terminally differentiated will not fluoresce (due to the titration out of protein during cell division).

E5 can be used for spatial and temporal visualization of newly synthesized vs. accumulated fusion  
20 proteins. That is, E5 could function like a fusion tag. Possible applications envisaged at different organizational levels. At the cellular level, E5 may help to visualize and distinguish the newly synthesized proteins in various compartments such as outer membrane, microvillae, ER, Golgi, mitochondria, nuclei, various components of cellular matrix and focal adhesion complexes. At the tissue level, E5 may be helpful in visualizing newly formed vs. preexisting structures e.g. membrane junctions, components of extracellular  
25 matrix.

One of the most fascinating applications of E5 seems to be in the study of the mother-daughter relationship during the cell division and migration. A wide horizon is opening in the fields of development as well as in the adult organisms to study the cell migration and differentiation. Allowing visualization of the expression "history", E5 can help to distinguishing between the mother cells where the promoter is actually  
30 active vs. the daughter cells containing the accumulated protein but not producing fresh protein anymore. It would enable the study of the cell fates during development and organ remodeling, thus distinguishing between cell migration and cell expansion or differentiation.

In conclusion, E5 is basically applicable to any situation where GFP was previously used. Main advantage is that E5 can track down "the history" of promoter activity or protein localization in cells or  
35 tissues. With a better protein stability than GFP, E5 allows longer analysis window (wild type drFP583 is stable for at least 4 weeks in *Xenopus*, while EGFP starts to faint after two weeks).

#### F. Characterization and Applications of E8 Mutant

E8 (N42H) has two fluorescence maximums, green and red, at all times and it folds much faster than drFP583 (Table 7).

Since it detects both green and red fluorescence simultaneously, E8 may be useful for studying processes related to blood circulation and proteins/cells trafficking. Blood absorbs the green fluorescence; thus only the red fluorescence will be visible while the protein is trafficking in the blood. Both green and red fluorescence could be detected outside the bloodstream making the whole process easy to visualize and record. Monitoring both red and green fluorescence simultaneously may also help to reduce the background fluorescence problems for some tissues or cells.

#### G. Generation of drFP583/dmFP592 Hybrid Using Shuffling Procedure

Non-humanized wild type coding region fragments from drFP583 and dmFP592 were amplified by PCR (22 cycles, 95°C, 15 sec., 68°C 1 min 20 sec.) using 1 ng of corresponding bacterial expression plasmids (pQE-30 derivatives with drFP583 and dmFP592 inserts, respectively) as templates.

##### Oligonucleotides

A (ACATGG ATCCAGGTCTTCCAAGAATGTTATC, SEQ ID No. 23),

B (TAGTACTCG AGCCAAGTTCAGCCTTA, SEQ ID No. 24),

C (ACATGGATCCAG TTGTTC CAAGAATGTGAT, SEQ ID No. 25), and

D (TAGTACTCGAGGCCATTA CCGCTAATC, SEQ ID No. 26)

were used as primers for amplifying these fragments in a concentration of 0.2 mM.

The PCR products were then purified by QIAquick PCR Purification Kit (QIAGEN). Afterwards, the purified fragments drFP583 and dmFP592 (300-500 ng each) were digested with restriction endonucleases EcoRI, HindIII and DraI (10 U each) simultaneously. Reactions were performed in BamHI restriction buffer (NEB) supplemented BSA for 3h at 37°C. Total reaction volume was 30 ml. Upon completion, the resulted restriction fragments from each restriction reaction were separated by electrophoresis in agarose gels (1.5%), cut from gel and purified by QIAquick Gel Purification Kit (QIAGEN). The resulting sets of the purified restriction fragments from both drFP583 and dmFP592 were combined together and 50 ng of them were put into ligation mix (1X T4 DNA ligation buffer, 400 NEB U of T4 DNA ligase) in total volume of 30 ml. The ligation was performed for 3h at room temperature and stopped by heating at 70°C within 20 min.

The ligation mixture was then diluted by water ten-folds, and 1 ml of the dilution was preformed for PCR reaction (20 cycles, 95°C, 15 sec. 68°C 1min 20 sec) as template. Four oligonucleotides A, B, C, and D (SEQ ID Nos. 58-61, respectively) were used simultaneously as primers for amplifying these fragments in a concentration of 0.1 mM each. After electrophoresis in an agarose gel (1.5%), the target fragment was purified by QIAquick Gel Purification Kit (QIAGEN) and digested with restriction endonucleases BamHI and XhoI (30-50 U each) simultaneously in BamH I restriction buffer (NEB) supplemented with BSA for 3h at 37°C. After purification, the resulting fragment was cloned in pQE-30 plasmid linearized by BamHI and Sall. Ligation reaction was performed in 1X T4 DNA ligation buffer and 400 NEB U of T4 DNA ligase with



a total volume of 20 ml for overnight at 16°C. After transformation of *E. coli* cells by 1/5 of the ligation volume and incubation on LB/1% agar plates which were supplemented by 100 mg/ml Ampicillin and 0.1 mM IPTG at 37°C for overnight, the resulting *E. coli* colonies were screened visually under fluorescent microscope using rhodamine filter set. The brightest red colonies were picked up and placed in 200 ml LB medium with 100 mg/ml of Ampicillin. At OD<sub>600</sub>=0.6, the *E. coli* culture was induced by IPTG (final concentration was 1 mM) and the fermentation continued for overnight. Purification of recombinant protein containing N-terminus 6×his tag was performed using TALON metal-affinity resin according to manufacturer's protocol.

#### H. Spectral Properties of drFP583/dmFP592 Hybrid

The emission and excitation spectra for drFP583/dmFP592 hybrid protein are basically the same as for dmFP592. Table 8 lists the spectral properties of drFP583/dmFP592 hybrid protein.

**TABLE 8**

Spectral Properties of drFP583/dmFP592 Hybrid

| nFP Name        | Absorbance Maximum nm | Emission Maximum nm | Maximum Extinction Coeff. | Relative Quantum Yield* | Relative Brightness ** |
|-----------------|-----------------------|---------------------|---------------------------|-------------------------|------------------------|
| drFP583/dmFP592 | 573                   | 592                 | 35,000                    | 0.24                    | 0.3                    |

\*relative quantum yield was determined as compared to the quantum yield of *A. victoria* GFP.

\*\*relative brightness is extinction coefficient multiplied by quantum yield divided by the same value for *A. victoria* GFP.

#### I. Humanized drFP583/dmFP592 Hybrid and Mutants

drFP583/dmFP592 hybrid was humanized. Further, two mutants were generated based on the humanized drFP583/dmFP592, i.e., drFP583/dmFP592-2G and drFP583/dmFP592-Q3. drFP583/dmFP592-2G contains two substitutions, K15Q and T217S. This mutant was derived from the humanized drFP583/dmFP592 hybrid gene by random mutagenesis using Diversity PCR Mutagenesis Kit (Clontech) according to the corresponding protocol. drFP583/dmFP592-Q3 contains three substitutions, K15Q and K83M and T217S. drFP583/dmFP592-Q3 mutant was derived from drFP583/dmFP592-2G mutant by random mutagenesis using Diversity PCR Mutagenesis Kit (Clontech) according to the corresponding protocol.

drFP583/dmFP592-2G has similar brightness and folding rate as for non-humanized drFP583/dmFP592 hybrid. While drFP583/dmFP592-Q3 could be seen in *E. coli* cells as more dark red than parental variant, i.e., drFP583/dmFP592-2G, and the purified protein solution has purple color. drFP583/dmFP592-Q3 has the emission maximum of 616 nm and excitation maximum of 580 nm.

#### J. Applications of Hybrid Mutants

Similar to fluorescent protein drFP583 or dmFP592, drFP583/dmFP592-Q3 can be used as a tool for investigation of protein expression, transport and protein interactions *in vivo*, monitoring of promoter activity,

and as a transcription reporter or fusion tag. Besides, drFP583/dmFP592-Q3 can be chosen as the most convenient partner to one of the existing green fluorescent protein variants in two/triple color labeling assays for simultaneous detection of expression of two or more proteins *in vivo* due to its strongly red-shifted position of emission maximum and practical absence of excitation in green part of spectrum except any spectral overlapping and background fluorescence.

The method of generating drFP583/dmFP592 hybrid can have a general utility for generating hybrid genes (i.e., genes containing parts of different genes in various combinations) with improved fluorescent characteristics.

Additionally, drFP583/dmFP592-Q3 is the first red-shifted mutant, which demonstrates that spectral-shifted mutant could be obtained by random mutagenesis.

## VII. Characterization of asFP600 and Mutants thereof

### A. Mutant Generation

A mutant of asFP600 was generated, Mut1. Compared with wild type asFP600, Mut1 has the following substitutions: T to A at position 70 (numbering according to GFP) and A to S at position 148. Target substitution A148S was generated by means of site-specific mutagenesis using PCR with primers that carried the mutation. During this mutagenesis random substitution T70A was generated by introducing a wrong nucleotide in PCR. The substitution T70A is not necessary for fluorescence and practically does not affect the fluorescence. Table 9 lists the spectral properties of Mut1. Another mutant of asFP600 was generated, having a substitution of the alanine at position 184 to Serine.

**TABLE 9**

**Spectral Properties of the Isolated Mut1**

| Species          | NFP Name | Absorbance Maximum Nm | Emission Maximum nm | Maximum Extinction Coeff. | Quantum Yield | Relative Brightness * |
|------------------|----------|-----------------------|---------------------|---------------------------|---------------|-----------------------|
| Anemonia sulcata | Mut1     | 573                   | 595                 | 15,500                    | 0.05          | 0.03                  |

\*relative brightness is extinction coefficient multiplied by quantum yield divided by the same value for *A. victoria* GFP.

### B. Construction and Functional Analysis of Vectors

Non-humanized mutant asFP600 (RNFP) DNA were amplified via PCR and reconstructed to EGFP-N1 backbone. This vector (pRNFP-N1) has the same multiple cloning sites as EGFP-N1.

Functional test of the generated vector was performed by transient transfection in 293 cells. 24 hours post transfection, expression of asFP600 was examined under fluorescent microscope. asFP600 showed good fluorescent intensity, however, the expression of asFP600 concentrated at the nucleus.

C. Generation of Cytosol Expressed asFP600

Since the nuclear localization of asFP600 limited some of the application of this protein as transcription reporter or pH sensor, cytosol expression of this protein would be needed for this purpose. A nuclear export sequence in humanized codon usage was fused to the N-terminus of asFP600, and placed into the EGFP-N1 vector, resulted in pNE-RNFP.

Functional test of NE-RNFP is performed by transiently transfect the pNE-RNFP into 293 cells. 24 hours post transfection, expression of NE-RNFP is examined under fluorescence microscope. Red fluorescence was observed to be distributed in the cytosol but not in the nucleus.

10 D. Generation of Destabilized asFP600 Vectors as Transcription Reporters

Since asFP600 is very stable, it is necessary to generate destabilized versions of asFP600 in order to observe the rapid turnover of the protein. By using the same technology for destabilized EGFP, two destabilized NE-RNFP vectors were constructed by fusing mouse ODC degradation domain to the C-terminal of NE-RNFP. The d1 version of destabilized RNFP has three E to A mutations within MODC degradation domain comparing to d2 version, therefore result in a shorter half-life of the protein to which MODC degradation domain fused. Destabilized d1RNFP and d2RNFP were constructed in EGFP-N1 backbone.

E. Functional Analysis of Destabilized asFP600

d2 version of the none-humanized asFP600 was transiently transfected into 293 cells. One day after transfection, CHX was added to inhibit protein synthesis. 3 hours after treatment, cells were examined under fluorescent microscope. It showed that fluorescent intensity decreased ~50%.

F. Construction and Functional Test for Humanized Mut1

Humanized Mut1 was generated. The humanized Mut1 was then placed into the pEGFP-N1 backbone. This vector has the same multiple cloning sites as pEGFP-N1. Construction of C1 and pEGFP is in the process.

It is evident from the above discussion and results that the subject invention provides important new chromoproteins and fluorescent proteins and nucleic acids encoding the same, where the subject proteins and nucleic acids find use in a variety of different applications. As such, the subject invention represents a significant contribution to the art.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

5

WHAT IS CLAIMED IS:

1. An Anthozoa chromo- or fluorescent protein present in other than its natural environment.
- 5 2. The protein according to Claim 1, wherein said protein has an absorbance maximum ranging from about 300 to 700 nm.
3. The protein according to Claim 2, wherein said protein has an absorbance maximum ranging from about 350 to 650 nm.
- 10 4. The protein according to Claim 3, wherein said protein has an absorbance maximum ranging from about 400 to 600 nm.
5. The protein according to Claims 1 to 4, wherein said protein has an excitation spectrum ranging from about 300 to 700 nm and an emission spectrum ranging from about 400 to 800 nm.
- 15 6. The protein according to Claim 5, wherein said protein has an excitation spectrum ranging from about 350 to 650 nm and an emission spectrum ranging from about 425 to 775 nm.
- 20 7. The protein according to Claim 6, wherein said protein has an excitation spectrum ranging from about 400 to 600 nm and an emission spectrum ranging from about 450 to 750 nm.
8. The protein according to Claims 1 to 7, wherein said protein has an amino acid sequence substantially the same as or identical to the sequence of SEQ ID NOS: 02, 04, 06, 08, 10, 12, 14, 16, 18.
- 25 9. The protein according to Claim 8, wherein said protein has a sequence identity of at least about 60% with a sequence selected from the group consisting of SEQ ID NOS: 02, 04, 06, 08, 10, 12, 14, 16, 18.
10. The protein according to Claim 9, wherein said protein has a sequence identity of at least about 75% with a sequence selected from the group consisting of SEQ ID NOS: 02, 04, 06, 08, 10, 12, 14, 16, 18.
- 30 11. A fragment of a protein according to Claims 1 to 10.
12. A nucleic acid present in other than its natural environment, wherein said nucleic acid has a nucleotide sequence encoding an Anthozoa chromo- or fluorescent protein according to Claims 1 to 10, or a fragment thereof according to Claim 11.

13. A nucleic acid according to Claim 12, wherein said nucleic acid has a nucleic acid sequence that is substantially the same as or identical to the nucleotide sequence of SEQ ID NOS: 01, 03, 05, 07, 09, 11, 13, 15, 17.
- 5 14. The nucleic acid according to Claim 13, wherein said nucleic acid has a sequence similarity of at least about 60% with a sequence selected from the group consisting of SEQ ID NOS: 01, 03, 05, 07, 09, 11, 13, 15, 17.
- 10 15. The nucleic acid according to Claim 14, wherein said nucleic acid has a sequence similarity of at least about 75% with a sequence selected from the group consisting of SEQ ID NOS: 01, 03, 05, 07, 09, 11, 13, 15, 17.
16. A fragment of the nucleic acid according to Claims 12 to 15.
- 15 17. An isolated nucleic acid or mimetic thereof that hybridizes under stringent conditions to the nucleic acid according to Claims 12 to 16 or its complementary sequence.
18. A construct comprising a vector and a nucleic acid according to Claims 12 to 17.
- 20 19. An expression cassette comprising a transcriptional initiation region functional in an expression host, a nucleic acid having a nucleotide sequence found in the nucleic acid according to Claim 12 to 17 under the transcriptional regulation of said transcriptional initiation region, and a transcriptional termination region functional in said expression host.
- 25 20. A cell, or the progeny thereof, comprising an expression cassette according to Claim 19 as part of an extrachromosomal element or integrated into the genome of a host cell as a result of introduction of said expression cassette into said host cell.
- 30 21. A method of producing a protein according to Claims 1 to 10, said method comprising:  
growing a cell according to Claim 20, whereby said protein is expressed; and  
isolating said protein substantially free of other proteins.
22. An antibody binding specifically to a protein according to Claims 1 to 10 or a fragment according to Claim 11.
- 35 23. The antibody according to Claim 22, wherein said antibody is a polyclonal antibody.

24. The antibody according to Claim 22, wherein said antibody is a monoclonal antibody.
25. A transgenic cell or the progeny thereof comprising transgene selected from the group consisting of a nucleic acids according to any of Claims 12 to 17.
- 5
26. A transgenic organism capable of expressing a protein according to Claims 1 to 10.
27. In an application that employs a chromo- or fluorescent protein, the improvement comprising:  
employing a protein according to Claims 1 to 10.
- 10
28. In an application that employs a nucleic acid encoding a chromo- or fluorescent protein, the improvement comprising:  
employing a nucleic acid according to Claims 12 to 17.
- 15
29. A kit comprising a protein according to Claims 1 to 10 or a means for producing the same.
30. A kit comprising a nucleic acid according to Claims 12 to 17.

1/9

## FIGURE 1

cDNA sequence of wild type amFP486

ATGGCTCTTTCAAACAAGTTTATCGGAGATGACATGAAAATGACCTACC  
ATATGGATGGCTGTGTCAATGGGCATTACTTTACCGTCAAAGGTGAAGG  
CAACGGGAAGCCATACGAAGGGACGCAGACCTCGACTTTTAAAGTCACC  
ATGGCCAACGGTGGGCCCCTTGCAATTCTCCTTTGACATACTATCTACAG  
TGTTCAAGTATGGAAATCGATGCTTTACTGCGTATCCTACCAGTATGCC  
CGACTATTTCAAACAAGCATTTCCTGACGGAATGTCATATGAAAGGACT  
TTTACCTATGAAGATGGAGGAGTTGCTACAGCCAGTTGGGAAATAAGCC  
TTAAAGGCAACTGCTTTGAGCACAAATCCACGTTTCATGGAGTGAACCTT  
TCCTGCTGATGGACCTGTGATGGCGAAGATGACAACTGGTTGGGACCCA  
TCTTTTGAGAAAATGACTGTCTGCGATGGAATATTGAAGGGTGATGTCA  
CCGCGTTCCTCATGCTGCAAGGAGGTGGCAATTACAGATGCCAATTCCA  
CACTTCTTACAAGACAAAAAAACCGGTGACGATGCCACCAAACCATGCG  
GTGGAACATCGCATTGCGAGGACCGACCTTGACAAAGGTGGCAACAGTG  
TTCAGCTGACGGAGCACGCTGTTGCACATATAACCTCTGTTGTCCCTTT  
C (SEQ ID NO:01)

amino acid sequence of wild type amFP486

MALSNKFIGDDMKMTYHMDGCVNGHYFTVKGEENGKPYEGTQTSTFKVTMANGGPLAFSPDILST  
VFKYGNRCFTAYPTS  
MPDYFKQAFPDGMSYERTFTYEDGGVATASWEISLKGNCFEHKSTFHGVNFPADGPVMAKMTTGW  
DPSFEKMTVCDGILK  
GDVTAFLMLQGGGNYRCQFHTSYKTKKPVTMPNHAVEHRIARTDLDKGGNSVQLTEHAVAHITS  
VVPF  
(SEQ ID NO:02)



2/9

Figure 2

## cDNA sequence of wild type cFP484

TATAGGANCATNNGGGNGATTGGGGTCCAAAGCATTGTAACCAACGCAGATAACCCCCAG  
 TGGTNTCAAACGCAGANAACGCGGGAACATTGGAAAATTGANTNTTAAGGAGGCAAGGAA  
 TCGGGAGTAAAGTTGCGAGAACTGAAAAAATGAAGTGTAAATTTGTGTTCTGCCTGTCC  
 TTCTTGGTCCTCGCCATCACAACCGCAACATTTTTTTGAGAAACGAGGCTGACTTAGAA  
 GAGAAGACATTGAGAATACCAAAGCTCTAACCACCATGGGTGTGATTAAACCAGACATG  
 AAGATTAAGCTGAAGATGGAAGGAAATGTAAACGGGCATGCTTTTGTGATCGAAGGAGAA  
 GGAGAAGGAAAGCCTTACGATGGGACACACACTTTAAACCTGGAAGTGAAGGAAGGTGCG  
 CCTCTGCCTTTTTCTTACGATATCTTGTCAAACGCGTTCCAGTACGGAACAGAGCATTG  
 ACAAATATCCAGACGATATAGCAGACTATTTCAAGCAGTCGTTTCCCGAGGGATATTCC  
 TGGGAAAGAACCATGACTTTTGAAGACAAAGGCATTGTCAAAGTGAAAAGTGACATAAGC  
 ATGGAGGAAGACTCCTTTATCTATGAAATTCGTTTTGATGGGATGAACTTTCCTCCCAAT  
 GGTCCGGTTATGCAGAAAAAACTTTGAAGTGGGAACCATCCACTGAGATTATGTACGTG  
 CGTGATGGAGTGCTGGTCGGAGATATTAGCCATTCTCTGTGCTGGAGGGAGGTGGCCAT  
 TACCGATGTGACTTCAAAGTATTTACAAAGCAAAAAAAGTTGTCAAATTGCCAGACTAT  
 CACTTTGTGGACCATCGCATTGAGATCTTGAACCATGACAAGGATTACAACAAAGTAACG  
 CTGTATGAGAAATGCAGTTGCTCGCTATTCTTTGCTGCCAAGTCAGGCCTAGACAACAAGG  
 ATACTGAAAACATATTTGTCTGAGGGTTTGTGTTGTTTTTAAAGACATCAGCTCAGCA  
 TTCGTTAGTTGTAACAAAAATAGCTTTAATTTTTTGGTGGGATTAAATCATAGGGATTG  
 TTTTAGTAATCATTTTGCTTAATAAAAAGTGCCTTG (SEQ ID NO:03)

## amino acid sequence of wild type cFP484

M K C K F V F C L S  
 F L V L A I T N A N I F L R N E A D L E  
 E K T L R I P K A L T T M G V I K P D M  
 K I K L K M E G N V N G H A F V I E G E  
 G E G K P Y D G T H T L N L E V K E G A  
 P L P F S Y D I L S N A F Q Y G N R A L  
 T K Y P D D I A D Y F K Q S F P E G Y S  
 W E R T M T F E D K G I V K V K S D I S  
 M E E D S F I Y E I R F D G M N F P P N  
 G P V M Q K K T L K W E P S T E I M Y V  
 R D G V L V G D I S H S L L L E G G G H  
 Y R C D F K S I Y K A K K V V K L P D Y  
 H F V D H R I E I L N H D K D Y N K V T  
 L Y E N A V A R Y S L L P S Q A (SEQ ID NO:04)

3/9

Figure 3

cDNA sequence of zFP506

ATGGCTCAGTCAAAGCACGGTCTAACAAAAGAAATGACAATGAAATACCGTATG  
GAAGGGTGCATCGATGGACATAAATTTGTGATCACGGGAGAGGGCATTGGATAT  
CCGTTCAAAGGGAAACAGGCTATTAATCTGTGTGTGGTCGAAGGTGGACCATTG  
CCATTTGCCGAAGACATATTGTGAGCTGCCTTTATGTACGGAAACAGGGTTTTC  
ACTGAATATCCTCAAGACATAGCTGACTATTTCAAGAACTCGTGTCTGCTGGT  
TATACATGGGACAGGTCTTTTCTCTTTGAGGATGGAGCAGTTTGCATATGTAAT  
GCAGATATAACAGTGAGTGTTGAAGAAAAGTGCATGTATCATGAGTCCAAATTT  
TATGGAGTGAATTTTCTGCTGATGGACCTGTGATGAAAAAGATGACAGATAAC  
TGGGAGCCATCCTGCGAGAAGATCATACCAGTACCTAAGCAGGGGATATTGAAA  
GGGGATGTCTCCATGTACCTCCTTCTGAAGGATGGTGGGCGTTTACGGTGCCAA  
TTCGACACAGTTTACAAAGCAAAGTCTGTGCCAAGAAAGATGCCGGACTGGCAC  
TTCATCCAGCATAAGCTCACCCGTGAAGACCGCAGCGATGCTAAGAATCAGAAA  
TGGCATCTGACAGAACATGCTATTGCATCCGGATCTGCATTGCCC (SEQ ID  
NO:05)

amino acid sequence of zFP506

MAQSKHGLTKEMTMKYRMEGCVDPGHKFVITGEGIGYPFKGKQAINLCVVEGGPLPFAEDILSAAFMYGNRVFTEYPQ  
DIA  
DYFKNSCPAGYTWDRSFLFEDGAVCICNADITVSVSEENCMYHESKFYGVNFPADGPMKMTDNWEPSCKEIIPVK  
QGI  
LKGDVSMYLLKDGRLRCQFDTVYKAKSVPRKMPDWHFIQHKLTREDRSDAKNQKWLTEHAIASGSALP  
(SEQ ID NO:06)

Figure 4

## cDNA sequence of zFP538

gagttgagtt tctcgacttc agttgtatca attttggggc atcaagcgat ctattttcaa  
 catgggtcat tcaaagcacg gtctaaaaga agaaatgaca atgaaatacc acatggaagg  
 gtgcgtcaac ggacataaat ttgtgatcac gggcgaaggc attggatata cgttcaaagg  
 gaaacagact attaactctgt gtgtgatcga agggggacca ttgccatttt ccgaagacat  
 attgtcagct ggctttaagt acggagacag gatttttact gaatatacctc aagacatagt  
 agactatttc aagaactcgt gtcctgctgg atatacatgg ggcaggctctt ttctctttga  
 ggatggagca gtctgcatat gcaatgtaga tataacagtg agtggtcaaag aaaactgcat  
 ttatcataag agcatattta atggaatgaa ttttctgct gatggacctg tgatgaaaaa  
 gatgacaact aactgggaag catcctgcga gaagatcatg ccagtaccta agcaggggat  
 actgaaaggg gatgtctcca tgtacctcct tctgaaggat ggtgggctgt accggtgcca  
 gttcgacaca gtttacaaaag caaagtctgt gccaaagtaag atgccggagt ggcacttcat  
 ccagcataag ctctccgtg aagaccgcag cgatgctaag aatcagaagt ggcagctgac  
 agagcatgct attgcattcc cttctgcctt ggctgataa gaatgtagtt ccaacatttt  
 aatgcatgtg cttgtcaatt attctgataa aaatgtagtt gagttgaaaa cagacaagta  
 caaataaagc acatgtaaat cgtct (SEQ ID NO:07)

## amino acid sequence of zFP538

Met Ala His Ser Lys His Gly Leu Lys Glu Glu Met Thr Met Lys  
 Tyr His Met Glu Gly Cys Val Asn Gly His Lys Phe Val Ile Thr  
 Gly Glu Gly Ile Gly Tyr Pro Phe Lys Gly Lys Gln Thr Ile Asn  
 Leu Cys Val Ile Glu Gly Gly Pro Leu Pro Phe Ser Glu Asp Ile  
 Leu Ser Ala Gly Phe Lys Tyr Gly Asp Arg Ile Phe Thr Glu Tyr  
 Pro Gln Asp Ile Val Asp Tyr Phe Lys Asn Ser Cys Pro Ala Gly  
 Tyr Thr Trp Gly Ser Phe Leu Phe Glu Asp Gly Ala Val Cys Ile  
 Cys Asn Val Asp Ile Thr Val Ser Val Lys Glu Asn Cys Ile Tyr  
 His Lys Ser Ile Phe Asn Gly Met Asn Phe Pro Ala Asp Gly Pro  
 Val Met Lys Lys Met Thr Thr Asn Trp Glu Ala Ser Cys Glu Lys  
 Ile Met Pro Val Pro Lys Gln Gly Ile Leu Lys Gly Asp Val Ser  
 Met Tyr Leu Leu Leu Lys Asp Gly Gly Arg Tyr Arg Cys Gln Phe  
 Asp Thr Val Tyr Lys Ala Lys Ser Val Pro Ser Lys Met Pro Glu  
 Trp His Phe Ile Gln His Lys Leu Leu Arg Glu Asp Arg Ser Asp  
 Ala Lys Asn Gln Lys Trp Gln Leu Thr Glu His Ala Ile Ala Phe  
 Pro Ser Ala Leu Ala (SEQ ID NO:08)

5/9

FIGURE 5

cDNA sequence of dsFP483

ACGGTCAGGGACACGGTGACCCACTTTGGTATTCTAACAAAATGAGTTGGTCCAAGAGTG  
TGATCAAGGAAGAAATGTTGATCGATCTTCATCTGGAAGGAACGTTCAATGGGCACTACT  
TTGAAATAAAAGGCAAAGGAAAAGGGAAGCCTAATGAAGGCACCAATACCGTCACGCTCG  
AGGTTACCAAGGGTGGACCTCTGCCATTTGGTTGGCATATTTTGTGCCACAATTTTCAGT  
ATGGAACAAGGCATTTGTCCACCACCCTGACGACATACCTGATTATCTAAAGCTGTCAT  
TTCCGGAGGGATATACATGGGAACGGTCCATGCACCTTGAAGACGGTGGCTTGTGTTGTA  
TCACCAATGATATCAGTTTGACAGGCAACTGTTTCAACTACGACATCAAGTTCACTGGCT  
TGAACCTTCTCCAAATGGACCCGTTGTGTCAGAAGAAGACAACCTGGCTGGGAACCGAGCA  
CTGAGCGTTTGTATCCTCGTGATGGCGTGTTGATAGGAGACATCCATCATGCTCTCACAG  
TGGAAGGAGGTGGTCATTACGTATGTGACATTAATACTGTTTACAGGGCCAAGAAGCCCG  
TAAAGATGCCAGGGTATCATTATGTTGACACCAAACCTGGTTATAAGGAGCAACGACAAAG  
AATTCATGAAAGTTGAGGAGCATGAAATCGCCGTTGCACGCCACCATCCGCTCCAAAGCC  
AATGAAGCTTAAGTAAAGCAAAAAGGTGACGAGGCATGATAGTATGACATGATAGTATGA  
CATGATAGTATGACATGATAGTAAGAATTGTAAGCAAAAGGCTTTGCTTATTAACTTGT  
AATTGAAAAC (SEQ ID NO:09)

amino acid sequence of dsFP483

|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|   |   |   |   |   |   |   |   |   |   |   |   | M | S | W | S | K | S | V |   |
| I | K | E | E | M | L | I | D | L | H | L | E | G | T | F | N | G | H | Y | F |
| E | I | K | G | K | G | K | G | K | P | N | E | G | T | N | T | V | T | L | E |
| V | T | K | G | G | P | L | P | F | G | W | H | I | L | C | P | Q | F | Q | Y |
| G | N | K | A | F | V | H | H | P | D | D | I | P | D | Y | L | K | L | S | F |
| P | E | G | Y | T | W | E | R | S | M | H | F | E | D | G | G | L | C | C | I |
| T | N | D | I | S | L | T | G | N | C | F | N | Y | D | I | K | F | T | G | L |
| N | F | P | P | N | G | P | V | V | Q | K | K | T | T | G | W | E | P | S | T |
| E | R | L | Y | P | R | D | G | V | L | I | G | D | I | H | H | A | L | T | V |
| E | G | G | G | H | Y | V | C | D | I | K | T | V | Y | R | A | K | K | P | V |
| K | M | P | G | Y | H | Y | V | D | T | K | L | V | I | R | S | N | D | K | E |
| F | M | K | V | E | E | H | E | I | A | V | A | R | H | H | P | L | Q | S | Q |

(SEQ ID NO:10)

FIGURE 6

## cDNA sequence of drFP583

GTCTCCCAAGCAGTGGTATCAACGCAGAGTACGGGGGAGTTTCAGCCAGTGACGGT  
CAGTGACAGGGTGAGCCACTTGGTATACCAACAAAATGAGGTCTTCCAAGAATGTTA  
TCAAGGAGTTTCATGAGGTTTAAGGTTTCGCATGGAAGGAACGGTCAATGGGCACGAGT  
TTGAAATAGAAGGCGAAGGAGAGGGGAGGCCATACGAAGGCCACAATACCGTAAAGC  
TTAAGGTAACCAAGGGGGGACCTTTGCCATTTGCTTGGGATATTTTGTCAACCAAT  
TTCAGTATGGAAGCAAGGTATATGTCAAGCACCTGCCGACATACCAGACTATAAAA  
AGCTGTCTATTTCTGAAGGATTTAAATGGGAAAGGGTCATGAACTTTGAAGACGGTG  
GCGTCGTTACTGTAACCCAGGATTCAGTTTGCAGGATGGCTGTTTCATCTACAAGT  
CAAGTTCATTGGCGTTGAACCTTTCCTTCCGATGGACCTGTTATGCAAAAGAAGACAA  
TGGGCTGGGAAGCCAGCACTGAGCGTTTGTATCCTCGTGATGGCGTGTTGAAAGGAG  
AGATTCATAAGGCTCTGAAGCTGAAAGACGGTGGTCATTACCTAGTTGAATCAAAA  
GTATTTACATGGCAAAGAAGCCTGTGCAGCTACCAGGGTACTACTATGTTGACTCCA  
AACTGGATATAACAAGCCACAACGAAGACTATACAATCGTTGAGCAGTATGAAAGAA  
CCGAGGGACGCCACCATCTGTTCTTTAAGGCTGAACCTGGCTCAGACGTGGGTGAG  
CGGTAATGACCACAAAAGGCAGCGAAGAAAAACCATGATCGTTTTTTTTTAGGTTGGC  
AGCCTGAAATCGTAGGAAATACATCAGAAATGTTACAAACAGG (SEQ ID NO:11)

## amino acid sequence of drFP583

Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val  
Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu  
Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val  
Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln  
Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro  
Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val  
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser  
Leu Gln Asp Gly Cys Phe Ile Tyr Lys Ser Ser Ser Leu Ala Leu Asn  
Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu  
Ala Ser Thr Glu Arg Leu Gly His Tyr Leu Val Glu Phe Lys Ser Ile  
Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr Tyr Tyr Val Asp  
Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu  
Gln Tyr Glu Arg Thr Glu Gly Arg His His Leu Phe Leu  
(SEQ ID NO:12)

FIGURE 7

## Amino Acid and Nucleotide Sequence for asFP600

ATGGCTTCCTTTTTTAAAGAAGACTATGCCCTTTAAGACGACCATTGAAGGGACGGTTA  
ATGGCCACTACTTCAAGTGTACAGGAAAAGGAGAGGGCAACCCATTTGAGGGTACGCA  
GGAAATGAAGATAGAGGTCATCGAAGGAGGTCCATTGCCATTTGCCCTTCCACATTTTG  
TCAACGAGTTGTATGTACGGTAGTAAGGCCTTCATCAAGTATGTGTCAGGAATTCCTG  
ACTACTTCAAGCAGTCTTTCCCTGAAGGTTTTACTTGGGAAAGAACCACAACCTACGA  
GGATGGAGGCTTTCTTACAGCTCATCAGGACACAAGCCTAGATGGAGATTGCCTCGTT  
TACAAGGTCAAGATTCTTGGTAATAATTTTCCTGCTGATGGCCCCGTGATGCAGAACA  
AAGCAGGAAGATGGGAGCCATCCACCGAGATAGTTTATGAAGTTGACGGTGTCTGCG  
TGGACAGTCTTTGATGGCCCTTAAGTGCCCTGGTGGTTCGTCATCTGACTTGCCATCTC  
CATACTACTTACAGGTCCAAAAAACCAGCTGCTGCCTTGAAGATGCCAGGATTTTCATT  
TTGAAGATCATCGCATCGAGATAATGGAGGAAGTTGAGAAAGGCAAGTGCTATAAACA  
GTACGAAGCAGCAGTGGGCAGGTACTGTGATGCTGCTCCATCCAAGCTTGGACATAAC  
(SEQ ID NO:13)

## Amino acid

MASFLKKTMPFKTTIEGTVNGHYFKCTGKGEGNPFEGTQEMKIEVIEGGPLPFAFHIL  
STSCMYGSKAFIKYVSGIPDYF  
KQSFPEGFTWERTTTYEDGGFLTAHQDTSLDGDCLVYKVKILGNNFPADGPVMQNKAG  
RWEPTSEIVYEVDGVLRGQSLM  
ALKCPGGRHLTCHLHTTYRSKKPAAALKMPGFHFEDHRIEIMEEVEKGKCYQYEA AVGRYCD AAPS KL  
GHN (SEQ ID NO:14)

Figure 8

## cDNA sequence of dgFP512

```

attcacctcg gtgatttgta agagaaagga tcaccatcaa gagaagagct gtaaaagtta 60
atatttttact gtactttctac cagcatgagt gcacttaaag aagaaatgaa aatcaacctt 120
acaatggaag gtgttggttaa cgggcttcca ttttaagatcc gtgggggatgg aaaaggcaaa 180
ccataccagg gatcacagga gttaaccttg acggtgggta aaggcggggc tctgcctttc 240
tcttatgata ttctgacaac gatgtttcag tacggcaaca gggcattcgt aaactaccca 300
gaggacatac cagatatattt caagcagacc tgttctgggc ctaatgggtg atattcctgg 360
caaaggacca tgacttatga agacggaggg gtttgactg ctacaagcaa catcagcgtg 420
gttggcgaca ctttcaatta tgacattcac tttatgggag cgaattttcc tcttgatggg 480
ccagtgatgc agaaaagaac aatgaaatgg gaacatcca ctgagataat gtttgaacgt 540
gatggaatgc tgaggggtga cattgccatg tctctgttgc tgaagggagg gggccattac 600
cgatgtgatt ttgaaactat ttataaaccc aataagggtg tcaagatgcc agattacat 660
tttgtggacc actgcattga gataacgagt caacaggatt attacaacgt ggttgagctg 720
accgaggttg ctgaagcccg ctactcttcg ctggagaaaa tcggcaaatc aaaggcgtaa 780
atccaagcaa tctaagaaaa caacaaggca ttaaaccgaa tcaccgtttt gaatttttcg 840
ttcggaattt cttggtaaaa ctaggtttag aacgtttcat ttcgctggac ttctttgact 900
cagctgtaga caagaaaga (SEQ ID NO:15) 919

```

## amino acid sequence of dgFP512

```

Met Ser Ala Leu Lys Glu Glu Met Lys Ile Asn Leu Thr Met Glu
Gly Val Val Asn Gly Leu Pro Phe Lys Ile Arg Gly Asp Gly Lys
Gly Lys Pro Tyr Gln Gly Ser Gln Glu Leu Thr Leu Thr Val Val
Lys Gly Gly Pro Leu Pro Phe Ser Tyr Asp Ile Leu Thr Thr Met
Phe Gln Tyr Gly Asn Arg Ala Phe Val Asn Tyr Pro Glu Asp Ile
Pro Asp Ile Phe Lys Gln Thr Cys Ser Gly Pro Asn Gly Gly Tyr
Ser Trp Gln Arg Thr Met Thr Tyr Glu Asp Gly Gly Val Cys Thr
Ala Thr Ser Asn Ile Ser Val Val Gly Asp Thr Phe Asn Tyr Asp
Ile His Phe Met Gly Ala Asn Phe Pro Leu Asp Gly Pro Val Met
Gln Lys Arg Thr Met Lys Trp Glu Pro Ser Thr Glu Ile Met Phe
Glu Arg Asp Gly Met Leu Arg Gly Asp Ile Ala Met Ser Leu Leu
Leu Lys Gly Gly Gly His Tyr Arg Cys Asp Phe Glu Thr Ile Tyr
Lys Pro Asn Lys Val Val Lys Met Pro Asp Tyr His Phe Val Asp
His Cys Ile Glu Ile Thr Ser Gln Gln Asp Tyr Tyr Asn Val Val
Glu Leu Thr Glu Val Ala Glu Ala Arg Tyr Ser Ser Leu Glu Lys
Ile Gly Lys Ser Lys Ala
(SEQ ID NO:16)

```

FIGURE 9

## cDNA sequence of dmFP592

```

agtttcagcc agtgacaggg tgagctgccca ggtattctaa caagatgagt tgttccaaga    60
atgtgatcaa ggagttcatg aggttcaagg ttcgtatgga aggaacggtc aatgggcacg    120
agtttgaaat aaaaggcgaa ggtgaaggga ggccttacga aggtcactgt tccgtaaagc    180
ttatggtaac caagggtgga cctttgccat ttgcttttga tattttgtca ccacaatttc    240
agtatggaag caaggtatat gtcaaacacc ctgccgacat accagactat aaaaagctgt    300
catttcctga gggatttaaa tgggaaaggg tcatgaactt tgaagacggg ggcgtgggta    360
ctgtatccca agattccagt ttgaaagacg gctgtttcat ctacgaggtc aagttcattg    420
gggtgaactt tccttctgat ggacctgtta tgcagaggag gacacggggc tgggaagcca    480
gctctgagcg tttgtatcct cgtgatgggg tgctgaaagg agacatccat atggctctga    540
ggctggaagg aggcggccat tacctcgttg aattcaaaag tatttacatg gtaaagaagc    600
cttcagtgca gttgccaggc tactattatg ttgactccaa actgggatatg acgagccaca    660
acgaagatta cacagtcgtt gagcagtatg aaaaaaccca gggacgccac catccgttca    720
ttaagcctct gcagtgaact cggctcagtc atggattagc ggtaatggcc aaaaaggca    780
cgatgatcgt tttttaggaa tgcagccaaa aattgaagggt tatgacagta gaaatacaag    840
caacaggctt tgcttattaa acatgtaatt gaaaac                                876

```

(SEQ ID NO:17)

## amino acid sequence of dmFP592

```

Met Ser Cys Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys
Val Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Lys
Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly His Cys Ser Val Lys
Leu Met Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Phe Asp Ile
Leu Ser Pro Gln Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His
Pro Ala Asp Ile Pro Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly
Phe Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val
Thr Val Ser Gln Asp Ser Ser Leu Lys Asp Gly Cys Phe Ile Tyr
Glu Val Lys Phe Ile Gly Val Asn Phe Pro Ser Asp Gly Pro Val
Met Gln Arg Arg Thr Arg Gly Trp Glu Ala Ser Ser Glu Arg Leu
Tyr Pro Arg Asp Gly Val Leu Lys Gly Asp Ile His Met Ala Leu
Arg Leu Glu Gly Gly Gly His Tyr Leu Val Glu Phe Lys Ser Ile
Tyr Met Val Lys Lys Pro Ser Val Gln Leu Pro Gly Tyr Tyr Tyr
Val Asp Ser Lys Leu Asp Met Thr Ser His Asn Glu Asp Tyr Thr
Val Val Glu Gln Tyr Glu Lys Thr Gln Gly Arg His His Pro Phe
Ile Lys Pro Leu Gln

```

(SEQ ID NO:18)



## SEQUENCE LISTING

<110> Lukyanov, Sergey Anatolievich  
 Fradkov, Acrady Fedorovich  
 Labas, Yulii Aleksandrovich  
 Matz, Mikhail Vladimirovich  
 Terskikh, Alexey

<120> Anthozoa Derived  
 Chromophores/Fluorophores and Methods for Using the Same

<130> CLON-035WO10

<140> PCT/US/  
 <141> 2000-10-13

<150> 09/418,529  
 <151> 1999-10-14

<150> 09/418,917  
 <151> 1999-10-15

<150> 09/418,922  
 <151> 1999-10-15

<150> 09/444,341  
 <151> 1999-11-19

<150> 09/444,338  
 <151> 1999-12-09

<150> 09/458,477  
 <151> 1999-12-09

<160> 18

<170> FastSEQ for Windows Version 4.0

<210> 1  
 <211> 687  
 <212> DNA  
 <213> coral

<220>  
 <221> CDS  
 <222> (1)...(687)

<400> 1  
 atg gct ctt tca aac aag ttt atc gga gat gac atg aaa atg acc tac 48  
 Met Ala Leu Ser Asn Lys Phe Ile Gly Asp Asp Met Lys Met Thr Tyr  
 1 5 10 15  
 cat atg gat ggc tgt gtc aat ggg cat tac ttt acc gtc aaa ggt gaa 96  
 His Met Asp Gly Cys Val Asn Gly His Tyr Phe Thr Val Lys Gly Glu  
 20 25 30  
 ggc aac ggg aag cca tac gaa ggg acg cag acc tcg act ttt aaa gtc 144  
 Gly Asn Gly Lys Pro Tyr Glu Gly Thr Gln Thr Ser Thr Phe Lys Val  
 35 40 45  
 acc atg gcc aac ggt ggg ccc ctt gca ttc tcc ttt gac ata cta tct 192

```

Thr Met Ala Asn Gly Gly Pro Leu Ala Phe Ser Phe Asp Ile Leu Ser
  50                      55                      60

aca gtg ttc aag tat gga aat cga tgc ttt act gcg tat cct acc agt      240
Thr Val Phe Lys Tyr Gly Asn Arg Cys Phe Thr Ala Tyr Pro Thr Ser
  65                      70                      75                      80

atg ccc gac tat ttc aaa caa gca ttt cct gac gga atg tca tat gaa      288
Met Pro Asp Tyr Phe Lys Gln Ala Phe Pro Asp Gly Met Ser Tyr Glu
                      85                      90                      95

agg act ttt acc tat gaa gat gga gga gtt gct aca gcc agt tgg gaa      336
Arg Thr Phe Thr Tyr Glu Asp Gly Gly Val Ala Thr Ala Ser Trp Glu
                      100                      105                      110

ata agc ctt aaa ggc aac tgc ttt gag cac aaa tcc acg ttt cat gga      384
Ile Ser Leu Lys Gly Asn Cys Phe Glu His Lys Ser Thr Phe His Gly
                      115                      120                      125

gtg aac ttt cct gct gat gga cct gtg atg gcg aag atg aca act ggt      432
Val Asn Phe Pro Ala Asp Gly Pro Val Met Ala Lys Met Thr Thr Gly
                      130                      135                      140

tgg gac cca tct ttt gag aaa atg act gtc tgc gat gga ata ttg aag      480
Trp Asp Pro Ser Phe Glu Lys Met Thr Val Cys Asp Gly Ile Leu Lys
                      145                      150                      155                      160

ggg gat gtc acc gcg ttc ctc atg ctg caa gga ggt ggc aat tac aga      528
Gly Asp Val Thr Ala Phe Leu Met Leu Gln Gly Gly Gly Asn Tyr Arg
                      165                      170                      175

tgc caa ttc cac act tct tac aag aca aaa aaa ccg gtg acg atg cca      576
Cys Gln Phe His Thr Ser Tyr Lys Thr Lys Lys Pro Val Thr Met Pro
                      180                      185                      190

cca aac cat gcg gtg gaa cat cgc att gcg agg acc gac ctt gac aaa      624
Pro Asn His Ala Val Glu His Arg Ile Ala Arg Thr Asp Leu Asp Lys
                      195                      200                      205

ggg ggc aac agt gtt cag ctg acg gag cac gct gtt gca cat ata acc      672
Gly Gly Asn Ser Val Gln Leu Thr Glu His Ala Val Ala His Ile Thr
                      210                      215                      220

tct gtt gtc cct ttc
Ser Val Val Pro Phe
225

```

&lt;210&gt; 2

&lt;211&gt; 229

&lt;212&gt; PRT

&lt;213&gt; coral

&lt;400&gt; 2

```

Met Ala Leu Ser Asn Lys Phe Ile Gly Asp Asp Met Lys Met Thr Tyr
  1                      5                      10                      15
His Met Asp Gly Cys Val Asn Gly His Tyr Phe Thr Val Lys Gly Glu
  20                      25                      30
Gly Asn Gly Lys Pro Tyr Glu Gly Thr Gln Thr Ser Thr Phe Lys Val
  35                      40                      45
Thr Met Ala Asn Gly Gly Pro Leu Ala Phe Ser Phe Asp Ile Leu Ser
  50                      55                      60
Thr Val Phe Lys Tyr Gly Asn Arg Cys Phe Thr Ala Tyr Pro Thr Ser

```

```

65          70          75          80
Met Pro Asp Tyr Phe Lys Gln Ala Phe Pro Asp Gly Met Ser Tyr Glu
          85          90          95
Arg Thr Phe Thr Tyr Glu Asp Gly Gly Val Ala Thr Ala Ser Trp Glu
          100          105          110
Ile Ser Leu Lys Gly Asn Cys Phe Glu His Lys Ser Thr Phe His Gly
          115          120          125
Val Asn Phe Pro Ala Asp Gly Pro Val Met Ala Lys Met Thr Thr Gly
          130          135          140
Trp Asp Pro Ser Phe Glu Lys Met Thr Val Cys Asp Gly Ile Leu Lys
          145          150          155          160
Gly Asp Val Thr Ala Phe Leu Met Leu Gln Gly Gly Gly Asn Tyr Arg
          165          170          175
Cys Gln Phe His Thr Ser Tyr Lys Thr Lys Lys Pro Val Thr Met Pro
          180          185          190
Pro Asn His Ala Val Glu His Arg Ile Ala Arg Thr Asp Leu Asp Lys
          195          200          205
Gly Gly Asn Ser Val Gln Leu Thr Glu His Ala Val Ala His Ile Thr
          210          215          220
Ser Val Val Pro Phe
225

```

```

<210> 3
<211> 1116
<212> DNA
<213> coral

```

```

<220>
<221> misc_feature
<222> (8)...(8)
<223> N denote A, T, G or C

```

```

<221> misc_feature
<222> (12)...(12)
<223> N denote A, T, G or C

```

```

<221> misc_feature
<222> (13)...(13)
<223> N denote A, T, G or C

```

```

<221> misc_feature
<222> (17)...(17)
<223> N denote A, T, G or C

```

```

<221> misc_feature
<222> (65)...(65)
<223> N denote A, T, G or C

```

```

<221> misc_feature
<222> (77)...(77)
<223> N denote A, T, G or C

```

```

<221> misc_feature
<222> (92)...(92)
<223> N denote A, T, G or C

```

```

<221> misc_feature
<222> (94)...(94)
<223> N denote A, T, G or C

```

```

<400> 3
tataggancca tnnnggngat tgggggtccaa agcattgtaa ccaacgcaga taacccccag      60
tggntntcaaa cgcaganaac gcgggaacat tggaaaattg antntttaagg aggcaaggaa      120

```

```

tcgggagtaa agttgcgaga aactgaaaaa atgaagtgtgta aatttgtgtt ctgcctgtcc 180
ttcttgggtcc tcgccatcac aaacgcgaac atttttttga gaaacgaggc tgacttcgaa 240
gagaagacat ttagaataacc aaaagctcta accaccatgg gtgtgattaa accagacatg 300
aagattaagc tgaagatgga aggaaatgta aacgggcatg cttttgtgat tgaaggagaa 360
ggagaaggaa agccttacga tgggacacac acttttaaacc tggaaagtga ggaaggtgcg 420
cctctgcctt tttcttacga tatcttgtca aacgcgttcc agtacggaaa cagagcattg 480
acaaaatacc cagacgatat agcagactat ttcaagcagt cgtttcccga gggatattcc 540
tgggaaagaa ccatgacttt tgaagacaaa ggcattgtca aagtgaaaag tgacataagc 600
atggaggaag actcctttat ctatgaaatt cgttttgatg ggatggactt tcctcccaat 660
gggccgggta tgcagaaaaa aactttgaag tgggaaccat ccactgagat tatgtacgtg 720
cgtgatggag tgctggtcgg agatattagc cattctctgt tgctggaggg aggtggccat 780
taccgatgtg acttcaaaaag tattttacaaa gcaaaaaaag ttgtcaaatt gccagactat 840
cactttgtgg accatcgcac tgagatcttg aaccatgaca aggattacaa caaagtaacg 900
ctgtatgaga atgcagttgc tcgctattct ttgctgcaa gtcaggccta gacaacaagg 960
atactgaaaa catatttgtc tgaggggttg tgttgtttt taaaagacat cagctcagca 1020
ttcgttagtt gtaacaaaaa atagctttta tttttggtgg gattaaatca tagggatttg 1080
ttttagtaat cattttgctt aataaaaagt gccttg 1116

```

<210> 4  
 <211> 266  
 <212> PRT  
 <213> coral

```

<400> 4
Met Lys Cys Lys Phe Val Phe Cys Leu Ser Phe Leu Val Leu Ala Ile
  1           5           10           15
Thr Asn Ala Asn Ile Phe Leu Arg Asn Glu Ala Asp Phe Glu Glu Lys
  20           25           30
Thr Phe Arg Ile Pro Lys Ala Leu Thr Thr Met Gly Val Ile Lys Pro
  35           40           45
Asp Met Lys Ile Lys Leu Lys Met Glu Gly Asn Val Asn Gly His Ala
  50           55           60
Phe Val Ile Glu Gly Glu Gly Glu Gly Lys Pro Tyr Asp Gly Thr His
  65           70           75           80
Thr Leu Asn Leu Glu Val Lys Glu Gly Ala Pro Leu Pro Phe Ser Tyr
  85           90           95
Asp Ile Leu Ser Asn Ala Phe Gln Tyr Gly Asn Arg Ala Leu Thr Lys
  100          105          110
Tyr Pro Asp Ile Ala Asp Tyr Phe Lys Gln Ser Phe Pro Glu Gly
  115          120          125
Tyr Ser Trp Glu Arg Thr Met Thr Phe Glu Asp Lys Gly Ile Val Lys
  130          135          140
Val Lys Ser Asp Ile Ser Met Glu Glu Asp Ser Phe Ile Tyr Glu Ile
  145          150          155          160
Arg Phe Asp Gly Met Asp Phe Pro Pro Asn Gly Pro Val Met Gln Lys
  165          170          175
Lys Thr Leu Lys Trp Glu Pro Ser Thr Glu Ile Met Tyr Val Arg Asp
  180          185          190
Gly Val Leu Val Gly Asp Ile Ser His Ser Leu Leu Leu Glu Gly Gly
  195          200          205
Gly His Tyr Arg Cys Asp Phe Lys Ser Ile Tyr Lys Ala Lys Lys Val
  210          215          220
Val Lys Leu Pro Asp Tyr His Phe Val Asp His Arg Ile Glu Ile Leu
  225          230          235          240
Asn His Asp Lys Asp Tyr Asn Lys Val Thr Leu Tyr Glu Asn Ala Val
  245          250          255
Ala Arg Tyr Ser Leu Leu Pro Ser Gln Ala
  260          265

```

<210> 5  
 <211> 693  
 <212> DNA  
 <213> coral

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(693)

&lt;400&gt; 5

|   |     |
|---|-----|
| atg gct cag tca aag cac ggt cta aca aaa gaa atg aca atg aaa tac | 48  |
| Met Ala Gln Ser Lys His Gly Leu Thr Lys Glu Met Thr Met Lys Tyr |     |
| 1 5 10 15   |     |
| cgt atg gaa ggg tgc gtc gat gga cat aaa ttt gtg atc acg gga gag | 96  |
| Arg Met Glu Gly Cys Val Asp Gly His Lys Phe Val Ile Thr Gly Glu |     |
| 20 25 30  |     |
| ggc att gga tat ccg ttc aaa ggg aaa cag gct att aat ctg tgt gtg | 144 |
| Gly Ile Gly Tyr Pro Phe Lys Gly Lys Gln Ala Ile Asn Leu Cys Val |     |
| 35 40 45  |     |
| gtc gaa ggt gga cca ttg cca ttt gcc gaa gac ata ttg tca gct gcc | 192 |
| Val Glu Gly Gly Pro Leu Pro Phe Ala Glu Asp Ile Leu Ser Ala Ala |     |
| 50 55 60  |     |
| ttt aac tac gga aac agg gtt ttc act gaa tat cct caa gac aaa gct | 240 |
| Phe Asn Tyr Gly Asn Arg Val Phe Thr Glu Tyr Pro Gln Asp Lys Ala |     |
| 65 70 75 80   |     |
| gac tat ttc aag aac tcg tgt cct gct ggt tat aca tgg gac agg tct | 288 |
| Asp Tyr Phe Lys Asn Ser Cys Pro Ala Gly Tyr Thr Trp Asp Arg Ser |     |
| 85 90 95  |     |
| ttt ctc ttt gag gat gga gca gtt tgc ata tgt aat gca gat ata aca | 336 |
| Phe Leu Phe Glu Asp Gly Ala Val Cys Ile Cys Asn Ala Asp Ile Thr |     |
| 100 105 110   |     |
| gtg agt gtt gaa gaa aac tgc atg tat cat gag tcc aaa ttt tat gga | 384 |
| Val Ser Val Glu Glu Asn Cys Met Tyr His Glu Ser Lys Phe Tyr Gly |     |
| 115 120 125   |     |
| gtg aat ttt cct gct gat gga cct gtg atg aaa aag atg aca gat aac | 432 |
| Val Asn Phe Pro Ala Asp Gly Pro Val Met Lys Lys Met Thr Asp Asn |     |
| 130 135 140   |     |
| tgg gag cca tcc tgc gag aag atc ata cca gta cct aag cag ggg ata | 480 |
| Trp Glu Pro Ser Cys Glu Lys Ile Ile Pro Val Pro Lys Gln Gly Ile |     |
| 145 150 155 160   |     |
| ttg aaa ggg gat gtc tcc atg tac ctc ctt ctg aag gat ggt ggg cgt | 528 |
| Leu Lys Gly Asp Val Ser Met Tyr Leu Leu Lys Asp Gly Gly Arg     |     |
| 165 170 175   |     |
| tta cgg tgc caa ttc gac aca gtt tac aaa gca aag tct gtg cca aga | 576 |
| Leu Arg Cys Gln Phe Asp Thr Val Tyr Lys Ala Lys Ser Val Pro Arg |     |
| 180 185 190   |     |
| aag atg ccg gac tgg cac ttc atc cag cat aag ctc acc cgt gaa gac | 624 |
| Lys Met Pro Asp Trp His Phe Ile Gln His Lys Leu Thr Arg Glu Asp |     |
| 195 200 205   |     |
| cgc agc gat gct aag aat cag aaa tgg cat ctg aca gaa cat gct att | 672 |
| Arg Ser Asp Ala Lys Asn Gln Lys Trp His Leu Thr Glu His Ala Ile |     |
| 210 215 220   |     |
| gca tcc gga tct gca ttg ccc                                     | 693 |
| Ala Ser Gly Ser Ala Leu Pro                                     |     |

225

230

<210> 6  
 <211> 231  
 <212> PRT  
 <213> coral

<400> 6  
 Met Ala Gln Ser Lys His Gly Leu Thr Lys Glu Met Thr Met Lys Tyr  
 1 5 10 15  
 Arg Met Glu Gly Cys Val Asp Gly His Lys Phe Val Ile Thr Gly Glu  
 20 25 30  
 Gly Ile Gly Tyr Pro Phe Lys Gly Lys Gln Ala Ile Asn Leu Cys Val  
 35 40 45  
 Val Glu Gly Gly Pro Leu Pro Phe Ala Glu Asp Ile Leu Ser Ala Ala  
 50 55 60  
 Phe Asn Tyr Gly Asn Arg Val Phe Thr Glu Tyr Pro Gln Asp Lys Ala  
 65 70 75 80  
 Asp Tyr Phe Lys Asn Ser Cys Pro Ala Gly Tyr Thr Trp Asp Arg Ser  
 85 90 95  
 Phe Leu Phe Glu Asp Gly Ala Val Cys Ile Cys Asn Ala Asp Ile Thr  
 100 105 110  
 Val Ser Val Glu Glu Asn Cys Met Tyr His Glu Ser Lys Phe Tyr Gly  
 115 120 125  
 Val Asn Phe Pro Ala Asp Gly Pro Val Met Lys Lys Met Thr Asp Asn  
 130 135 140  
 Trp Glu Pro Ser Cys Glu Lys Ile Ile Pro Val Pro Lys Gln Gly Ile  
 145 150 155 160  
 Leu Lys Gly Asp Val Ser Met Tyr Leu Leu Leu Lys Asp Gly Gly Arg  
 165 170 175  
 Leu Arg Cys Gln Phe Asp Thr Val Tyr Lys Ala Lys Ser Val Pro Arg  
 180 185 190  
 Lys Met Pro Asp Trp His Phe Ile Gln His Lys Leu Thr Arg Glu Asp  
 195 200 205  
 Arg Ser Asp Ala Lys Asn Gln Lys Trp His Leu Thr Glu His Ala Ile  
 210 215 220  
 Ala Ser Gly Ser Ala Leu Pro  
 225 230

<210> 7  
 <211> 693  
 <212> DNA  
 <213> coral

<220>  
 <221> CDS  
 <222> (1)...(693)

<400> 7  
 atg gct cat tca aag cac ggt cta aaa gaa gaa atg aca atg aaa tac 48  
 Met Ala His Ser Lys His Gly Leu Lys Glu Glu Met Thr Met Lys Tyr  
 1 5 10 15  
 cac atg gaa ggg tgc gtc aac gga cat aaa ttt gtg atc acg ggc gaa 96  
 His Met Glu Gly Cys Val Asn Gly His Lys Phe Val Ile Thr Gly Glu  
 20 25 30  
 ggc att gga tat ccg ttc aaa ggg aaa cag act att aat ctg tgt gtg 144  
 Gly Ile Gly Tyr Pro Phe Lys Gly Lys Gln Thr Ile Asn Leu Cys Val  
 35 40 45  
 atc gaa ggg gga cca ttg cca ttt tcc gaa gac ata ttg tca gct ggc 192

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|-----|
| Ile | Glu | Gly | Gly | Pro | Leu | Pro | Phe | Ser | Glu | Asp | Ile | Leu | Ser | Ala | Gly |  |     |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |  |     |
| ttt | aag | tac | gga | gac | agg | att | ttc | act | gaa | tat | cct | caa | gac | ata | gta |  | 240 |
| Phe | Lys | Tyr | Gly | Asp | Arg | Ile | Phe | Thr | Glu | Tyr | Pro | Gln | Asp | Ile | Val |  |     |
|     | 65  |     |     |     | 70  |     |     |     | 75  |     |     |     |     |     | 80  |  |     |
| gac | tat | ttc | aag | aac | tcg | tgt | cct | gct | gga | tat | aca | tgg | ggc | agg | tct |  | 288 |
| Asp | Tyr | Phe | Lys | Asn | Ser | Cys | Pro | Ala | Gly | Tyr | Thr | Trp | Gly | Arg | Ser |  |     |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |  |     |
| ttt | ctc | ttt | gag | gat | gga | gca | gtc | tgc | ata | tgc | aat | gta | gat | ata | aca |  | 336 |
| Phe | Leu | Phe | Glu | Asp | Gly | Ala | Val | Cys | Ile | Cys | Asn | Val | Asp | Ile | Thr |  |     |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |  |     |
| gtg | agt | gtc | aaa | gaa | aac | tgc | att | tat | cat | aag | agc | ata | ttt | aat | gga |  | 384 |
| Val | Ser | Val | Lys | Glu | Asn | Cys | Ile | Tyr | His | Lys | Ser | Ile | Phe | Asn | Gly |  |     |
|     |     |     | 115 |     |     |     | 120 |     |     |     |     | 125 |     |     |     |  |     |
| atg | aat | ttt | cct | gct | gat | gga | cct | gtg | atg | aaa | aag | atg | aca | act | aac |  | 432 |
| Met | Asn | Phe | Pro | Ala | Asp | Gly | Pro | Val | Met | Lys | Lys | Met | Thr | Thr | Asn |  |     |
|     |     |     | 130 |     |     | 135 |     |     |     |     | 140 |     |     |     |     |  |     |
| tgg | gaa | gca | tcc | tgc | gag | aag | atc | atg | cca | gta | cct | aag | cag | ggg | ata |  | 480 |
| Trp | Glu | Ala | Ser | Cys | Glu | Lys | Ile | Met | Pro | Val | Pro | Lys | Gln | Gly | Ile |  |     |
|     |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |  |     |
| ctg | aaa | ggg | gat | gtc | tcc | atg | tac | ctc | ctt | ctg | aag | gat | ggg | ggg | cgt |  | 528 |
| Leu | Lys | Gly | Asp | Val | Ser | Met | Tyr | Leu | Leu | Leu | Lys | Asp | Gly | Gly | Arg |  |     |
|     |     |     |     | 165 |     |     |     | 170 |     |     |     |     |     | 175 |     |  |     |
| tac | cgg | tgc | cag | ttc | gac | aca | gtt | tac | aaa | gca | aag | tct | gtg | cca | agt |  | 576 |
| Tyr | Arg | Cys | Gln | Phe | Asp | Thr | Val | Tyr | Lys | Ala | Lys | Ser | Val | Pro | Ser |  |     |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |  |     |
| aag | atg | ccg | gag | tgg | cac | ttc | atc | cag | cat | aag | ctc | ctc | cgt | gaa | gac |  | 624 |
| Lys | Met | Pro | Glu | Trp | His | Phe | Ile | Gln | His | Lys | Leu | Leu | Arg | Glu | Asp |  |     |
|     |     |     | 195 |     |     |     | 200 |     |     |     |     | 205 |     |     |     |  |     |
| cgc | agc | gat | gct | aag | aat | cag | aag | tgg | cag | ctg | aca | gag | cat | gct | att |  | 672 |
| Arg | Ser | Asp | Ala | Lys | Asn | Gln | Lys | Trp | Gln | Leu | Thr | Glu | His | Ala | Ile |  |     |
|     |     |     | 210 |     |     | 215 |     |     |     |     | 220 |     |     |     |     |  |     |
| gca | ttc | cct | tct | gcc | ttg | gcc |     |     |     |     |     |     |     |     |     |  | 693 |
| Ala | Phe | Pro | Ser | Ala | Leu | Ala |     |     |     |     |     |     |     |     |     |  |     |
|     |     |     |     |     | 225 |     | 230 |     |     |     |     |     |     |     |     |  |     |

&lt;210&gt; 8

&lt;211&gt; 231

&lt;212&gt; PRT

&lt;213&gt; coral

&lt;400&gt; 8

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| Met | Ala | His | Ser | Lys | His | Gly | Leu | Lys | Glu | Glu | Met | Thr | Met | Lys | Tyr |  |  |
|     | 1   |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |  |  |
| His | Met | Glu | Gly | Cys | Val | Asn | Gly | His | Lys | Phe | Val | Ile | Thr | Gly | Glu |  |  |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |  |  |
| Gly | Ile | Gly | Tyr | Pro | Phe | Lys | Gly | Lys | Gln | Thr | Ile | Asn | Leu | Cys | Val |  |  |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |  |  |
| Ile | Glu | Gly | Gly | Pro | Leu | Pro | Phe | Ser | Glu | Asp | Ile | Leu | Ser | Ala | Gly |  |  |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |  |  |
| Phe | Lys | Tyr | Gly | Asp | Arg | Ile | Phe | Thr | Glu | Tyr | Pro | Gln | Asp | Ile | Val |  |  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     | 80  |     |
| Asp | Tyr | Phe | Lys | Asn | Ser | Cys | Pro | Ala | Gly | Tyr | Thr | Trp | Gly | Arg | Ser |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Phe | Leu | Phe | Glu | Asp | Gly | Ala | Val | Cys | Ile | Cys | Asn | Val | Asp | Ile | Thr |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Val | Ser | Val | Lys | Glu | Asn | Cys | Ile | Tyr | His | Lys | Ser | Ile | Phe | Asn | Gly |
|     |     | 115 |     |     |     | 120 |     |     |     |     |     | 125 |     |     |     |
| Met | Asn | Phe | Pro | Ala | Asp | Gly | Pro | Val | Met | Lys | Lys | Met | Thr | Thr | Asn |
|     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Trp | Glu | Ala | Ser | Cys | Glu | Lys | Ile | Met | Pro | Val | Pro | Lys | Gln | Gly | Ile |
|     | 145 |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Leu | Lys | Gly | Asp | Val | Ser | Met | Tyr | Leu | Leu | Leu | Lys | Asp | Gly | Gly | Arg |
|     |     |     | 165 |     |     |     |     | 170 |     |     |     |     |     | 175 |     |
| Tyr | Arg | Cys | Gln | Phe | Asp | Thr | Val | Tyr | Lys | Ala | Lys | Ser | Val | Pro | Ser |
|     |     | 180 |     |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Lys | Met | Pro | Glu | Trp | His | Phe | Ile | Gln | His | Lys | Leu | Leu | Arg | Glu | Asp |
|     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Arg | Ser | Asp | Ala | Lys | Asn | Gln | Lys | Trp | Gln | Leu | Thr | Glu | His | Ala | Ile |
|     | 210 |     |     |     | 215 |     |     |     |     |     | 220 |     |     |     |     |
| Ala | Phe | Pro | Ser | Ala | Leu | Ala |     |     |     |     |     |     |     |     |     |
| 225 |     |     |     |     | 230 |     |     |     |     |     |     |     |     |     |     |

<210> 9  
 <211> 850  
 <212> DNA  
 <213> coral

|             |            |             |            |            |             |  |  |  |  |  |  |  |  |  |  |  |     |
|-------------|------------|-------------|------------|------------|-------------|--|--|--|--|--|--|--|--|--|--|--|-----|
| <400> 9     |            |             |            |            |             |  |  |  |  |  |  |  |  |  |  |  |     |
| acgggtcaggg | acacggtgac | ccacttttgg  | attctaacaa | aatgagttgg | tccaagagtg  |  |  |  |  |  |  |  |  |  |  |  | 60  |
| tgatcaagga  | agaaatgttg | atcgatcttc  | atctggaagg | aacgttcaat | gggcactact  |  |  |  |  |  |  |  |  |  |  |  | 120 |
| ttgaaataaaa | aggcaaagga | aaagggaagc  | ctaataagga | caccaatacc | gtcacgctcg  |  |  |  |  |  |  |  |  |  |  |  | 180 |
| agggttaccaa | gggtggacct | ctgccatttg  | gttggcatat | tttgtgcca  | caatttcagt  |  |  |  |  |  |  |  |  |  |  |  | 240 |
| atggaaacaa  | ggcatttgtc | caccaccctg  | acgacatacc | tgattatcta | aagctgtcat  |  |  |  |  |  |  |  |  |  |  |  | 300 |
| ttccggaggg  | atatacatgg | gaacggtcca  | tgacttttga | agacggtggc | ttgtgttgta  |  |  |  |  |  |  |  |  |  |  |  | 360 |
| tcaccaatga  | tatcagtttg | acaggcaact  | gtttcaacta | cgacatcaag | ttcactggct  |  |  |  |  |  |  |  |  |  |  |  | 420 |
| tgaactttcc  | tccaaatgga | cccgttgtgc  | agaagaagac | aactggctgg | gaaccgagca  |  |  |  |  |  |  |  |  |  |  |  | 480 |
| ctgagcgttt  | gtatcctcgt | gatggcgtgt  | tgataggaga | catccatcat | gctctcacag  |  |  |  |  |  |  |  |  |  |  |  | 540 |
| tggaaggagg  | tggtcattac | gtatgtgaca  | ttaaaactgt | ttacagggcc | aagaagcccg  |  |  |  |  |  |  |  |  |  |  |  | 600 |
| taaagatgcc  | agggtatcac | tatgttgaca  | ccaaactggt | tataaggagc | aacgacaaaag |  |  |  |  |  |  |  |  |  |  |  | 660 |
| aattcatgaa  | agttgaggag | catgaaatcg  | ccgttgcacg | ccaccatccg | ctccaaagcc  |  |  |  |  |  |  |  |  |  |  |  | 720 |
| aatgaagctt  | aagtaaagca | aaaagggtgac | gaggcatgat | agtatgacat | gatagtatga  |  |  |  |  |  |  |  |  |  |  |  | 780 |
| catgatagta  | tgacatgata | gtaagaattg  | taagcaaaag | gctttgctta | ttaaacttgt  |  |  |  |  |  |  |  |  |  |  |  | 840 |
| aattgaaaac  |            |             |            |            |             |  |  |  |  |  |  |  |  |  |  |  | 850 |

<210> 10  
 <211> 227  
 <212> PRT  
 <213> coral

|          |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |  |
|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| <400> 10 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |  |
| Met      | Ser | Trp | Ser | Lys | Ser | Val | Ile | Lys | Glu | Glu | Met | Leu | Ile | Asp | Leu |  |  |
| 1        |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |  |  |
| His      | Leu | Glu | Gly | Thr | Phe | Asn | Gly | His | Tyr | Phe | Glu | Ile | Lys | Gly | Lys |  |  |
|          |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |  |  |
| Gly      | Lys | Gly | Lys | Pro | Asn | Glu | Gly | Thr | Asn | Thr | Val | Thr | Leu | Glu | Val |  |  |
|          |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |  |  |
| Thr      | Lys | Gly | Gly | Pro | Leu | Pro | Phe | Gly | Trp | His | Ile | Leu | Cys | Pro | Gln |  |  |
|          | 50  |     |     |     |     | 55  |     |     |     | 60  |     |     |     |     |     |  |  |
| Phe      | Gln | Tyr | Gly | Asn | Lys | Ala | Phe | Val | His | His | Pro | Asp | Asp | Ile | Pro |  |  |
| 65       |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |     |  |  |
| Asp      | Tyr | Leu | Lys | Leu | Ser | Phe | Pro | Glu | Gly | Tyr | Thr | Trp | Glu | Arg | Ser |  |  |
|          |     |     | 85  |     |     |     |     |     | 90  |     |     |     |     | 95  |     |  |  |
| Met      | His | Phe | Glu | Asp | Gly | Gly | Leu | Cys | Cys | Ile | Thr | Asn | Asp | Ile | Ser |  |  |



```

      100      105      110
Leu Thr Gly Asn Cys Phe Asn Tyr Asp Ile Lys Phe Thr Gly Leu Asn
      115      120      125
Phe Pro Pro Asn Gly Pro Val Val Gln Lys Lys Thr Thr Gly Trp Glu
      130      135      140
Pro Ser Thr Glu Arg Leu Tyr Pro Arg Asp Gly Val Leu Ile Gly Asp
145      150      155      160
Ile His His Ala Leu Thr Val Glu Gly Gly Gly His Tyr Val Cys Asp
      165      170      175
Ile Lys Thr Val Tyr Arg Ala Lys Lys Pro Val Lys Met Pro Gly Tyr
      180      185      190
His Tyr Val Asp Thr Lys Leu Val Ile Arg Ser Asn Asp Lys Glu Phe
      195      200      205
Met Lys Val Glu Glu His Glu Ile Ala Val Ala Arg His His Pro Leu
      210      215      220
Gln Ser Gln
225

```

<210> 11  
 <211> 898  
 <212> DNA  
 <213> coral

```

<400> 11
gtcctcccaa gcagtgggtat caacgcagag tacgggggag tttcagccag tgacgggtcag      60
tgacaggggtg agccacttgg tataccaaca aaatgaggtc ttccaagaat gttatcaagg      120
agttcatgag gtttaagggtt cgcattggaag gaacgggtcaa tgggcacgag tttgaaatag      180
aaggcgaagg agagggggagg ccatacgaag gccacaatac cgtaaagctt aaggtaacca      240
agggggggacc tttgccattt gcttgggata ttttgtcacc acaatttcag tatggaagca      300
aggatatatgt caagcaccct gccgacatac cagactataa aaagctgtca tttcctgaag      360
gatttaaatg ggaaagggtc atgaactttg aagacgggtg cgtcgttact gtaaccagg      420
attccagttt gcaggatggc tgtttcatct acaagtcaag ttcattggcg ttgaactttc      480
cttccgatgg acctgttatg caaaagaaga caatgggctg ggaagccagc actgagcggt      540
tgtatcctcg tgatggcgtg ttgaaaggag agattcataa ggctctgaag ctgaaagacg      600
gtggtcatta cctagttgaa ttcaaaagta ttacatggc aaagaagcct gtgcagctac      660
caggggtacta ctatgttgac tccaaactgg atataacaag ccacaacgaa gactatacaa      720
tcgttgagca gtatgaaaga accgagggac gccaccatct gttcctttta ggctgaactt      780
ggctcagacg tgggtgagcg gtaatgacca caaaggcag cgaagaaaaa ccatgatcgt      840
tttttttagg ttggcagcct gaaatcgtag gaaatacatc agaaatgtta caaacagg      898

```

<210> 12  
 <211> 205  
 <212> PRT  
 <213> coral

```

<400> 12
Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val
 1      5      10      15
Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
      20      25      30
Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val
      35      40      45
Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
      50      55      60
Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
65      70      75      80
Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val
      85      90      95
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
      100      105      110
Leu Gln Asp Gly Cys Phe Ile Tyr Lys Ser Ser Ser Leu Ala Leu Asn
      115      120      125
Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu

```

|                     |                     |                         |
|---------------------|---------------------|-------------------------|
| 130                 | 135                 | 140                     |
| Ala Ser Thr Glu Arg | Leu Gly His Tyr Leu | Val Glu Phe Lys Ser Ile |
| 145                 | 150                 | 155                     |
| Tyr Met Ala Lys Lys | Pro Val Gln Leu Pro | Gly Tyr Tyr Tyr Val Asp |
| 165                 | 170                 | 175                     |
| Ser Lys Leu Asp Ile | Thr Ser His Asn Glu | Asp Tyr Thr Ile Val Glu |
| 180                 | 185                 | 190                     |
| Gln Tyr Glu Arg Thr | Glu Gly Arg His His | Leu Phe Leu             |
| 195                 | 200                 | 205                     |

<210> 13  
 <211> 696  
 <212> DNA  
 <213> coral

<220>  
 <221> CDS  
 <222> (1)...(696)

<400> 13

|   |     |
|---|-----|
| atg gct tcc ttt tta aag aag act atg ccc ttt aag acg acc att gaa | 48  |
| Met Ala Ser Phe Leu Lys Lys Thr Met Pro Phe Lys Thr Thr Ile Glu |     |
| 1 5 10 15   |     |
| ggg acg gtt aat ggc cac tac ttc aag tgt aca gga aaa gga gag ggc | 96  |
| Gly Thr Val Asn Gly His Tyr Phe Lys Cys Thr Gly Lys Gly Glu Gly |     |
| 20 25 30  |     |
| aac cca ttt gag ggt acg cag gaa atg aag ata gag gtc atc gaa gga | 144 |
| Asn Pro Phe Glu Gly Thr Gln Glu Met Lys Ile Glu Val Ile Glu Gly |     |
| 35 40 45  |     |
| ggt cca ttg cca ttt gcc ttc cac att ttg tca acg agt tgt atg tac | 192 |
| Gly Pro Leu Pro Phe Ala Phe His Ile Leu Ser Thr Ser Cys Met Tyr |     |
| 50 55 60  |     |
| ggt agt aag gcc ttc atc aag tat gtg tca gga att cct gac tac ttc | 240 |
| Gly Ser Lys Ala Phe Ile Lys Tyr Val Ser Gly Ile Pro Asp Tyr Phe |     |
| 65 70 75 80   |     |
| aag cag tct ttc cct gaa ggt ttt act tgg gaa aga acc aca acc tac | 288 |
| Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Thr Tyr |     |
| 85 90 95  |     |
| gag gat gga ggc ttt ctt aca gct cat cag gac aca agc cta gat gga | 336 |
| Glu Asp Gly Gly Phe Leu Thr Ala His Gln Asp Thr Ser Leu Asp Gly |     |
| 100 105 110   |     |
| gat tgc ctc gtt tac aag gtc aag att ctt ggt aat aat ttt cct gct | 384 |
| Asp Cys Leu Val Tyr Lys Val Lys Ile Leu Gly Asn Asn Phe Pro Ala |     |
| 115 120 125   |     |
| gat ggc ccc gtg atg cag aac aaa gca gga aga tgg gag cca tcc acc | 432 |
| Asp Gly Pro Val Met Gln Asn Lys Ala Gly Arg Trp Glu Pro Ser Thr |     |
| 130 135 140   |     |
| gag ata gtt tat gaa gtt gac ggt gtc ctg cgt gga cag tct ttg atg | 480 |
| Glu Ile Val Tyr Glu Val Asp Gly Val Leu Arg Gly Gln Ser Leu Met |     |
| 145 150 155 160   |     |
| gcc ctt aag tgc cct ggt ggt cgt cat ctg act tgc cat ctc cat act | 528 |
| Ala Leu Lys Cys Pro Gly Gly Arg His Leu Thr Cys His Leu His Thr |     |
| 165 170 175   |     |

act tac agg tcc aaa aaa cca gct gct gcc ttg aag atg cca gga ttt 576  
 Thr Tyr Arg Ser Lys Lys Pro Ala Ala Ala Leu Lys Met Pro Gly Phe  
 180 185 190

cat ttt gaa gat cat cgc atc gag ata atg gag gaa gtt gag aaa ggc 624  
 His Phe Glu Asp His Arg Ile Glu Ile Met Glu Glu Val Glu Lys Gly  
 195 200 205

aag tgc tat aaa cag tac gaa gca gca gtg ggc agg tac tgt gat gct 672  
 Lys Cys Tyr Lys Gln Tyr Glu Ala Ala Val Gly Arg Tyr Cys Asp Ala  
 210 215 220

gct cca tcc aag ctt gga cat aac 696  
 Ala Pro Ser Lys Leu Gly His Asn  
 225 230

<210> 14  
 <211> 232  
 <212> PRT  
 <213> coral

<400> 14  
 Met Ala Ser Phe Leu Lys Lys Thr Met Pro Phe Lys Thr Thr Ile Glu  
 1 5 10 15  
 Gly Thr Val Asn Gly His Tyr Phe Lys Cys Thr Gly Lys Gly Glu Gly  
 20 25 30  
 Asn Pro Phe Glu Gly Thr Gln Glu Met Lys Ile Glu Val Ile Glu Gly  
 35 40 45  
 Gly Pro Leu Pro Phe Ala Phe His Ile Leu Ser Thr Ser Cys Met Tyr  
 50 55 60  
 Gly Ser Lys Ala Phe Ile Lys Tyr Val Ser Gly Ile Pro Asp Tyr Phe  
 65 70 75 80  
 Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Thr Tyr  
 85 90 95  
 Glu Asp Gly Gly Phe Leu Thr Ala His Gln Asp Thr Ser Leu Asp Gly  
 100 105 110  
 Asp Cys Leu Val Tyr Lys Val Lys Ile Leu Gly Asn Asn Phe Pro Ala  
 115 120 125  
 Asp Gly Pro Val Met Gln Asn Lys Ala Gly Arg Trp Glu Pro Ser Thr  
 130 135 140  
 Glu Ile Val Tyr Glu Val Asp Gly Val Leu Arg Gly Gln Ser Leu Met  
 145 150 155 160  
 Ala Leu Lys Cys Pro Gly Gly Arg His Leu Thr Cys His Leu His Thr  
 165 170 175  
 Thr Tyr Arg Ser Lys Lys Pro Ala Ala Ala Leu Lys Met Pro Gly Phe  
 180 185 190  
 His Phe Glu Asp His Arg Ile Glu Ile Met Glu Glu Val Glu Lys Gly  
 195 200 205  
 Lys Cys Tyr Lys Gln Tyr Glu Ala Ala Val Gly Arg Tyr Cys Asp Ala  
 210 215 220  
 Ala Pro Ser Lys Leu Gly His Asn  
 225 230

<210> 15  
 <211> 919  
 <212> DNA  
 <213> coral

<400> 15  
 attcacctcg gtgatttgta agagaaagga tcaccatcaa gagaagagct gtaaaagtta 60  
 atatttttact gtactttctac cagcatgagt gcacttaaag aagaaatgaa aatcaacctt 120

```

acaatggaag gtgttggttaa cgggcttcca ttttaagatcc gtgggggatgg aaaaggcaaaa 180
ccataccagg gatcacagga gttaaccttg acgggtgggta aaggcggggcc tctgcctttc 240
tcttatgata ttctgacaac gatgtttcag tacggcaaca gggcattcgt aaactaccca 300
gaggacatac cagatatattt caagcagacc tgttctgggtc ctaatgggtgg atattcctgg 360
caaaggacca tgacttatga agacgggaggc gtttgactgt ctacaagcaa catcagcgtg 420
gttggcgaca ctttcaatta tgacattcac tttatgggag cgaattttcc tcttgatggg 480
ccagtgatgc agaaaagaac aatgaaatgg gaaccatcca ctgagataat gtttgaacgt 540
gatggaatgc tgaggggtga cattgccatg tctctgttgc tgaagggagg gggccattac 600
cgatgtgatt ttgaaactat ttataaacc aataaggttg tcaagatgcc agattaccat 660
tttgtggacc actgcattga gataacgagt caacaggatt attacaacgt ggttgagctg 720
accgaggttg ctgaagcccg ctactcttcg ctggagaaaa tcggcaaatc aaaggcgtaa 780
atccaagcaa tctaagaaaa caacaaggca ttaaaccgaa tcaccgtttt gaatttttcg 840
ttcggaaattt cttggtaaaa ctagggttag aacgtttcat ttcgctggac ttctttgact 900
cagctgtaga caagaaaga

```

<210> 16  
 <211> 231  
 <212> PRT  
 <213> coral

```

<400> 16
Met Ser Ala Leu Lys Glu Glu Met Lys Ile Asn Leu Thr Met Glu Gly
 1      5      10      15
Val Val Asn Gly Leu Pro Phe Lys Ile Arg Gly Asp Gly Lys Lys
 20     25     30
Pro Tyr Gln Gly Ser Gln Glu Leu Thr Leu Thr Val Val Lys Gly Gly
 35     40     45
Pro Leu Pro Phe Ser Tyr Asp Ile Leu Thr Thr Met Phe Gln Tyr Gly
 50     55     60
Asn Arg Ala Phe Val Asn Tyr Pro Glu Asp Ile Pro Asp Ile Phe Lys
 65     70     75     80
Gln Thr Cys Ser Gly Pro Asn Gly Gly Tyr Ser Trp Gln Arg Thr Met
 85     90     95
Thr Tyr Glu Asp Gly Gly Val Cys Thr Ala Thr Ser Asn Ile Ser Val
100    105    110
Val Gly Asp Thr Phe Asn Tyr Asp Ile His Phe Met Gly Ala Asn Phe
115    120    125
Pro Leu Asp Gly Pro Val Met Gln Lys Arg Thr Met Lys Trp Glu Pro
130    135    140
Ser Thr Glu Ile Met Phe Glu Arg Asp Gly Met Leu Arg Gly Asp Ile
145    150    155    160
Ala Met Ser Leu Leu Lys Gly Gly Gly His Tyr Arg Cys Asp Phe
165    170    175
Glu Thr Ile Tyr Lys Pro Asn Lys Val Val Lys Met Pro Asp Tyr His
180    185    190
Phe Val Asp His Cys Ile Glu Ile Thr Ser Gln Gln Asp Tyr Tyr Asn
195    200    205
Val Val Glu Leu Thr Glu Val Ala Glu Ala Arg Tyr Ser Ser Leu Glu
210    215    220
Lys Ile Gly Lys Ser Lys Ala
225    230

```

<210> 17  
 <211> 876  
 <212> DNA  
 <213> coral

```

<400> 17
agtttcagcc agtgacaggg tgagctgcca ggtatttctaa caagatgagt tgttccaaga 60
atgtgatcaa ggagttcatg aggttcaagg ttcgtatgga aggaacggtc aatgggcacg 120
agtttgaaat aaaaggcgaa ggtgaaggga ggccttacga aggtcactgt tccgtaaagc 180
ttatggtaac caagggtgga cctttgccat ttgcttttga tattttgtca ccacaatttc 240
agtatggaag caaggtatat gtcaaacacc ctgccgacat accagactat aaaaagctgt 300

```

```

catttcctga gggattttaa tgggaaaggg tcatgaactt tgaagacggg ggcgtgggta 360
ctgtatccca agattccagt ttgaaagacg gctgtttcat ctacgagggt aagttcattg 420
gggtgaactt tccttctgat ggacctgtta tgcagaggag gacacggggc tgggaagcca 480
gctctgagcg tttgtatcct cgtgatgggg tgctgaaagg agacatccat atggctctga 540
ggctggaagg aggcggccat tacctcgttg aattcaaaag tatttacctg gtaaagaagc 600
cttcagtcca gttgccaggc tactattatg ttgactccaa actggatatg acgagccaca 660
acgaagatta cacagtcggt gagcagtatg aaaaaaccca gggacgccac catccgttca 720
ttaagcctct gcagtgaact cggctcagtc atggattagc ggtaatggcc acaaaaggca 780
cgatgatcgt tttttaggaa tgcagccaaa aattgaaggt tatgacagta gaaatacaag 840
caacaggcct tgcttattaa acatgtaatt gaaaac 876

```

<210> 18  
 <211> 230  
 <212> PRT  
 <213> coral

```

<400> 18
Met Ser Cys Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val
 1      5      10      15
Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Lys Gly Glu
 20      25      30
Gly Glu Gly Arg Pro Tyr Glu Gly His Cys Ser Val Lys Leu Met Val
 35      40      45
Thr Lys Gly Gly Pro Leu Pro Phe Ala Phe Asp Ile Leu Ser Pro Gln
 50      55      60
Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
 65      70      75      80
Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val
 85      90      95
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Ser Gln Asp Ser Ser
100      105      110
Leu Lys Asp Gly Cys Phe Ile Tyr Glu Val Lys Phe Ile Gly Val Asn
115      120      125
Phe Pro Ser Asp Gly Pro Val Met Gln Arg Arg Thr Arg Gly Trp Glu
130      135      140
Ala Ser Ser Glu Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly Asp
145      150      155      160
Ile His Met Ala Leu Arg Leu Glu Gly Gly Gly His Tyr Leu Val Glu
165      170      175
Phe Lys Ser Ile Tyr Met Val Lys Lys Pro Ser Val Gln Leu Pro Gly
180      185      190
Tyr Tyr Tyr Val Asp Ser Lys Leu Asp Met Thr Ser His Asn Glu Asp
195      200      205
Tyr Thr Val Val Glu Gln Tyr Glu Lys Thr Gln Gly Arg His His Pro
210      215      220
Phe Ile Lys Pro Leu Gln
225      230

```

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 April 2001 (19.04.2001)

PCT

(10) International Publication Number  
WO 01/27150 A3

(51) International Patent Classification<sup>7</sup>: C12N 15/12, 09/458.144 9 December 1999 (09.12.1999) US  
15/62, 15/63, C07K 14/435, 16/18, C12Q 1/25 09/457.898 9 December 1999 (09.12.1999) US  
PCT/US99/29405  
(21) International Application Number: PCT/US00/28477 10 December 1999 (10.12.1999) US  
60/211.627 14 June 2000 (14.06.2000) US  
(22) International Filing Date: 13 October 2000 (13.10.2000) 60/211.687 14 June 2000 (14.06.2000) US  
60/211.609 14 June 2000 (14.06.2000) US  
(25) Filing Language: English 60/211.626 14 June 2000 (14.06.2000) US  
60/211.880 14 June 2000 (14.06.2000) US  
(26) Publication Language: English 60/211.607 14 June 2000 (14.06.2000) US  
60/211.766 14 June 2000 (14.06.2000) US  
(30) Priority Data: 60/211.888 14 June 2000 (14.06.2000) US  
60/212.070 14 June 2000 (14.06.2000) US  
09/418.529 14 October 1999 (14.10.1999) US  
09/418.917 15 October 1999 (15.10.1999) US  
09/418.922 15 October 1999 (15.10.1999) US  
09/444.341 19 November 1999 (19.11.1999) US  
09/444.338 19 November 1999 (19.11.1999) US  
09/458.477 9 December 1999 (09.12.1999) US  
09/457.556 9 December 1999 (09.12.1999) US  
(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:  
US 09/418.529 (CIP)  
Filed on 14 October 1999 (14.10.1999)  
US 09/418.917 (CIP)  
Filed on 15 October 1999 (15.10.1999)

[Continued on next page]

(54) Title: ANTHOZOA DERIVED CHROMO/FLUOROPROTEINS AND METHODS FOR USING THE SAME

cDNA sequence of drFP583

GTCTCCCAAGCAGTGGTATCAACGCAGAGTACGGGGGAGTTTCAGCCAGTGACGGT  
CAGTGACAGGGTGAGCCACTTGGTATACCAACAAAATGAGGTCTTCCAAGAATGTTA  
TCAAGGAGTTCATGAGGTTTAAGGTTCCGATGGAAGGAACGGTCAATGGGCACGAGT  
TTGAAATAGAGGGCGAAGGAGAGGGGAGGCCATACGAAGGCCACAATACCGTAAAGC  
TTAAGGTAACCAAGGGGGGACCTTTGCCATTGCTTGGGATATTTGTCAACCACAAT  
TTCAGTATGGAAGCAAGGTATATGTCAAGCACCTCGCCGACATACCAGACTATAAAA  
AGCTGTCATTCTGAAGGATTAAATGGGAAAGGGTCATGAACCTTGAAGACGGTG  
GCGTCGTTACTGTAACCCAGGATTCCAGTTTGCAGGATGGCTGTTTCATCTACAAGT  
CAAGTTCATTGGCGTTGAACCTTCCCTTCCGATGGACCTGTTATGCAAAAGAAGACAA  
TGGGCTGGGAAGCCAGCACTGAGCGTTGTATCCTCGTGATGGCGTGTGAAAGGAG  
AGATTGTAAGGCTCTGAAGCTGAAAGACGGTGGTTCATTACCTAGTTGAATTCAAAA  
GTATTTACATGGCAAGAAGCCTGTGCAGCTACCAGGGTACTACTATGTTGACTCCA  
AACTGGATATAACAAGCCACAACGAAGACTATACAATCGTTGAGCAGTATGAAAGAA  
CCGAGGGACGCCACCATCTGTTCCCTTAAGGCTGAACCTGGCTCAGACGTTGGGTGAG  
CGGTAATGACCACAAAAGGCAGCGAAGAAAACCATGATCGTTTTTTTAGGTTGGC  
AGCCTGAAATCGTAGGAAATACATCAGAAATGTTACAAACAGG (SEQ ID NO:11)

amino acid sequence of drFP583

Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val  
Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu  
Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val  
Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln  
Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro  
Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val  
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser  
Leu Gln Asp Gly Cys Phe Ile Tyr Lys Ser Ser Ser Leu Ala Leu Asn  
Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu  
Ala Ser Thr Glu Arg Leu Gly His Tyr Leu Val Glu Phe Lys Ser Ile  
Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr Tyr Val Asp  
Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu  
Gln Tyr Glu Arg Thr Glu Gly Arg His His Leu Phe Leu  
(SEQ ID NO:12)

(57) Abstract: Anthozoa derived chromo/fluoroproteins and mutants thereof, as well as nucleic acid compositions encoding the same, are provided. Specific proteins of interest include chromo/fluoroproteins from the following specific anthozoa species: Anemonia majano, Clavularia sp., Zoanthus sp., Zoanthus sp., Discosoma striata, Discosoma sp. "red", Anemonia sulcata, Discosoma sp. "green", Discosoma sp. "magenta", and mutants thereof. Also provided are fragments of the subject proteins and nucleic acids encoding the same, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications that include the subject proteins are provided.

WO 01/27150 A3



- |          |                               |  |
|----------|-------------------------------|--|
| US       | 09/418,922 (CIP)              | Sergey Anatolievich [RU/RU]; ul. Golubinskaya d. 13/1 kv.161, Moscow (RU). <b>FRADKOV, Arcady Fedorovich</b> [RU/RU]; ul. Dnepropetrovskaya, 35/2-14, Moscow, 113570 (RU). <b>LABAS, Yulii Aleksandrovich</b> [RU/RU]; ul. Generala Tyuleneva, 35-416, Moscow, 117465 (RU). <b>MATZ, Mikhail Vladimirovich</b> [RU/RU]; ul. Teplii stan 7/2-28, Moscow, 117465 (RU). <b>TERSIKH, Alexey</b> [RU/US]; 1760 Halford Ave. #163, Santa Clara, CA 95051 (US). |
| Filed on | 15 October 1999 (15.10.1999)  |  |
| US       | 09/444,341 (CIP)              |  |
| Filed on | 19 November 1999 (19.11.1999) |  |
| US       | 09/444,338 (CIP)              |  |
| Filed on | 19 November 1999 (19.11.1999) |  |
| US       | 09/458,477 (CIP)              |  |
| Filed on | 9 December 1999 (09.12.1999)  |  |
| US       | 09/457,556 (CIP)              |  |
| Filed on | 9 December 1999 (09.12.1999)  |  |
| US       | 09/458,144 (CIP)              |  |
| Filed on | 9 December 1999 (09.12.1999)  |  |
| US       | 09/457,898 (CIP)              |  |
| Filed on | 9 December 1999 (09.12.1999)  |  |
| US       | 60/211,627 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | 60/211,687 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | 60/211,609 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | 60/211,626 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | 60/211,880 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | 60/211,607 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | 60/211,766 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | 60/211,888 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | 60/212,070 (CIP)              |  |
| Filed on | 14 June 2000 (14.06.2000)     |  |
| US       | PCT/US99/29405 (CIP)          |  |
| Filed on | 10 December 1999 (10.12.1999) |  |
- (71) **Applicant** (for all designated States except US): **CLON-TECH LABORATORIES INC.** [US/US]; 1020 East Meadow Drive, Palo Alto, CA 94303 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants** (for US only): **LUKYANOV,**
- (74) **Agent:** **FIELD, Bret, E.;** Bozicevic, Field & Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA 94025 (US).
- (81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- (88) **Date of publication of the international search report:**  
6 December 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# INTERNATIONAL SEARCH REPORT

International Application No.

PC/US 00/28477

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/62 C12N15/63 C07K14/435 C07K16/18  
C12Q1/25

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBL, MEDLINE, STRAND

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.   |
|------------|---|-------------------------|
| X          | WO 99 49019 A (SZENT GYORGYI CHRISTOPHER<br>;BRYAN BRUCE J (US); PROLUME LTD (US))<br>30 September 1999 (1999-09-30)<br>SEQ ID NO's: 15, 16 (Renilla mulleri GFP,<br>DNA and protein); 23-27 (Renilla<br>reniformis GFP, peptide fragments); 30-32<br>(Ptilosarcus gurneyi GFP, DNA and protein)<br>page 13 -page 24; figures 3-5; examples<br>3,9,10 | 1-8,<br>11-13,<br>16-30 |
| Y          | example 3   | 12-17                   |
| X          | DE 197 18 640 A (WIEDENMANN JOERG)<br>22 July 1999 (1999-07-22)<br>page 5, line 1 -page 7, line 68; tables<br>1,2<br>page 8, line 36-39   | 1-11,27,<br>29          |
| Y          | page 5, line 5 -page 11, line 16; tables<br>1,2   | 12-17                   |
|            | ---   |                         |
|            | -/--  |                         |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 March 2001

Date of mailing of the international search report

18.05.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Steffen, P



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/28477

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | <p>WARD W W ET AL: "AN ENERGY TRANSFER PROTEIN IN COELENTERATE BIOLUMINESCENCE CHARACTERIZATION OF THE RENILLA GREEN-FLUORESCENT PROTEIN" JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS),US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 254, no. 3, 10 February 1979 (1979-02-10), pages 781-788, XP002030243 abstract page 783, right-hand column, paragraphs 2,3 page 784, left-hand column, paragraph 4 -page 787, left-hand column, paragraph 5; figures 4,5; tables I,II</p> <p style="text-align: center;">---</p> | 1-7,11, 27,29         |
| X          | <p>DOVE SOPHIE G ET AL: "Isolation and partial characterization of the pink and blue pigments of pocilloporid and acroporid corals." BIOLOGICAL BULLETIN (WOODS HOLE), vol. 189, no. 3, 1995, pages 288-297, XP000974081 ISSN: 0006-3185 page 291, left-hand column, paragraph 4 -page 294, left-hand column, paragraph 1; figures 1,3,4,6,8</p> <p style="text-align: center;">---</p>  | 1-4                   |
| A          | <p>TSIEN R Y: "THE GREEN FLUORESCENT PROTEIN" ANNUAL REVIEW OF BIOCHEMISTRY,PALTO ALTO, CA,US, vol. 67, 1998, pages 509-544, XP000946725</p> <p style="text-align: center;">---</p>  |                       |
| A          | <p>TSIEN R.Y.: "ROSY DAWN FOR FLUORESCENT PROTEINS" NATURE BIOTECHNOLOGY, vol. 17, no. 10, October 1999 (1999-10), pages 956-957, XP002159040</p> <p style="text-align: center;">---</p>   |                       |
| P,X        | <p>MATZ M V ET AL: "FLUORESCENT PROTEINS FROM NONBIOLUMINESCENT ANTHOZOA SPECIES" NATURE BIOTECHNOLOGY,NATURE PUBLISHING,US, vol. 17, no. 10, 1999, pages 969-973, XP000882891 ISSN: 1087-0156 page 972 -page 973; table 2</p> <p style="text-align: center;">-----</p>  | 1-30                  |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/28477

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-7 all completely; 8-30 all partially

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-7 (all completely), 8-30 (all partly)

An isolated Anthozoa chromo- or fluorescent protein with absorbance maximum as set forth in claims 1-4 and excitation/emission ranges as set forth in claims 5-7. Isolated proteins and nucleic acids according to claims 1-7, and proteins and nucleic acids having the sequence substantially as depicted in SEQ ID NO's 2 and 1, about 60% or 75% sequence identity thereto, fragments thereof as well as hybridising nucleic acids thereto. Furthermore constructs, expression cassettes, cells, methods of production, antibodies, organisms, applications as well as kits all relating to claims 1-7 and SEQ ID NO's 2 and 1.

1.1. Claims: 8-30 (all partly)

Isolated proteins or nucleic acids according to claims 1-7, having the sequence substantially as depicted in SEQ ID NO's 2 and 1, about 60% or 75% sequence identity thereto, fragments thereof, hybridising nucleic acids thereto. Furthermore constructs, expression cassettes, cells, methods of production, antibodies, organisms, applications as well as kits all relating to SEQ ID NO's 2 and 1.

2. Claims: 8-30 (all partly)

Isolated proteins and nucleic acids, corresponding to claims 8 and 12, and said proteins or nucleic acids having the sequence substantially as depicted in SEQ ID NO's 4 and 3, about 60% or 75% sequence identity thereto, fragments thereof as well as hybridising nucleic acids thereto. Furthermore constructs, expression cassettes, cells, methods of production, antibodies, organisms, applications as well as kits all relating to SEQ ID NO's 4 and 3.

3. Claims: 8-30 (all partly)

As subject 2, but limited to SEQ ID NO's 6 and 5.

4. Claims: 8-30 (all partly)

As subject 2, but limited to SEQ ID NO's 8 and 7.

5. Claims: 8-30 (all partly)

As subject 2, but limited to SEQ ID NO's 10 and 9.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

6. Claims: 8-30 (all partly)

As subject 2, but limited to SEQ ID NO's 12 and 11.

7. Claims: 8-30 (all partly)

As subject 2, but limited to SEQ ID NO's 14 and 13.

8. Claims: 8-30 (all partly)

As subject 2, but limited to SEQ ID NO's 16 and 15.

9. Claims: 8-30 (all partly)

As subject 2, but limited to SEQ ID NO's 18 and 17.

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.